US20100166724A1 - Uses of thioredoxin - Google Patents
Uses of thioredoxin Download PDFInfo
- Publication number
- US20100166724A1 US20100166724A1 US12/694,577 US69457710A US2010166724A1 US 20100166724 A1 US20100166724 A1 US 20100166724A1 US 69457710 A US69457710 A US 69457710A US 2010166724 A1 US2010166724 A1 US 2010166724A1
- Authority
- US
- United States
- Prior art keywords
- thioredoxin
- cells
- trx
- transfected
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108060008226 thioredoxin Proteins 0.000 title claims abstract description 689
- 229940094937 thioredoxin Drugs 0.000 title claims abstract description 304
- 102000002933 Thioredoxin Human genes 0.000 title claims abstract description 32
- 230000006907 apoptotic process Effects 0.000 claims abstract description 96
- 230000010261 cell growth Effects 0.000 claims abstract description 90
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 49
- 230000005764 inhibitory process Effects 0.000 claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 210000004027 cell Anatomy 0.000 claims description 471
- 101000852559 Homo sapiens Thioredoxin Proteins 0.000 claims description 73
- 230000014509 gene expression Effects 0.000 claims description 52
- 210000004881 tumor cell Anatomy 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 33
- 102000056461 human TXN Human genes 0.000 claims description 30
- 230000004936 stimulating effect Effects 0.000 claims description 24
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 12
- 230000006654 negative regulation of apoptotic process Effects 0.000 claims description 11
- 230000004565 tumor cell growth Effects 0.000 claims description 10
- 230000007423 decrease Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 239000003324 growth hormone secretagogue Substances 0.000 abstract description 3
- 102100036407 Thioredoxin Human genes 0.000 description 646
- 206010028980 Neoplasm Diseases 0.000 description 151
- 230000000694 effects Effects 0.000 description 79
- 230000012010 growth Effects 0.000 description 70
- 102220489643 Thioredoxin_C35S_mutation Human genes 0.000 description 63
- 102220489637 Thioredoxin_C32S_mutation Human genes 0.000 description 60
- 108020004999 messenger RNA Proteins 0.000 description 59
- 201000011510 cancer Diseases 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 52
- 102000013090 Thioredoxin-Disulfide Reductase Human genes 0.000 description 47
- 108010079911 Thioredoxin-disulfide reductase Proteins 0.000 description 47
- 108090000623 proteins and genes Proteins 0.000 description 46
- 239000013598 vector Substances 0.000 description 43
- 230000001965 increasing effect Effects 0.000 description 41
- 239000002299 complementary DNA Substances 0.000 description 39
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 38
- 206010006187 Breast cancer Diseases 0.000 description 37
- 208000026310 Breast neoplasm Diseases 0.000 description 37
- 238000001890 transfection Methods 0.000 description 37
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 34
- 230000015572 biosynthetic process Effects 0.000 description 32
- 230000004663 cell proliferation Effects 0.000 description 32
- 239000003102 growth factor Substances 0.000 description 29
- 230000003647 oxidation Effects 0.000 description 28
- 238000007254 oxidation reaction Methods 0.000 description 28
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 27
- 239000000539 dimer Substances 0.000 description 27
- 206010017758 gastric cancer Diseases 0.000 description 27
- 230000035755 proliferation Effects 0.000 description 27
- 229960003957 dexamethasone Drugs 0.000 description 26
- 208000010749 gastric carcinoma Diseases 0.000 description 26
- 230000002269 spontaneous effect Effects 0.000 description 26
- 201000000498 stomach carcinoma Diseases 0.000 description 26
- 108020004414 DNA Proteins 0.000 description 25
- 239000000758 substrate Substances 0.000 description 24
- 230000009467 reduction Effects 0.000 description 22
- 230000000638 stimulation Effects 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 210000001519 tissue Anatomy 0.000 description 21
- 239000000710 homodimer Substances 0.000 description 20
- 238000001727 in vivo Methods 0.000 description 20
- 230000004614 tumor growth Effects 0.000 description 19
- 230000003247 decreasing effect Effects 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 230000001590 oxidative effect Effects 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 230000002018 overexpression Effects 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 16
- 102000004316 Oxidoreductases Human genes 0.000 description 16
- 108090000854 Oxidoreductases Proteins 0.000 description 16
- 239000012091 fetal bovine serum Substances 0.000 description 16
- 230000005757 colony formation Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 238000010186 staining Methods 0.000 description 15
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 14
- 230000001640 apoptogenic effect Effects 0.000 description 14
- 230000002496 gastric effect Effects 0.000 description 14
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 14
- 229920000936 Agarose Polymers 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 230000001093 anti-cancer Effects 0.000 description 13
- 230000008901 benefit Effects 0.000 description 13
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 13
- 230000003834 intracellular effect Effects 0.000 description 13
- 230000004083 survival effect Effects 0.000 description 13
- 102000003676 Glucocorticoid Receptors Human genes 0.000 description 12
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 108700020796 Oncogene Proteins 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 230000004071 biological effect Effects 0.000 description 12
- 230000000670 limiting effect Effects 0.000 description 12
- 230000035945 sensitivity Effects 0.000 description 12
- 230000005740 tumor formation Effects 0.000 description 12
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000001086 cytosolic effect Effects 0.000 description 11
- 230000007246 mechanism Effects 0.000 description 11
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 11
- 239000007800 oxidant agent Substances 0.000 description 11
- 239000012188 paraffin wax Substances 0.000 description 11
- 229920003023 plastic Polymers 0.000 description 11
- 239000004033 plastic Substances 0.000 description 11
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 10
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 102000040945 Transcription factor Human genes 0.000 description 10
- 108091023040 Transcription factor Proteins 0.000 description 10
- 210000001185 bone marrow Anatomy 0.000 description 10
- 238000001962 electrophoresis Methods 0.000 description 10
- 210000002950 fibroblast Anatomy 0.000 description 10
- 210000004877 mucosa Anatomy 0.000 description 10
- 230000007170 pathology Effects 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 230000002441 reversible effect Effects 0.000 description 10
- 101000801882 Dictyostelium discoideum Putative thioredoxin-5 Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000003364 immunohistochemistry Methods 0.000 description 9
- 210000004940 nucleus Anatomy 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108090000695 Cytokines Proteins 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 8
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 8
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 8
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 235000018417 cysteine Nutrition 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 8
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 8
- 229960005420 etoposide Drugs 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 238000003153 stable transfection Methods 0.000 description 8
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 8
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 8
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 7
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 7
- 238000012288 TUNEL assay Methods 0.000 description 7
- 229940041181 antineoplastic drug Drugs 0.000 description 7
- 239000003638 chemical reducing agent Substances 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 235000004400 serine Nutrition 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 101000835317 Mus musculus Thioredoxin Proteins 0.000 description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 6
- BLTCBVOJNNKFKC-QUDYQQOWSA-N N-acetylsphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@H](CO)NC(C)=O BLTCBVOJNNKFKC-QUDYQQOWSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 6
- 108010018242 Transcription Factor AP-1 Proteins 0.000 description 6
- 102100023132 Transcription factor Jun Human genes 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000002596 correlated effect Effects 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 229960005309 estradiol Drugs 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000000833 heterodimer Substances 0.000 description 6
- 230000002055 immunohistochemical effect Effects 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 201000009030 Carcinoma Diseases 0.000 description 5
- 230000006820 DNA synthesis Effects 0.000 description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000003197 catalytic effect Effects 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 239000003862 glucocorticoid Substances 0.000 description 5
- 238000007901 in situ hybridization Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000001613 neoplastic effect Effects 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000003248 secreting effect Effects 0.000 description 5
- 125000003396 thiol group Chemical group [H]S* 0.000 description 5
- 208000008732 thymoma Diseases 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- BPBPYQWMFCTCNG-UHFFFAOYSA-N 2-(butan-2-yldisulfanyl)-1H-imidazole Chemical compound CCC(C)SSC1=NC=CN1 BPBPYQWMFCTCNG-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 230000002424 anti-apoptotic effect Effects 0.000 description 4
- 238000006664 bond formation reaction Methods 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 238000004624 confocal microscopy Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 4
- 238000012303 cytoplasmic staining Methods 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 238000010562 histological examination Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000011065 in-situ storage Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000012758 nuclear staining Methods 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000010827 pathological analysis Methods 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- UHEPSJJJMTWUCP-DHDYTCSHSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N UHEPSJJJMTWUCP-DHDYTCSHSA-N 0.000 description 3
- UIOKLEZTPFZUMQ-UHFFFAOYSA-N 2-(1h-imidazol-2-yldisulfanyl)-1h-imidazole Chemical class N=1C=CNC=1SSC1=NC=CN1 UIOKLEZTPFZUMQ-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 3
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 3
- 230000004568 DNA-binding Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010061968 Gastric neoplasm Diseases 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102220472229 Protein Wnt-2_C37S_mutation Human genes 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108700019146 Transgenes Proteins 0.000 description 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000003782 apoptosis assay Methods 0.000 description 3
- 238000000211 autoradiogram Methods 0.000 description 3
- 210000002960 bfu-e Anatomy 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 3
- 230000000925 erythroid effect Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 230000033116 oxidation-reduction process Effects 0.000 description 3
- 150000002972 pentoses Chemical class 0.000 description 3
- 230000034918 positive regulation of cell growth Effects 0.000 description 3
- 210000001236 prokaryotic cell Anatomy 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102100024341 10 kDa heat shock protein, mitochondrial Human genes 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 101150009389 BZLF1 gene Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102100035882 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 108091008794 FGF receptors Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 2
- 102000003983 Flavoproteins Human genes 0.000 description 2
- 108010057573 Flavoproteins Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000636168 Grapevine leafroll-associated virus 3 (isolate United States/NY1) Movement protein p5 Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010064912 Malignant transformation Diseases 0.000 description 2
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 108700020978 Proto-Oncogene Proteins 0.000 description 2
- 102000052575 Proto-Oncogene Human genes 0.000 description 2
- 240000002878 Prunus cerasus Species 0.000 description 2
- 101001059240 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Site-specific recombinase Flp Proteins 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- GLEVLJDDWXEYCO-UHFFFAOYSA-N Trolox Chemical compound O1C(C)(C(O)=O)CCC2=C1C(C)=C(C)C(O)=C2C GLEVLJDDWXEYCO-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- GRRMZXFOOGQMFA-UHFFFAOYSA-J YoYo-1 Chemical compound [I-].[I-].[I-].[I-].C12=CC=CC=C2C(C=C2N(C3=CC=CC=C3O2)C)=CC=[N+]1CCC[N+](C)(C)CCC[N+](C)(C)CCC[N+](C1=CC=CC=C11)=CC=C1C=C1N(C)C2=CC=CC=C2O1 GRRMZXFOOGQMFA-UHFFFAOYSA-J 0.000 description 2
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 108010053098 biotin receptor Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000012866 crystallographic experiment Methods 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000007711 cytoplasmic localization Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 125000002228 disulfide group Chemical group 0.000 description 2
- 150000002019 disulfides Chemical class 0.000 description 2
- 108010046025 early pregnancy factor Proteins 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000013110 gastrectomy Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 231100000405 induce cancer Toxicity 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 208000019420 lymphoid neoplasm Diseases 0.000 description 2
- 230000036212 malign transformation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000329 molecular dynamics simulation Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000004987 nonapoptotic effect Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 150000004053 quinones Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 150000003450 sulfenic acids Chemical class 0.000 description 2
- 210000004876 tela submucosa Anatomy 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 108010029377 transcription factor TFIIIC Proteins 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 101150072359 trx gene Proteins 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000002424 x-ray crystallography Methods 0.000 description 2
- OIXLLKLZKCBCPS-RZVRUWJTSA-N (2s)-2-azanyl-5-[bis(azanyl)methylideneamino]pentanoic acid Chemical compound OC(=O)[C@@H](N)CCCNC(N)=N.OC(=O)[C@@H](N)CCCNC(N)=N OIXLLKLZKCBCPS-RZVRUWJTSA-N 0.000 description 1
- AVFYBUNTBGASMF-UHFFFAOYSA-N 1,1-bis(sulfanylidene)-3h-dithiole Chemical compound S=S1(=S)SCC=C1 AVFYBUNTBGASMF-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- YVOOPGWEIRIUOX-UHFFFAOYSA-N 2-azanyl-3-sulfanyl-propanoic acid Chemical compound SCC(N)C(O)=O.SCC(N)C(O)=O YVOOPGWEIRIUOX-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 101000633271 Arabidopsis thaliana Thioredoxin H9 Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 101000867659 Bos taurus Catalase Proteins 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 101100263760 Caenorhabditis elegans vms-1 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101000898643 Candida albicans Vacuolar aspartic protease Proteins 0.000 description 1
- 101000898783 Candida tropicalis Candidapepsin Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 101000898784 Cryphonectria parasitica Endothiapepsin Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 102100037373 DNA-(apurinic or apyrimidinic site) endonuclease Human genes 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 101710088570 Flagellar hook-associated protein 1 Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010084238 NAD+ peroxidase Proteins 0.000 description 1
- 101150008132 NDE1 gene Proteins 0.000 description 1
- -1 NF-KB Proteins 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710127332 Protease I Proteins 0.000 description 1
- 102000006010 Protein Disulfide-Isomerase Human genes 0.000 description 1
- 206010037127 Pseudolymphoma Diseases 0.000 description 1
- VSWDORGPIHIGNW-UHFFFAOYSA-N Pyrrolidine dithiocarbamic acid Chemical compound SC(=S)N1CCCC1 VSWDORGPIHIGNW-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 101000933133 Rhizopus niveus Rhizopuspepsin-1 Proteins 0.000 description 1
- 101000910082 Rhizopus niveus Rhizopuspepsin-2 Proteins 0.000 description 1
- 101000910079 Rhizopus niveus Rhizopuspepsin-3 Proteins 0.000 description 1
- 101000910086 Rhizopus niveus Rhizopuspepsin-4 Proteins 0.000 description 1
- 101000910088 Rhizopus niveus Rhizopuspepsin-5 Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 230000010632 Transcription Factor Activity Effects 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000005739 apoptotic body formation Effects 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000000339 bright-field microscopy Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000012986 chain transfer agent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 210000001728 clone cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002308 embryonic cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910000341 lead(IV) sulfide Inorganic materials 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 201000010968 pleomorphic carcinoma Diseases 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000035409 positive regulation of cell proliferation Effects 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108020003519 protein disulfide isomerase Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000034932 regulation of DNA biosynthetic process Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 150000003410 sphingosines Chemical class 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 150000003455 sulfinic acids Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90209—Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
Definitions
- the present invention generally relates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or eliminating thioredoxin-associated apoptosis inhibition and agents that are useful in inhibiting thioredoxin stimulated cell growth.
- Thioredoxin is a low molecular weight (M r 11,000-12,000) redox protein found in both prokaryotic and eukaryotic cells. (Holmgren A., J. Biol. Chem., 264:13963-13966, 1989), that undergoes reversible thiol reduction by the NADPH-dependent enzyme thioredoxin reductase.
- Human thioredoxin which has 5 cysteine (Cys) residues, is a 11.5 kDa protein with 27% amino acid identity to E. coli thioredoxin. Human thioredoxin contains 3 additional Cys residues not found in bacterial thioredoxin that give it unique biological properties.
- Cys32 and Cys35 are the conserved catalytic site cysteine residues that undergo reversible oxidation to cystine. Cys92, Cys69 and Cys73 are found in mammalian but not in bacterial thioredoxins, Cys73 appears to be particularly important for maintaining the biological activity of thioredoxin in an oxidizing environment.
- Thioredoxin reduces a variety of intracellular proteins including enzymes such as ribonucleotide reductase which is important for DNA synthesis, and critical Cys residues in transcription factors such as NF- K B, AP-1 and the glucocorticoid receptor, thus, altering their binding to DNA.
- enzymes such as ribonucleotide reductase which is important for DNA synthesis
- critical Cys residues in transcription factors such as NF- K B, AP-1 and the glucocorticoid receptor
- thioredoxin is identical to a growth factor reported to be secreted by human HTLV-1 transformed leukemia cell lines (Fox J A, et al., Proc. Natl. Acad. Sci. USA, 84:2663-2677, 1987). It has also been found that human recombinant thioredoxin will stimulate the growth of a wide variety of fibroblast and human solid tumor cell lines in culture (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995; Oblong J E, et al., J. Biol. Chem., 269:11714-11720, 1994). E. coli thioredoxin does not stimulate cell proliferation.
- Thioredoxin was first studied for its ability to act as reducing co-factor for ribonucleotide reductase, the first unique step in DNA synthesis. (Laurent T C, et al., 15 J. Biol. Chem., 239:3436-3444, 1964) More recently thioredoxin has been shown to exert redox control over a number of transcription factors modulating their binding to DNA and thus, regulating gene transcription. Transcription factors regulated by thioredoxin include NF- K B (Matthews J R, et al., Nucl. Acids Res., 20:3821-3830, 1992), TFIIIC (Cromlish J A, et al., J, Biol.
- thioredoxin can regulate AP-1 (Fos/Jun heterodimer) (Abate C, et al., Science 249:1157-1161, 1990).
- Thioredoxin is also a growth factor with a unique mechanism of action.
- ADF has been reported to be secreted by virally transformed leukemic cell lines and to stimulate their growth (Yodoi J, et al., Adv. Cancer Res., 57:381-411, 1991). These observations have been extended to show that human recombinant thioredoxin stimulates the proliferation of both normal fibroblasts and a wide variety of human solid and leukemic cancer cell lines. (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995) Powis G, et al., Oncol. Res., 6:539-544, 1994; Oblong J E, et al., J. Biol.
- mutant thioredoxins Recombinant modified thioredoxins, otherwise called mutant thioredoxins, have been developed, but no indications of uses were known in the art for any particular mutant form.
- cysteine (Cys) residues at the conserved -Cys32-Gly-Pro-Cys35-Lys active site of thioredoxin undergo reversible oxidation-reduction catalyzed by the NADPH-dependent flavoprotein thioredoxin reductase, (Luthman M, et al., Biochem., 21:6628-6633, 1982).
- Thioredoxin mRNA has been found to be over expressed by some human tumor cells (Gasdaska P Y, et al., Biochem. Biophys. Acta., 1218:292-296, 1994; Grogan T, et al., Cancer Res., 1997, in press) and since it is secreted from cells by a leaderless secretary pathway (Rubartelli. A, et al., J. Biol. Chem., 267:24161-24164, 1992) it could be a growth factor for some human cancers (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995).
- thioredoxin itself is known, its use in identifying agents that inhibit cell growth stimulated by thioredoxin has not been previously shown.
- Human thioredoxin reductase has been characterized as a protein (Oblong J E, et al., Biochem., 32:7271-7277, 1993).
- the general properties and the cDNA base sequence of human thioredoxin reductase is known in the art. However, it has not been disclosed or suggested in the art that thioredoxin reductase be used as an anti-tumor drug target.
- the myelodysplastic syndromes are a heterogeneous class of life threatening diseases characterized by ineffective hematopoiesis and progressive, refractory cytopenia (List A F, et al. J. Clin. Oncol., 8:1424-1441, 1990). Transformation to acute leukemia may occur in one-third of the patients.
- the underlying defect is decreased multilineage progenitor cell growth associated with decreased sensitivity to growth factor stimulation (Merchav S, et al., Leukemia, 5:340-346, 1991).
- GM-CSF granulocyte-macrophage colony stimulating factor
- G-CSF human granulocyte colony stimulating factor
- IL-3 displays multilineage progenitor stimulatory effects in normal marrow clinical trials have shown limited ability to improve hematopoiesis in MDS (List A F, et al., Blood, 82 (Suppl. 1):377a, 1993).
- current treatment for MD is limited by the ability of cytokines to stimulate hematopoietic progenitor cells and the decreased sensitivity of these cells to growth factors.
- the present invention relates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or preventing thioredoxin-associated apoptosis inhibition in tumor cells and agents that are useful in inhibiting thioredoxin stimulated growth of tumor cells.
- a non-limiting embodiment of the invention involves a method of inhibiting minor cell growth in a tumor cell that over-expresses thioredoxin comprising contacting said tumor cell with a cell growth inhibiting effective amount of an inhibitor of thioredoxin expression.
- agents can include, inter alia, small molecular compounds that complex with and interfere with the biological action of thioredoxin, preferably those that complex with active Cys residues, antisense inhibitors of thioredoxin expression, antibodies, or inhibitors of nucleic acid expression.
- a further non-limiting embodiment of the invention involves a method of reducing inhibition of apoptosis in tumor cells that over-express thioredoxin comprising contacting said tumor cells with an effective amount of an agent that inhibits thioredoxin.
- agents can include, inter alia, antibodies to this redoxin, compounds that inhibit the activity of this redoxin, preferably those that inhibit the activity of active Cys residues in the protein, cross-linking agents and the like.
- a further non-limiting embodiment of the invention involves a method of identifying an agent that inhibits tumor cell growth in cells that over-express thioredoxin comprising measuring thioredoxin expression or activity in a first sample of said cells; contacting a second sample of said cells with an agent to be tested; measuring expression or activity of thioredoxin in said second sample; comparing expression or activity of thioredoxin in said first sample and said second sample; whereby a decrease in expression or activity of thioredoxin in said second sample is indicative of an agent that inhibits tumor cell growth.
- a further non-limiting embodiment of the invention involves a method of identifying an agent that reduces inhibition of apoptosis in a tumor cell that over-expresses thioredoxin comprising measuring thioredoxin expression or activity in a first sample of said cells; contacting a second sample of said cells with an agent to be tested; measuring expression or activity of thioredoxin in said second sample; comparing expression or activity of thioredoxin in said first sample and said second sample; whereby a decrease in expression or activity of thioredoxin in said second sample is indicative of an agent that reduces inhibition of apoptosis.
- a further non-limiting embodiment of the invention involves a method of identifying an agent that reduces thioredoxin induced inhibition of apoptosis in a tumor cell growth.
- a further non-limiting embodiment of the invention involves a method of stimulating cell growth comprising introducing a nucleic acid encoding a human thioredoxin having Ser at amino acid reside 73 under conditions whereby said nucleic acid is expressed.
- a further non-limiting embodiment of the invention involves a composition comprising an agent that is useful in reducing or eliminating thioredoxin-associated apoptosis inhibition and an acceptable carrier.
- a further non-limiting embodiment of the invention involves a composition comprising an agent that is useful in inhibiting thioredoxin stimulated cell growth and an acceptable carrier.
- the present invention is based, at least in part, on the discovery that thioredoxin protein is over-expressed in certain human tumor cells; that thioredoxin stimulates the growth of cancer cells; that thioredoxin inhibits apoptosis; that thioredoxin is over-expressed in some human primary tumors and is correlated with increased tumor cell growth and decreased apoptosis; and that agents that inhibit thioredoxin also have anti-tumor activity.
- the present invention involves the new uses of thioredoxin, thioredoxin reductase, and mutant forms of thioredoxin for use in screening for anti-tumor agents. It has not been known in the art to use thioredoxin and/or thioredoxin reductase in a screening assay for anti-thioredoxin and/or anti-thioredoxin reductase agents for use as anti-tumor compounds.
- the present invention further relates to the use of thioredoxin and/or thioredoxin reductase antibodies for use as anti-tumor agents.
- the present invention further relates to the use of anti-sense thioredoxin or anti-sense thioredoxin reductase compounds for use as anti-tumor agents.
- the present invention further relates to the use of thioredoxin nucleic acid probes and/or thioredoxin antibodies in a diagnostic assay for certain cancers.
- the present invention further relates to the use of thioredoxin as a target for agents to be used in combination with existing and new treatment therapies, such as drugs and radiation, that reduce or prevent the thioredoxin-induced inhibition of apoptosis in tumor cells or to increase the sensitivity of tumor cells to these modalities.
- mutant forms of thioredoxin provide proteins with additional growth stimulating activity.
- FIG. 1 shows a chart that illustrates the stimulation of human bone marrow colony formation by Cys73->Ser mutant thioredoxin in accordance with the present invention, wherein the effects of Cys73->Ser thioredoxin on colony formation are shown by (o) multilineage progenitors (CFU-GEMM); (•) erythroid progenitors (BFU-E): and ( ⁇ ) myeloid progenitors (CFU-GM), measured over 10 days as described. (Values represent the mean of 4 determinations and bars represent S.D.)
- CFU-GEMM multilineage progenitors
- BFU-E erythroid progenitors
- CFU-GM myeloid progenitors
- FIG. 2 shows a chart that illustrates potentiation of IL-2 induced MCF-7 breast cancer cell growth by Cys 73 ->Ser mutant thioredoxin in accordance with the present invention, wherein cells were growth arrested for 48 hr. in medium with 0.5% serum (10 cells) then stimulated in the absence of medium with either IL-2 or Cys 32 ->Ser mutant thioredoxin at the concentrations shown and cell number was measured after 48 hr. (Each point represents the mean of 3 determinations and bars represent S.E., and the dotted line shows stimulation by 10% serum.)
- FIG. 3 shows a chart that illustrates the inhibition of thioredoxin stimulated MCF-7 cell growth by receptor antibodies in accordance with the present invention, wherein cell proliferation was measured as described in FIG. 2 ; the concentrations of agents used were Cys 73 ->Ser mutant thioredoxin (Thioredoxin) 1 ⁇ M, monoclonal antibodies to FGF receptor, IL-2-receptor and EGF-receptor 4 ⁇ g/ml, and EGF 10 nM; and the EGF and EGFR were added as a negative control. (Values represent the mean of 3 determinations and bars represent S.E., and the dotted line shows the effect of 10% serum alone.)
- FIGS. 4A-B illustrate comparative charts showing the effects of thioredoxin and C32S/C35S cDNA transfection on proliferation of MCF-7 cells.
- 3 ⁇ 10 4 cells were plated in 3.8 cm 2 plastic culture dishes in DMEM with 10% fbs and cell number measured 7 days later.
- 10 cells were plated in 2 cm 2 wells containing soft agarose and colonies measuring >60 microns counted 7 days later.
- FIG. 5 illustrates a chart showing the growth of Trx and C32S/C35S-transfected MCF-7 breast cells in Scid mice.
- Female Scid mice implanted s.c. 2 days previously with a 21 day release pellet of 0.25 mg 17- ⁇ estradiol were injected subcutaneously with 2 ⁇ 10 6 transfected MCF 7 cells in 0.1 ml 0.9%, NaCl and 0.1 ml matngel.
- (O) represents MCFneo, pDC304 vector-alone transfected MCF 7 cells;
- ⁇ represents Trx 12, thioredoxin transfected cells;
- ⁇ represents Trx 20, thioredoxin transfected cells;
- ⁇ represents Serb 4, C32S/C35S transfected cells; and
- ⁇ represents Serb 15, C32S/C35S transfected cells.
- FIG. 6 illustrates an autoradiogram showing Northern analysis of NIH 3T3 cells stably transfected with cDNA for human Trx and a redox-inactive mutant human Trx (C32S/C35S) hybridized with a full-length 32 P-labeled human Trx cDNA.
- the bottom band is endogenous mouse Trx mRNA, and the top band is the transfected human Trx mRNAs.
- the blots illustrate columns of NIH 3T3, wild-type NIH 3T3 cells; NeoC, cells transfected with the pRXneo vector; ThioAD and Thio6, cells transfected with C32S/C35S Trx in the pDC304neo vector; and Thio 9, cells transfected with human Trx cDNA in the pDC304neo vector.
- Values on right are molecular weight markers (in kb). Values below are the ratios of transfected Trx mRNA to endogenous Trx mRNA determined by phosphorimager analysis.
- FIG. 7 illustrates a chart showing the effects of transfection with Trx or C32S/C35S cDNA on the growth of Nit-H 3T3 cells.
- Cells were plated in plastic dishes at a density of 2 ⁇ 10 4 cells/cm 2 —in DMEM with 10% FBS and cell number measured daily.
- ⁇ NeoC vector alone-transfected cells.
- the apparent decrease in the number of cells after day 3 is due to detachment of cells from the plastic surface: ⁇ , ⁇ , and ⁇ , Thio6, ThioAD, and Thio9 cells transfected with Trx cDNA; ⁇ and ⁇ NIHBH and NIHBF: cells transfected with C32S/C35S cDNA.
- Values are the mean of three determinations: bars, SE. *, P ⁇ 0.05 compared with vector alone-transfected cells, shown for days 3 and 4 only. The study is typical of three repeat experiments.
- FIG. 8 illustrates a chart showing the stimulation of the proliferation of MCF-7 human breast cancer cells and mouse NIH 3T3 cells by human Trx.
- Cells were growth arrested in DMEM containing 0.5% FBS for 48 h so that there were 0.4 ⁇ 10 5 cells, at which time the medium was replaced with fresh DMEM with ( ⁇ ) or without ( ⁇ ) 1 ⁇ M human Trx. Cell numbers were measured 48 h later. Values are the mean of three determinations: bars, SE.
- FIGS. 9A-B illustrate comparative autoradiograms showing Northern analysis of MCF-7 breast cancer cells stably transfected with cDNA for wild-type Trx ( FIG. 9A ) and redox-inactive mutant Trx (C32S/C35S) hybridized with a full-length 32 P-labeled human Trx cDNA ( FIG. 9B ).
- MCFneo are cells transfected with pDC304 vector alone.
- the blots illustrate columns of MC Fneo, Trx20, Trx 14, Trx 12, and Trx9 in FIG. 9A and Serb 15, Serb 19, Serb 17, Serb 5, Serb 4 and MCFneo in FIG. 9B .
- the bottom band is endogenous Trx mRNA
- the top band is the transfected Trx mRNAs. Values below each column are the ratios of transfected Trx mRNA to endogenous Trx mRNA determined by phosphorimager analysis.
- FIGS. 10A-D illustrate light microscopy of Trx and C32S/C35S cDNA-transfected MCF-7 breast cancer cells.
- the cells were grown to 75% confluence on glass coverslips, fixed with methanol, stained with a Romanowski-type dye (Diff-Quick, Baxter), and observed with a ⁇ 100 oil immersion objective.
- FIG. 1A pDC304 vector alone-transfected MCF-7 cells
- FIG. 10B Trx 20 Trx-transfected MCF-7 cells
- FIG. IOC Serb 4 C32S/C35S-transfected MCF-7 cells
- FIG. 10D Serb 19 C32S/C35S-transfected MCF-7 cells.
- FIGS. 11A-B illustrate comparative charts showing the effects of Trx and C32S/C35S cDNA transfection on proliferation of MCF-7 cells.
- FIG. 1A cells (3 ⁇ 10) were plated in 3.8m-cm 2 plastic culture dishes in DMEM with 10% FBS, and cell number was measured 7 days later.
- FIG. 11B cells (10 4 ) were plated in 2-cm-wells containing soft agarose, and colonies measuring >60 ⁇ m were counted 7 days later.
- FIGS. 11A-B illustrate comparative charts showing the effects of Trx and C32S/C35S cDNA transfection on proliferation of MCF-7 cells.
- the chart shows control Neol vector alone-transfected MCF-7 cells, Trx 9, Trx 12, and Trx 20, MCF-7 cells transfected with human Trx cDNA: Serb 4, Serb 15, and Serb 19, MCF-7 cells transfected with C32/C35S cDNA. Values are the mean of three determinations: bars, SE, **, P ⁇ 0.01 compared with vector alone-transfected cells.
- FIG. 12 illustrates a chart showing the growth of Trx and C32S/C35S-transfected MCF-7 breast cancer cells is Scid mice.
- o MCFneo, pDC304 vector alone-transfected MCF-7 cells: ⁇ , Trx 12, Trx-transfected cells; ⁇ , Trx 20, thioredoxin-transfected cells: ⁇ .
- FIG. 13 illustrates a chart showing the stimulation of MCF-7 breast cancer cell growth by fresh and aged Trx and C73S.
- MCF-7 cells were growth arrested and the stimulation of cell proliferation measured over 2 days using 1 ⁇ M Trx or C73S that was fresh or had been stored as a 25 ⁇ M stock solution without reducing agent for 5 days or 90 days at 4′. Also shown for reference is the effect of 10% fetal bovine serum. Each value is the mean of 3 determinations, and bars are SEM.
- FIG. 14 illustrates a chart showing the reduction of aged Trx by thioredoxin reductase.
- the incubation mixture contained 0.1 M HEPES buffer, pH 7.6, 5 mM EDTA, 17 ⁇ M insulin, 100 ⁇ M NADPH, 15 ⁇ g/ml human thioredoxin reductase. Traces show the oxidation of NADPH at 340 nm at room temperature with: Line A represents 1 ⁇ M fresh Trx; Line B represents 30 nM fresh Trx; Line C represents 90-day aged 1 ⁇ M Trx; and Line D represents 1 ⁇ M. 90-day aged Trx and 30 nM fresh Trx.
- FIG. 15 illustrates a chart showing the effect of H 2 O 2 on the reduction of Trx (filled bars) and C73S (open bars) by thioredoxin reductase.
- Trx solutions were treated with varying amounts of H 2 O 2 for 18 hr. at room temperature.
- Reductase activity was measured by adding treated samples to a solution of 0.1 M HEPES buffer, pH 7.6, 5 mM EDTA, 17 ⁇ M. insulin, 100 ⁇ M NADPH, 15 ⁇ g/ml human thioredoxin reductase and measuring the rate of NADPH oxidation at 340 nm at room temperature.
- One hundred percent of thioredoxin reductase activity is defined as 0.1 absorbance unit/min/mM Trx or C73S Trx H 2 O 2 had no effect on the oxidation of NADPH.
- FIG. 16 illustrates an electrophoretic analysis showing the effect of storage on Trx studied by SDS-PAGE. Protein was stained with silver stain. Lane 1 represents fresh Trx; lane 2 represents Trx 48 hr. at room temperature without DTT; lane 3 represents Trx 7 days at room temperature without DTT; and lane 4 represents Trx stored 90 days at 4′ without DTT. Position of molecular mass markers in kDa are shown on the left.
- FIG. 17 illustrates an electrophoretic analysis showing the oxidation and alkylation of Trx studied by SDS-PAGE.
- Lane 1 represents fresh Trx
- lane 2 represents Trx stored at room temperature without DTT for 7 days
- lane 3 represents Trx as in lane 2 treated with 3 mM 2-mercaptoethanol
- lane 4 represents fresh Trx treated with 1 mM N-ethylmaleimide
- lane 5 represents fresh Trx treated with 1 mM diamide
- lane 6 represents fresh Trx treated with 2:1 (v:v) H 2 O
- lane 7 represents Trx as in lane 5 treated with 3 mM 2-mercaptoethanol
- lane 8 represents Trx as in lane 6 treated with 10 mM 2-mercaptoethanol.
- Position of molecular mass markers in kDa are shown on the left.
- FIG. 18 illustrates an electrophoretic analysis showing the oxidation and reduction of mutant Trxs studied by SDS-PAGE.
- Lane 1 represents fresh Trx;
- lane 2 represents fresh C73S Trx;
- lane 3 represents fresh C32S/C35S Trx;
- lane 4 represents C73S Trx treated with 1 mM diamide;
- lane 5 represents C73S Trx as in lane 4 treated with 10 mM DTT;
- lane 6 represents C32S/C35S Trx treated with 1 mM diamide;
- lane 7 represents C32S/C35S Trx as in lane 6 treated with 10 mM DTT.
- Position of molecular mass markers in kDa are shown on the left and right.
- FIG. 19 illustrates the position of cysteines in human Trx. Ribbons and ball-and-stick representation showing the relative positions of Cys 32 , Cys 35 , Cys 62 , Cys 69 and Cys 73 , based on the crystal coordinates for the wild type reduced protein (Weichsel A, et al., Structure 4:735-751, 1996). None of the thiols are in a position for disulfide bond formation except for the redox active pair Cys 32 and Cys 35 . The intermolecular disulfide bond requiring the least distortion in the protein would be between Cys 32 and Cys 73 .
- FIG. 20A shows a Northern blot hybridization analysis of total RNA extracted from: wild-type mouse WEH17.2 cells; from pDC304neo vector-alone transfected WEH17.2 cells (Neo); and from the rrx-transfected WEH17.2 clones Trx5 and Trx6.
- a full-length 32 P-labeled trx cDNA probe was used for hybridization, Top band, transfected human Trx mRNA; bottom band, mouse Trx mRNA.
- the values on the right show the position of molecular weight markers (kb).
- FIGS. 20 B( 1 )-( 4 ) illustrate fluorescence immunohistochemical staining of Trx in cells using immunoaffinity-purified rabbit antihuman Trx polyclonal antibody, biotinylated goat antirabbit IgG; fluorescein streptavidin, and laser scanning confocal microscopy.
- FIG. 20 B( 1 ) represents wild-type WEH17.2 cells;
- FIG. 20 B( 2 ) represents pDC304neo vector-alone transfected WEH17.2 cells;
- FIG. 20 B( 3 ) represents Trx5 trx transfected cells; and
- FIG. 20 B( 4 ) represents Trx6 trx-transfected cells.
- FIGS. 20 C( 1 )-( 2 ) illustrate a fluorescence immunohistochemical staining of Trx using Cy5-streptavidin fluorochrome and Y0Y0-1 to counterstain nuclear DNA showing that Trx is present in the cytoplasm and the nucleus of wild-type WEH17.2 cells (in FIG. 20 C( 1 )) and Trx6 frx-transfected cells (in FIG. 20 C( 2 )).
- FIG. 21 shows comparative charts illustrating the effects of trx and bcl-2 transfection in WEH17.2 cells on dexamethasone-induced apoptosis.
- FIG. 21A shows a chart illustrating apoptosis measured by an ELISA for histone-associated DNA fragments, expressed as relative nucleosomal enrichment.
- Wild represents wild-type WEH17.2 cells; Neo represents pDC304neo vector-alone-transfected WEHI7.2; W.Hbl2 represents bcl-2-transfected WEHI7.2; and Trx5 and Trx6 represent trx-transfected WEH17.2 cells.
- the cells were treated with, 0.01% ethanol vehicle ( ⁇ ) or I ⁇ M dexamethasone ( ⁇ ), and apoptosis was measured 24 h later. Columns, mean of four determinations; bars, SE. *, P ⁇ 0.05 compared to Neo control.
- FIGS. 21 B( 1 )-( 4 ) illustrate comparative charts of apoptosis measured by flow cytometry showing typical results. Regions R 1 , R 2 , and R 3 of the scattergrams represent live nonapoptotic, early apoptic, and late apoptotic cells, respectively.
- FIG. 21 B( 1 ) shows pDC304neo vector-alone-transfected control cells;
- FIG. 21 B( 2 ) shows pDC304neo vector-alone-transfected cells treated 48 h with 1 ⁇ M dexamethasone;
- FIG. 21 B( 3 ) shows Trx6 trx-transfected WEH17.2 cells; and
- FIG. 21 B( 4 ) shows Trx6 cells treated for 48 hr. with 1 ⁇ M dexamethasone.
- FIG. 22A shows a chart illustrating tumor formation in Scid mice by wild-type WEH17.2 cells (O and); bcl-2-transfected WEH17.2 (W. Hbl2) cells ( ⁇ and ⁇ ); and Trx6 rrx-transfected WEH17.2 cells ( ⁇ and ⁇ ).
- Twenty mice were injected s.c. with 2 ⁇ 10 cells and 0.1 ml matrigel in the flank. Tumor size was measured every 3-4 days with calipers, and tumor volumes were calculated.
- Nine days after tumor cell injection half of the mice were injected s.c. into the opposite flank with 1 mg/kg/day dexamethasone (o, ⁇ , and ⁇ ) or with vehicle alone (•, ⁇ , and ⁇ ). Mice were euthanized at the first measurement at which tumor volume exceeded 2 cm 3
- Data points mean of mice in each group; bars, SE. Results similar to the Trx6 cells were obtained with Trx5 cells.
- FIG. 22B illustrates 1- ⁇ m sections of epoxy-embedded tumor samples taken at day 14 stained with toluidine blue O examined by bright-field microscopy. Spontaneous apoptosis in wild-type WEH1 7.2 tumor are shown in FIG. 22 B( 1 ) and Trx6 tumor showing less spontaneous apoptosis are shown in FIG. 22 B( 2 ).
- FIG. 23 illustrates thioredoxin positive gastric carcinoma (Case 2).
- FIGS. 23A-B show that hematoxylin and eosin stains ( FIG. 23A and FIG. 23B ) reveal a pleomorphic carcinoma invading the gastric wall.
- FIGS. 23C-D show that the thioredoxin expression ( FIG. 23C and FIG. 23D ) is present in both the nuclei and cytoplasm of tumor cells in malignant glands and in rare associated leucocytes. Thioredoxin expression is absent in the adjacent stroma (1000 ⁇ to 400 ⁇ ).
- FIG. 24 illustrates thioredoxin negative gastric carcinoma (Case 8).
- FIG. 24A represents gastric carcinoma with complex glands in lower field of view with overlying normal gastric mucosa and submucosa. Hematoxylin and eosin (100 ⁇ ).
- FIG. 24B represents the same section as shown in FIG. 24A , negative control stained after biotin-avidin block to eliminate biotin receptor affect and stained with substituted irrelevant isotype matched monoclonal antibody (100 ⁇ , Diaminobenzidine).
- FIG. 24C represents the same section as shown in FIGS.
- FIG. 24A and B showing faint reactivity in normal upper mucosa (+), moderate reactivity in the submucosa (++) and the underlying gastric carcinoma appears negative for thioredoxin (0) (100 ⁇ ).
- FIG. 24D represents a higher magnification of FIG. 24(C showing detail with gastric pit cells having both nuclear and cytoplasmic stain and absent tumor staining (250 ⁇ ).
- FIG. 25 illustrates normal gastric mucosa-thioredoxin and Ki67 (proliferation antigen) expression.
- FIG. 25A shows normal gastric mucosa and gastric pits with underlying muscularis propria hematoxylin and eosin (100 ⁇ ).
- FIG. 25B shows the same section as shown in FIG. 25A , stained for thioredoxin with faint (+) mucosal staining and moderate (++) gastric pit staining (100 ⁇ ).
- FIG. 25C shows the same section as shown in FIG. 25B at higher magnification. Note the faint mucosal staining is solely cytoplasmic, while lower lying gastric pit cells are both cytoplasmic and nuclear (250 ⁇ ).
- FIG. 25D shows the nuclear Ki67 expression notable in lower mucosa and upper gastric pits (25O ⁇ ).
- FIG. 26 illustrates thioredoxin intense gastric carcinoma related to strong proliferation and weak apoptosis (Case 4).
- FIG. 26A shows complex adenocarcinoma cell glands (400 ⁇ , hematoxylin and eosin).
- FIG. 26B shows intense thioredoxin expression in gastric carcinoma cells (400 ⁇ )
- FIG. 26(C shows a high percentage of Ki67 positive cells indicating high proliferation (400 ⁇ ).
- FIG. 26D shows a rare Td+ ⁇ apoptotic cell 25 indicating weak apoptosis (Tunel assay, 400 ⁇ , same slide).
- FIG. 27 illustrates thioredoxin negative gastric carcinoma related to weak proliferation and strong apoptosis (Case 6).
- FIG. 27A shows complex adenocarcinoma glands (400 ⁇ , hematoxylin and eosin).
- FIG. 27B shows the absent thioredoxin expression (400 ⁇ ).
- FIG. 27C shows a low percentage of Ki67 positive cells indicating a low proliferative rate (400 ⁇ ).
- FIG. 27D shows a very high Tdt+ apoptotic cell rate indicating strong apoptosis (TUNEL assay, 400 ⁇ , same slide).
- Nucleotide means a monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base.
- the base is linked to the sugar moiety via the glycosidic carbon (1′ carbon of the pentose) and that combination of base and sugar is called a “nucleoside”.
- the base characterizes the nucleotide.
- the four DNA bases are adenine (“A”), guanine (“G”), cytosine (“C”), and thymine (“T”).
- A adenine
- G guanine
- C cytosine
- T thymine
- U RNA uracil
- DNA comprises deoxyribose as the sugar while RNA comprises ribose.
- amino acids are shown either by a three letter or one letter abbreviation as follows:
- DNA Sequence means a linear array of nucleotides connected one to the other by phosphodiester bonds between the 3′ and 5′ carbons of adjacent pentoses.
- Codon means a DNA sequence of three nucleotides (a triplet) which encodes through mRNA an amino acid, a translation start signal or a translation termination signal. The code however, is degenerate, with some amino acids being encoded by more than one triplet codon.
- the nucleotide triplets TTA, TTG, CTT, CTC, CTA and CTG all encode the amino acid leucine (“Leu”), TAG, TAA and TGA are translation stop signals and ATG is a translation start signal.
- Proteins are composed of a linear array of amino acids connected one to the other by peptide bonds between the alpha-amino and carboxyl groups of adjacent amino acids.
- Gene means the entire DNA of an organism, cell or a virus. It includes, inter alia, the structural genes coding for polypeptides, as well as regulatory regions including operator, promoter, terminator, enhancer and ribosome binding and interaction sequences.
- Gene means a DNA sequence which encodes through its template or messenger RNA (“mRNA”) a sequence of amino acids characteristic of a specific polypeptide.
- mRNA messenger RNA
- cDNA means a complementary or copy DNA prepared by using mRNA as a template for synthesizing the first strand of DNA using reverse transcriptase, an appropriate oligonucleotide primer and a mixture of nucleotides.
- PCR means a polymerase chain reaction whereby a specific DNA sequence, either genomic or cDNA, can be preferentially amplified by the enzyme Taq polymerase using synthetic, oligonucleotide sense and antisense primers, (which specify a target sequence), a mixture of nucleotides and a temperature thermocycling regime which allows sequential denaturing, annealing and synthesis of the target DNA between the primers.
- Transcription means the process of producing mRNA from a gene or DNA sequence.
- Translation means the process of producing a polypeptide from mRNA.
- “Expression” means the process undergone by a gene or DNA sequence to produce a polypeptide and comprises a combination of transcription and translation.
- Plasmid or “phagemid” means a nonchromosomal double-stranded DNA sequence comprising an intact “replicon” such that the plasmid is replicated in a host cell.
- the characteristics of that organism may be changed or transformed as a result of the DNA of the plasmid.
- AMP R ampicillin resistance
- a cell transformed by a plasmid is called a “transformant”.
- “Recombinant DNA Molecule” or “Hybrid DNA” means a molecule consisting of segments of DNA from different genomes which have been joined end-to-end outside of living cells and able to be maintained in living cells.
- Apoptosis is programmed cell death activated by a genetic program to implement a series of events that cause the death and disposal of a cell. This is in contrast to cell death occurring by necrosis, usually as a result of injury to the cell.
- Oncogene is a gene that encodes a protein able to transform cells in culture to induce cancer in animals.
- “Over-expression” in the context of determining over-expression of thioredoxin or recombinant modified thioredoxin is characterized by a two fold increase or more of the levels of thioredoxin or recombinant modified thioredoxin in a target sample compared with a control sample.
- NIH-3T3 cells transfected with human thioredoxin DNA that has been directed to the nucleus of the cells by a nuclear localization signal causes malignant transformation of the cells.
- stable transfection of mouse WEHI7.2 lymphoid cells with human thioredoxin DNA has been shown to inhibit apoptosis induced by a variety of agents including glucocorticoid, N-acetylsphingosine, staurosporine, thapsigargin and etoposide, which is similar to the pattern of inhibition of apoptosis caused by the anti-apoptotic oncogene bcl-2 in these cells.
- the thioredoxin transfected WEH17.2 cells form tumors in Scid mice that grow more rapidly and show less spontaneous apoptosis than vector-alone or bcl-2 transfected cells, and are resistant to growth inhibition by glucocorticoid. Therefore, the thioredoxin gene acts as an oncogene according to the standard definition of an oncogene: a gene that encodes a protein able to transform cells in culture or to induce cancer in animals (Lodish H, et al., “Cancer.” In: Lodish H, Baltimore D, Berk A, Zipursky S L, Matsudaira P, Darnell J, eds. Molecular Cell Biology . New York: Scientific American Books, pp. 1258, 1995).
- the thioredoxin gene offers an increased survival advantage as well as a growth advantage to tumors in vivo, unlike the known anti-apoptosis oncogene bcl-2 which offers only a survival advantage and requires other genetic changes for tumor growth (McDonnell T J, et al., Nature 349:254-256, 1991).
- thioredoxin DNA is over-expressed in certain human tumor cells resulting in the over production of thioredoxin.
- human tissue pathology samples were embedded and used it to study thioredoxin protein levels with a panel of human primary gastric carcinoma tissue samples, it has been found that thioredoxin is present in dividing normal basal crypt cells. It has been further learned that, as the cells differentiate and move down the villi to eventually be shed into the gastric lumen, thioredoxin levels decrease.
- Trx was originally studied for its ability to act as a cofactor for ribonucleotide reductase, the first unique step in DNA synthesis (Laurent, T. C, et al., J. Biol. Chem., 239:3436-3444, 1964). Human Trx was subsequently shown to modulate the DNA binding of several transcription factors that regulate cell proliferation, including nuclear factor KB (Hayashi., T, et al., J. Biol. Chem. 268:11380-11388, 1993), the glucocorticoid receptor (Grippo, J. F, et al., J. Biol. Chem.
- Trx is not taken up by cells (Gasdaska, J R., et al., Cell Growth & Differ., 6:1643-1650, 1995) and appears to stimulate cell growth by enhancing the action of other growth factors (Gasdaska, J.
- Trx redox activity of Trx is required for growth stimulation, and redox-inactive mutant Trxs do not stimulate cell growth (Oblong, J. E, et al., J. Biol. Chem., 269:11714-11720, 1994).
- Trx mRNA levels are increased compared with corresponding normal tissue in almost half human primary lung (Gasdaska, P. Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994) and colon tumors examined (Berggren, M, et al., Anticancer Res., (in press) 1996).
- Trx protein has been reported to be increased in human cervical neoplastic squamous epithelial cells (Fujii, S, et al., Cancer (Phila.), 68:1583-1591, 1991) and hepato-cellular carcinoma (Nakamura, H, et al., Cancer (Phila.), 69:2091-2097, 1992).
- Trx is excreted from cells (Ericson, M. L, et al., Lymphokine Cytokine Res., 11:201-207, 1992; Rubartelli, A, et al., J. Biol. Chem., 267:24161-24164, 1992; Rubartelli, A. et al., Cancer Res., 55:675-680, 1995) using a leaderless secretory pathway. (Rubartelli, A, et al., J. Biol. Chem., 267:24161-24164, 1992), and we have suggested that Trx might be a growth factor for some human cancers (Gasdaska. J.
- Trx plays in the transformed phenotype or cancer cells also is not known.
- the cDNAs were cloned into either the KpnI or SacI sites of the pRXneo mammalian transfection vector, under constitutive control of the Rous sarcoma virus promotor (Dieken, E. S, et al., Mol. Cell. Biol, 12:589-597, 1992), or into the NotI site of the pDC304neo mammalian transfection vector, in which constitutive expression is driven by the cytomegalovirus and SV-10 promoters (Gordon, D. A, et al., Exp. Cell Res., 217:368-377, 1995). Correct orientation of the cDNAs in the vectors was confirmed by restriction digestion.
- the pRXneo and pDC304neo vectors were obtained from Dr. Roger Miesfeld (University of Arizona, Arlington, Ariz.).
- NIH 3T3 cells Human MCF-7 breast cancer cells and murine NIH 3T3 cells were obtained from the American Tissue Type Collection. (Rockville, Md.), maintained in DMEM containing 10% FBS under 6% CO 2 at 37° C., and passaged before confluence. NIH 3T3 cells were transfected with Trx:pRXneo, Trx:pDC304neo, C32S/C35S:pDC304neo, or pRXneo alone. MCF-7 cells were transfected with Trx:pDC304neo, C32S/C35S:pDC304neo, or pDC304neo alone.
- Transfection used liposomes of N-[1,2,3-dioleolylpropyl]-N,N,N-trimethylammonium-methylsulfate (Boehringer Mannheim, Indianapolis, Ind.) according to the manufacturer's instructions. Cells were selected by growing for 4 weeks in DMEM with 10% FBS and 400 ⁇ g/ml G418 sulfate (Life Technologies, Gaithersburg, Md.). Cell colonies were isolated by trypsinization onto small squares of sterile filter paper and expanded by growing in the same medium. All studies were conducted on clonal cell lines between passages 3 and 10.
- Trx and C32S/C35S mRNA used a full-length [ ⁇ - 32 P]dCTP-labeled human Trx cDNA probe as described previously (Gasdaska, P. Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994), and the blots were quantified using a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.). Transfected Trx and C32S/C35S mRNA levels were expressed relative to endogenous Trx mRNA levels in the cells.
- MCF-7 cells Colony formation by MCF-7 cells was measured in soft agarose with DMEM and 10% FBS over 7 days, as described previously, (Alley, M. C, et al., Br. J. Cancer, 52:205-224, 1985).
- Tumor formation by transfected NIH 3T3 cells was studied by the s.c. injection of 10 7 transfected cells in 0.1 ml of sterile 0.9% NaCl into the backs of groups of four male Scid mice or six nude mice.
- Tumor formation by MCF-7 cells was studied by injecting 2 ⁇ 10 7 cells in 0.1 ml of sterile 0.9% NaCl and 0.1 ml of Matrigel (Becton Dickinson, Bedford, Mass.) s.c. into the backs of groups of four female Scid mice that had been implanted s.c. 2 days previously with 21-day release pellets of 0.25 mg of 17-P-estradiol (Innovative Research, Sarasota, Fla.).
- the 17-P-estradiol pellet was replaced at 21 days. Tumor volume was measured with calipers (Geran, R. I, et al., Cancer Chemother. Rep., 3:1-103, 1972) twice a week for 40 days. At the end of the study, the animals were killed, and tumors and other organs were taken for histological analysis.
- Transfection of mouse NIH 3T3 cells with Trx:pRXneo yielded 6 clones stably expressing Trx mRNA
- transfection with Trx:pDC304 yielded 4 clones
- transfection with C32S/C35S:pDC304 neo yielded 12 clones.
- the levels of transfected mRNA in some of the clones is shown in FIG. 6 .
- the human Trx and C32S/C35S mRNAs were larger than the endogenous mouse Trx mRNA, probably because the transfected Trx mRNAs also contain portions of the vector promoter region, the 5′ leader sequence, or the polyadenylate tail.
- the level of transfected Trx mRNA expression was relatively low, being only 0.2-1.4-fold the endogenous mouse Trx mRNA.
- Western blotting showed no significant increase in the level of Trx protein in the cells compared with wild-type or vector alone-transfected cells (results not shown).
- the Trx-transfected NIH 3T3 cells grew at the same rate on a plastic surface, but reached saturation densities up to twice that of the vector alone-transfected NIH 3T3 cells ( FIG. 7 ).
- the vector alone-transfected cells had the same growth characteristics of wild-type NIH 3T3 cells.
- NIH 3T3 cells transfected with the redox-inactive C32S/C35S Trx grew more slowly and reached a lower saturation density on a plastic surface than the vector alone-transfected cells.
- Neither the vector alone-transfected NIH 3T3 cells nor the Trx or C32S/C35S Trx transfected cells formed colonies in soft agarose (results not shown).
- Trx-transfected NIH 3T3 cells The ability of transfected NIH 3T3 cells to form tumors when inoculated into immunodeficient mice is used to identify neoplastic transforming genes (Pitot, H. C. Fundamentals of Oncology, p. 149. New York: Marcel Dekker, Inc., 1981).
- Trx-transfected NIH 3T3 cells Thio6 or ThioAD were injected i.m. into Scid or nude mice, there was no tumor formation over 40 days (results not shown).
- Trx expression at least at the level obtained in this study, was not, by itself, transforming.
- Transfection of MCF-7 cells with Trx:pDC304neo yielded 31 clones that stably overexpressed Trx mRNA, and transfection with C32S/C35S:pDC304neo yielded 45 clones stably expressing C32S/C35S mRNA.
- Expression of transfected mRNAs by some of the clones is shown in FIG. 9 .
- the transfected human Trx mRNAs in MCF-7 cells were larger than endogenous human Trx mRNA.
- the level of Trx mRNA expression was up to 0.8-fold and C32S/C35S mRNA up to 2.1-fold of the endogenous Trx mRNA levels.
- the Trx-transfected cells showed linear growth characteristics on plastic surfaces over 7 days.
- the Trx-transfected cells grew at the same rate as the vector alone-transfected MCF-7 cells ( FIG. 11 ). However, when grown in the absence of, or with 0.5% FBS for 2 days, the Trx-transfected cell grew at twice the rate of the vector alone-transfected cells (results not shown).
- the C32S/C35S-transfected cells grew at a significantly slower rate that was 56-78% of the vector alone-transfected cells ( FIG. 11 ).
- Colony formation was significantly increased between 3- and 4-fold for the Trx-transfected MCF-7 cells compared with the vector alone-transfected cells, and significantly decreased up to 73% for the C32S/C35S-transfected cells when the cells were grown in soft agarose.
- the vector alone-transfected cells showed growth characteristics identical to those of wild-type MCF-7 cells under all conditions (results not shown).
- Trx-transfected MCF-7 cells formed tumors in Scid mice, although they grew at a significantly slower rate than tumors formed by vector alone-transfected cells: 57% for Trx 12 cells and 38% for Trx 20 cells (both P ⁇ 0.05 by least squares regression analysis; FIG. 12 ). Tumor formation by the C32S/C35S-transfected MCF-7 cells was almost completely suppressed. Tissues from the injection site and other organs were taken for histological examination at the end of the study. The animals injected with vector alone or Trx-transfected cells showed large solid tumors.
- Trx levels in Transfected Mcf 7 Breast Cancer Cells and Media Clone Cell a Medium MCF-7 vector 1.0 ⁇ 0.0 1.0 ⁇ 0.0 Trx 9 0.9 ⁇ 0.0 1.6 ⁇ 0.5* Trx 12 1.2 ⁇ 0.1* 1.2 ⁇ 0.2 Trx 20 1.1 ⁇ 0.1 1.5 ⁇ 0.2 Serb 4 0.9 ⁇ 0.1 1.6 ⁇ 0.6* Serb 15 0.8 ⁇ 0.2 1.3 ⁇ 0.2 Serb 19 1.2 ⁇ 0.1* I.6 ⁇ Trx or redox-inactive C32S/C35S (Serb)-transfected MCF-7 breast cancer cells (10 6 ) were incubated in 5 ml of DMEM for 6 hr.
- Serb redox-inactive C32S/C35S
- Trx in the original cell pellet or in the medium measured by quantitative Western immunoblotting. Values are a mean of three separate determinations expressed relative to vector alone-transfected cells. a *P ⁇ 0.05 by a nonpaired/test compared with vector alone-transfected cells.
- Trx regulates the redox state and activity of a number of intracellular proteins that control cell growth, including ribonucleotide reductase (Laurent, T. C, et al., J. Biol. Chem., 239:3436-3444, 1964) and the DNA binding of several transcription factors (Hayashi, T, et al., J. Biol. Chem. 268:11380-11388, 1993; Grippo, J. F, et al. J. Biol. Chem., 258:13658-13664, 1983; Abate, C, et al., Science (Washington D.C.), 249:1157-1161, 1990).
- ribonucleotide reductase ribonucleotide reductase
- Trx Recombinant human Trx added to normal and cancer cells in culture stimulates their proliferation (Gasdaska, J. R, et al., Cell Growth & Differ., 6:1643-1650, 1995). However, it has not been demonstrated that endogenously produced Trx can stimulate cell proliferation. Furthermore, the role Trx may play in malignant transformation of cells is not known. The present study was undertaken to address some of these questions. NIH 3T3 cells transfected with Trx showed an increased cell saturation density when grown as a monolayer on plastic surfaces. Loss of contact inhibition is a feature of transformed cells (Pitot. H. C., Fundamentals of Oncology , p.
- Trx-transfected NIH 3T3 cells did not form tumors when inoculated into immunodeficient mice.
- the Trx-transfected MCF-7 cells did not show increased growth on plastic surfaces in normal FBS, but exhibited significantly increased anchorage-independent growth measured by colony formation in soft agarose.
- Trx-transfected MCF-7 cells were grown as xenografts in Scid mice, they exhibited decreased growth rate compared with vector alone-transfected MCF-7 cells. This may be because human Trx can stimulate the immune system of mice so that Trx secreted by the transfected MCF-7 cells might promote some immune rejection, even by the Scid mice, which, although deficient in mature B and T lymphocytes, have natural killer-, myeloid-, and antigen-presenting cells (Shultz, L. D. Am. J. Anat., 191:303-311, 1991).
- C32S/C35S is a redox-inactive mutant Trx that acts as competitive inhibitor of Trx reductase (Oblong, J. E, et al., J. Biol. Chem., 269:11714-11720, 1994).
- C32S/C35S acts in a dominant-negative manner to inhibit the effects of endogenous Trx and, in so doing, inhibits cell growth and reverses the transformed phenotype of MCF-7 breast cancer cells.
- Trx is known to be secreted from cells by a leaderless secretory pathway (Rubartelli, A, et al., J. Biol. Chem., 267:24161-24164, 1992).
- concentrations of Trx found in the medium up to 10 nm after 6 hr, are lower than those required to directly stimulate cell proliferation (Gasdaska, J.
- Trx binds to the surface of cells (Gasdaska, J. R, et al., Cell Growth & Differ., 6:1643-1650, 1995; Ifversen, P, et al., Hum. Antib. Hybrid, 4:115-123, 1993) so that secreted Trx could have a local effect at the outer cell surface although concentrations in the medium are low.
- Trx miRNA levels were not high, only up to 1-fold endogenous trx mRNA levels, and were independent of the mammalian transfection vector used. Typically mRNA levels resulting from transfection using such vectors are 10-50-fold or higher (Powis, G, et al., Anticancer Res., 15:1141-1146, 1995). It may be that high levels of Trx gene expression are toxic to cells. We have found only a low expression of the human Trx gene in transgenic mice. In contrast, some human tumors show very high levels of Trx mRNA compared with the normal tissue: more than 11-fold in human primary lung tumors (Gasdaska, P, et al., Proc. Am. Assoc.
- Trx reductase a redox-inactive dominant-negative Trx reverses the transformed phenotype of MCF-7 cells
- drugs that inhibit the redox activity of Trx might offer a novel approach to treating some forms of human cancer.
- inhibiting the enzyme responsible for the reduction of trx, the flavoprotein Trx reductase might also lead to a selective inhibition of cancer cell growth.
- some antitumor quinones, including doxorubicin and diaziquone are mechanism-based (suicide substrate) inhibitors of Trx reductase both in the purified form and in intact cells (Mau, B. L, et al., Biochem. Pharmacol, 43:1621-1626, 1992).
- Trx stable transfection of nontransformed mouse fibroblast-like cells and human breast cancer cells with human Trx leads to low levels of overexpression and increased cell saturation densities but no transformation, measured by tumor formation of NIH 3T3 cells in immunodeficient mice
- Stable transfection with redox-inactive mutant Trx results in a dominant-negative effect with inhibition of mouse cell and human breast cancer cell growth and reversion of the transformed phenotype of human breast cancer cells, measured by their ability to form colonies in soft agarose and to form tumors in mice.
- the Trx produced appears to be secreted mostly from cells, and whether the Trx is having an intracellular or extracellular action remains to be determined.
- thioredoxin was over-expressed in tumor cells compared to normal mucosa, and in all cases the over-expression was found only in the cancer cells and not in stromal cells or infiltrating lymphocytes. Levels of thioredoxin significantly higher than in normal dividing cells, were found in 5 ⁇ 8 of the over-expressing carcinomas.
- nuclear proliferation antigen was detected by Ki67 antibody and apoptosis by the in situ terminal deoxynucleotidyl transferase (TUNEL) assay were measured in the same tissue samples. (See Table 2).
- Thioredoxin expression was significantly and highly positively correlated with-nuclear proliferation antigen (p ⁇ 0.01) a marker of aggressive tumor growth and highly negatively correlated with apoptosis (p ⁇ 0.001) a form programmed cell death that is presumed to limit tumor growth.
- thioredoxin is over-expressed at the mRNA and protein level in a number of human primary tumors. Further, the expression of thioredoxin protein is directly associated with highly proliferative tumors.
- MCF-7 human breast cancer cells were transfected with cDNA for thioredoxin or with a catalytic site redox-inactive mutant thioredoxin, C32S/C35S, using two constitutive eukaryotic expression vectors (pRXneo and pDC304neo) and a number of clones were selected for each.
- the level of transfected thioredoxin and C32S/C35S thioredoxin mRNA was up to 2-fold the endogenous message. Both types of transfected cells showed increased thioredoxin protein production, measured by quantitative Western blotting, up to 100% that of mock-transfected cells.
- thioredoxin transfected cells formed tumors while the C32S/C335S transfected cells did not form tumors, as illustrated in FIG. 5 . This was confirmed by histology.
- a dominant-negative redox inactive thioredoxin can reverse the transformed phenotype and inhibits tumor growth in vivo providing molecular biology evidencing that thioredoxin is a novel target for anti-cancer drug development.
- thioredoxin is a known protein, it has not been disclosed or suggested that thioredoxin be used as a screen for anti-tumor agents. It has now been shown that stable transfection of the MCF-7 breast cancer cells with a redox-inactive mutant thioredoxin causes inhibition of anchorage-independent growth of the cells in soft agarose and causes complete inhibition of tumor formation in vivo.
- the redox-inactive mutant is formed from thioredoxin where the catalytic site cysteine residues are replaced with serine.
- mutant thioredoxin did not inhibit monolayer growth of the cells, i.e., does not inhibit normal cell growth, while it causes inhibition of anchorage-independent growth of the cells in soft agarose, i.e., does inhibit an in vitro characteristic of tumor cell growth. This is the activity that would be expected from drugs that inhibit thioredoxin.
- agents that inhibit thioredoxin may be antibodies, drugs or antisense.
- a series of unsymmetrical 2-imidazolyl disulfides were investigated as inhibitors of the thioredoxin system and as potential anti tumor agents.
- these agents such as 1-methylpropyl 2-imidazolyl disulfide, were originally identified as competitive inhibitors of thioredoxin reductase (Oblong J E, et al., Cancer Chemother. Pharmacol, 34:434-438, 1994) but it has now been shown that they also to bind irreversibly to Cys 73 of thioredoxin and to block its reduction by thioredoxin reductase.
- thioredoxin reductase is useful as an anti-cancer drug target. It has now been shown above that redox activity is necessary for the growth stimulating activity of thioredoxin. Since thioredoxin reductase is the only known way for thioredoxin to be reduced biologically it is an obvious extension of the above observations that thioredoxin reductase could also be a target for the development of anti-cancer drugs.
- human thioredoxin and specifically recombinant modified thioredoxin (mutated thioredoxin), does not undergo spontaneous oxidation and/or dimer formation, or protected against breakdown by blood and tissues, may have therapeutic utility in situations where stimulation of cell growth is preferred or required.
- such new uses include, and are not limited to, the beneficial use of thioredoxin and/or recombinant modified thioredoxin in stimulating cell proliferation in individuals (1) with myelodysplastic syndrome; (2) in need of bone marrow transplantation; (3) with post-chemotherapy to stimulate bone marrow growth; (4) in need of stimulation of the immune system; (5) in need of stimulation of wound healing; (6) such as transgenic animals in need of stimulation of body growth; (7) in need of simulation of the responses to cytokines and growth factors for growth stimulation effects; and (8) in gene therapy techniques.
- the underlying defect in myelodysplastic syndrome is decreased multilineage progenitor cell growth associated with decreased sensitivity to growth factor stimulation.
- Thioredoxin acts to increase the sensitivity of cells to growth factors and stimulates multilineage progenitor cells which provides a beneficial utility in individuals with MDS.
- Thioredoxin may be used to protect hematopoietic progenitor cells and to expand cells ex vivo for bone marrow cell growth. This would rely on a selective effect for bone marrow since tumor cells might also be stimulated by the thioredoxin.
- Cys73->Ser mutant thioredoxin will stimulate the proliferation of human immune cells in culture, which can provide a great benefit to individuals in need of stimulation of immune system cells.
- Wild-type and Cys73->Ser mutant thioredoxin also stimulates the growth of fibroblasts, which are important components of wound healing process. There would be a great advantage of using thioredoxins to stimulate wound healing, for example after surgery.
- transgenes with wild-type or mutant forms of thioredoxin, with or without tissue specific and/or inducible promoters, could be used to stimulate the development of the animal or the growth of selected organs.
- thioredoxin can potentiate the response of cells in culture to growth factors and cytokines such as IL-2 and basic fibroblast growth factor (bFGF). Combinations of thioredoxin with other growth factors or cytokines therefore increases the therapeutic usefulness of these growth factors where increased cell proliferation is the desired therapeutic effect.
- cytokines such as IL-2 and basic fibroblast growth factor (bFGF).
- thioredoxin or mutant thioredoxin genes into human cells provides a mechanism of improving the therapeutic usefulness of other cytokines or growth factors given directly or themselves as gene therapy, for example IL-2.
- thioredoxin mRNA has been found to be over expressed by some human tumor cells, it has been discovered that thioredoxin, specifically recombinant modified thioredoxin also stimulates cell growth.
- thioredoxin A novel mechanism or over-expression and secretion from the cells by a leaderless secretory pathway has important consequences for potential therapeutic uses of thioredoxin as explained below. It has been discovered that human recombinant thioredoxin undergoes spontaneous oxidation in air to give a form that will not stimulate cell growth. This spontaneous oxidation appears to involves Cys73 since a mutant thioredoxin where this residue has been converted to serine (Cys73->Ser thioredoxin) does not undergo this loss of activity.
- thioredoxin has a highly conserved hydrophobic dimer forming surface and that Cys73 stabilizes homodimer formation through a Cys73-Cys73 disulfide bond (Weichsel A, et al. Structure 4:735-751 (1996)).
- the active site Cys residues become relatively inaccessible in the thioredoxin homodimer so that it is a very poor substrate for thioredoxin reductase.
- the thioredoxin homodimer does not stimulate cell proliferation.
- the half life of recombinant human thioredoxin in phosphate buffered 0.9% NaCI at ⁇ 20° C. is 6-8 days.
- the wild type thioredoxin is not a good protein for therapeutic use because of is tendency to oxidize and lose biological activity.
- Cys73->Ser mutant Thioredoxin stimulates the growth of bone marrow was obtained directly by adding Cys 73 ->Ser mutant thioredoxin directly to human bone marrow and studying its effects on colony formation by the cells, as illustrated in FIG. 1 .
- Cys73->Ser mutant thioredoxin stimulates colony formation by the multilineage progenitor cells (CFU-GEMM) but does not stimulate the lineage specific erythroid progenitor (BFU-E) and myeloid progenitor (CFU-GM) cells.
- Cys73->Ser mutant thioredoxin in accordance with the present invention.
- Human bone marrow was obtained as excess material from normal allogeneic bone marrow donors.
- the effects of Cys 73 ->Ser thioredoxin on colony formation are shown by (o) multilineage progenitors (CFU-GEMM); (•) erythroid progenitors (BFU-E); and ( ⁇ ) myeloid progenitors (CFU-GM), as measured over 10 days as described. (Values are the mean of 4 determinations and bars are S.D.)
- FIG. 2 illustrates potentiation of IL-2 induced MCF-7 breast cancer cell growth by Cys73->Ser mutant thioredoxin, in accordance with the present invention.
- Cells were growth arrested for 48 hr, in medium with 0.5% serum (10 s cells) then stimulated in the absence of medium with either IL-2 or Cys32->Ser mutant thioredoxin at the concentrations shown, Cell number was measured after 48 hr.
- Each point on the chart represents the mean of 3 determinations and bars represent S.E.
- the dotted line shows stimulation by 10% serum.
- FIG. 3 illustrates the inhibition of thioredoxin stimulated MCF-7 cell growth by receptor antibodies, in accordance with the present invention.
- Cell proliferation was measured as described above in the context of FIG. 2 .
- the concentrations of agents used were Cys73->Ser mutant thioredoxin (Thioredoxin) 1 ⁇ M; monoclonal antibodies to FGF receptor, IL-2-receptor and EGF-receptor 4 ⁇ g/ml; and EGF 10 nM.
- the EGF and EGFR were added as a negative control. Values represent the mean of 3 determinations and bars represent S.E.
- the dotted line shows the effect of 10% serum alone.
- Thioredoxin/mutant thioredoxin may have use after bone marrow transplantation of cancer patients or together with chemotherapy to stimulate bone marrow recovery, or to stimulate the immune system in patients with AIDS.
- There may be other potential therapeutic applications for thioredoxin/mutant thioredoxin such as increasing the rate of wound healing. If a thioredoxin or mutant thioredoxin gene could be introduced into an animal as a transgene this might result in an increased growth rate of the animal.
- a thioredoxin transgenic mouse has been developed, although the levels of gene expression are very low and the animal does not show an increased growth rate. However, a gene for mutant thioredoxin might be more effective in this regard.
- mutant thioredoxins may not be limited to the Cys73->Ser mutant. Mutation of the other Cys residues can also affect biological activity. There are also other amino acid residues on the hydrophobic domain of the molecule that X-ray crystallographic studies have shown might also be important for dimer formation. Mutation of these and possibly other amino acid residues, might alter the biological activity of thioredoxin.
- Trx Thioredoxin
- Trx can exist in monomeric forms, some of which are mediated by Cys 73 that do not stimulate cell proliferation but can be reduced by thioredoxin reductase. Cys 73 is also involved in formation of an enzymatically inactive homodimer, which occurs on long term, storage or by chemical oxidation. Thus, although clearly involved in protein inactivation, Cys 73 is not necessary for the growth stimulating activity of Trx.
- Trx is a redox protein found in both eukaryotes and prokaryotes (Holmgren A., Annu. Rev. Biochem., 54:237-271, 1985).
- the redox activity of Trx arises from a highly conserved Trp-Cys-Gly-Pro-Cys-Lys active site sequence where the 2 cysteine residues (Cys) undergo reversible oxidation to cystine.
- Reduction of Trx is catalyzed by thioredoxin reductase (Luthman M, et al., Biochem., 21:6628-6633, 1982).
- Trx was originally identified in Escherichia coli as a hydrogen donor for ribonucleotide reductase (Laurent T C, et al., J. Biol. Chem., 239:3436-3444, 1964). Trx has since been found to act as an intracellular dithiol-disulfide reductase and to modulate the activity of a number of intracellular proteins (Fountoulakis M., J. Biol. Chem., 267:7095-7100, 1992; Kistner 25 A. et al., Toxicon., 31:1423-1434, 1993; Silverman R B et al., Biochem. Biophys. Res.
- Trx-like sequences are found in other proteins including protein disulfide isomerase (Freedman R B et al., Trends Biochem.
- Trx may play a role in the growth and transformed phenotype of some cancers. Trx is over expressed by a number of human cancers compared with normal tissue (Berggren M, et al., Anticancer Res. 17:3377-3380, 1997); Gasdaska P Y et al., Biochem. Biophys. Acta, 1218:292-296, 1994, Nakamura H, et al., Cancer 69:2091-2097, 1992).
- Trx acts exogenously as a redox-active growth factor.
- Human Trx is identical to the leukemic cell autocrine growth factor adult T-cell leukemic factor (Gasdaska P Y et al., Biochem. Biophys. Ada., 1218:292-296, 1994), and stimulates the growth of both normal fibroblasts (Oblong J E et al., J. Biol. Chem., 269:11714-11720, 1994) and human hematologic and solid tumor cancer cells in culture (Wakasugi N, et al. Proc. Natl. Acad.
- Trx appears to act by a helper mechanism that sensitizes the cells to growth factors secreted by the cells themselves (Gasdaska J R et al., Cell Growth Differ, 6:1643-1650, 1995).
- Trx Mutant human Trxs, where the Cys 32 and Cys 35 residues at the catalytic site (numbering of amino acid residues is from the N-terminal methionine, although this may be removed in some forms of Trx) are converted to serines (Ser) either singly or together, are redox inactive and do not stimulate cell growth (Oblong J E, et al., J. Biol. Chem., 269:11714-11720, 1994). Trx is secreted from cells by a leaderless secretory pathway (Rubartelli A, et al., J. Biol. Chem., 267:24161-24164, 1992) and could be acting as an autocrine factor for the growth of some cancer cells (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995).
- E. coli Trx unlike human Trx, does not stimulate the growth of human solid cancer cells (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995).
- the structures of E. coli and human Trx are similar, and both are substrates for human thioredoxin reductase.
- the surface residues of the two forms vary considerably (Weichsel A, et al., Structure 4:735-751, 1996).
- Trx has 3 additional cysteine residues, Cys 62 , Cys 69 and Cys 73 , in addition to those in the active site, which do not normally form intramolecular disulfide bonds (Weichsel A, et al., Structure 4:735-751, 1996; Forman-Kay J D et al., Biochem., 30:2685-2698, 1991). Trx can also form a homodimer with al 100 A 2 interface domain and a disulfide bond between Cys 73 from each monomer (Weichsel A, et al., Structure 4:735-751, 1996).
- Trx During our studies of cell growth stimulation by Trx we observed that storage of the Trx without a reducing agent for even a few days resulted in a loss of its growth-stimulating activity, although the Trx remained a substrate for reduction by thioredoxin reductase. We have, therefore, examined the, role of spontaneous and induced oxidation of Trx and cysteine-deleted mutant Trxs, and their ability to stimulate cell proliferation.
- Cys 32 ->Ser/Cys 35 ->Ser mutant Trx (C32S/C35S) were prepared and purified as previously described (Oblong J E et al., J. Biol. Chem., 269:11714-11720, 1994). Cys 73 ->Ser mutant human Trx (C73S) was prepared from single-stranded, sense strand human Trx cDNA ligated by polyethylene glycol precipitation into the pBluescript KS vector (Stratagene, La Jolla, Calif.) using helper phage.
- the single-stranded cDNA was used for oligonucleotide-directed in vitro mutagenesis (Version 2.1 Kit, Amersham, Buckinghamshire, U.K.) using oligonucleotide 5′-TGTTGCATGGATTTGACTTC-3′. Point mutagenesis was confirmed by dideoxy sequencing of base-denatured double-stranded. DNA using the Sequenase Version 2.0 kit (USB, Cleveland, Ohio). Novel Nde1 and BamH1 restricted sites were introduced at the 5′ and 3′ ends of the mutant Trx cDNA by oligonucleotide-directed PCR.
- Ndel/BamHI restricted fragments were extracted from agarose gels, ligated into a suitably restricted pET-3a expression vector (Studier F W et al., Methods Enzymol., 185:60-89, 1991), transformed into E. coli BL21 cells and confirmed by dideoxy sequencing.
- C73S Trx was expressed and purified as previously described (Oblong J E et al., J. Biol. Chem., 269:11714-11720, 1994). All Trxs were stored at ⁇ 20° as a 25 ⁇ M stock solution in 5 mM DTT. Before use, the DTT was removed by passing the Trx solution through a PD-10 desalting column (Pharmacia, Uppsala, Sweden).
- Trx solution was kept at 4° and used within 2 hr. (fresh) or stored in water or 0.1 M potassium phosphate-buffered 0.9% NaCI at 4° or ⁇ 20° for specified times.
- Oxidized Trx for cell growth studies was prepared by adding a 5-fold molar excess of H 2 O 2 , to a 25 ⁇ m Trx stock solution without DTT and 1 hr. later removing unrecalled H 2 O 2 using a PD-10 column.
- MCF-7 human breast cancer cells were obtained from the American Type Culture Collection (Rockville, Md.) maintained in DMEM containing 10% fetal bovine serum at 37° and 6% CO 2 , and passaged at 75% confluence.
- the effect of Trx and modified Trxs on MCF-7 cell growth was determined as previously described (Gasdaska J R et al., Cell Growth Differ., 6:1643-1650, 1995). Briefly, 105 cells were plated in a 35-mm culture dish in DMEM containing 10% fetal bovine serum and, after attachment for 24 hr., growth arrested using DMEM with 0.5% fetal bovine serum for 48 hr. The medium was then replaced with DMEM containing Trx or other additions for 2 days and cell number measured with a hemocytometer. All incubations were conducted in triplicate.
- Trx reduced/min/mg protein Human placenta thioredoxin reductase, specific activity 33.3 ⁇ mol Trx reduced/min/mg protein, was prepared as previously described (Oblong J E et al., Biochem., 32:7271-7277, 1993). Reduction of Trx and C73S by thioredoxin reductase was measured by the oxidation of NADPH at 340 nM with insulin as the final electron acceptor as described by Luthman and Holmgren (Luthman M, et al., Biochem., 21:6628-6633, 1982).
- Trxs A 25 ⁇ M solution of fresh Trx, mutant C73S or C32S/C35S Trxs, Trxs that had been aged at room temperature for 48 hr., 7 days, 90 days; or Trxs treated for 1 hr. with 1 mM diamide, 10 mM DTT, 3 mM 2-mercaptoethanol or 2:1 (v:v) H 2 O 2 , was mixed with an equal volume of loading buffer containing 3% SDS, 10% glycerol and 0.1% bromophenol blue in 0.05 M Tris-HCI, pH 6.8.
- Approximately 0.02 ng of the protein was 30 loaded in each lane of a 24 ⁇ 45 cm 16.5% polyacrylamide resolving gel (pH 8.4) containing 0.3% SDS, a 10% spacer gel and a 6% stacking gel and separated by electrophoresis using an anode buffer of 0.2M Tris-HCI, pH 8.9 and cathode buffer of 0.1 M Tris-HCI, 0.1% SDS, pH 8.2.
- the gel was run for 1. hr. at 400 volts before loading the samples and then at 400 volts for 24 hr. before fixing in 50% methanol, 7.5% acetic acid for 20 min, followed by 5% methanol, 7.5% acetic acid for 20 min, followed by 10% glutaraldehyde for 20 min.
- the gel was soaked in 2 L H 2 O overnight to remove unbound SDS and then silver stained (ICN Silver Stain Kit, Irvine, Calif.), Similar observations were made when the gels were stained with Coomassie Blue.
- Cys 73 ->Ser mutant Trx stimulated the proliferation of human MCF-7 breast cancer cells.
- the EC 50 for growth stimulation by C73S was 350 nM and the maximum effect was seen at 1 ⁇ M, which is similar to values we have previously reported for stimulation of MCF-7 cell proliferation by recombinant human Trx (Gasdaska J R et al., Cell Growth Differ 6:1643-1650, 1995).
- Storage of Trx in the absence of a reducing agent such as DTT at 40 for 5 days resulted in a 78% loss, and for 90 days a 98% loss of cell growth stimulating activity ( FIG. 13 ).
- C37S showed no loss of activity when stored under these conditions. Trx stored in the presence of bovine catalase at 1 unit/ml did not lose biological activity over a 5-day period (results not shown).
- C73S was a good substrate for reduction by human placental thioredoxin reductase with a K m of 0.20 ⁇ M and a V max of 6.3 nmol/min/ ⁇ g. These values are similar to those we have previously found for fresh Trx, which were a K m of 0.33 ⁇ M and a V max of 5.9 nmol/min/ ⁇ g (Oblong J E et al., Biochem., 32:7271-7277, 1993).
- Trx When stored in H 2 O either at ⁇ 20° or at room temperature Trx showed a loss of activity with a half-life of 20-30-days. The loss of Trx activity was more rapid when stored in phosphate-buffered 0.9% NaCl, with a half life of 8 days.
- Phosphate buffer is known to contain small amounts of iron (Poyer J L et al., J. Biol. Chem., 246:263-269, 1971), which could catalyze an oxidative process increasing the loss of Trx activity.
- Trx the lower pH of the solution in water could stabilize Trx or the increase in ionic strength of phosphate-buffered 0.9% NaCl could enhance the formation of the inactive homodimer of Trx.
- the aged Trx showed a slow, delayed reduction by thioredoxin reductase that was stimulated by catalytic amounts of fresh Trx ( FIG. 14 ). It is important to note that the loss of activity of Trx as a substrate for thioredoxin reductase was much slower than the loss of activity as a stimulator of cell growth. C73S did not show a loss of activity as substrate for thioredoxin reductase upon storage for up to 30 days.
- Trx The ability of Trx to act as a substrate for thioredoxin reductase was completely inhibited by treatment with 5 molar equivalents of H 2 O 2 , whereas C37S remained fully active after treatment with 100 molar equivalents of H 2 O 2 ( FIG. 15 ).
- Trx 30.5 20.1 8.2 7_8 C73S stable* stable* stable* stable* stable* stable* stable* 25 ⁇ Mstock solution of Trx of C73S in H 2 O or phosphate buffered 0.9% NaCl (PBS) free of D77 were stored frozen at ⁇ 20° or at room temperature (+21°) for up to 60 days and their ability to act as a substrate for reduction by human placental thioredoxin was measured. A first order decrease in activity was found for Trx and the results are expressed as half-life * ⁇ 10% loss of activity over 30 days.
- Electrophoretic analysis of freshly prepared human Trx stored in DTT showed a mixture of 5 bands of apparent molecular weights ranging from 8.1 to 11 kDa ( FIGS. 16 , 17 , and 18 , lane 1).
- Storage of Trx at room temperature without DTT resulted in a change in the banding pattern with disappearance of the 8.1-kDa band by 48 hr. ( FIG. 16 , lane 2).
- Storage of Trx without DTT for 7 days resulted in the loss of additional bands and the appearance of a new band at 23 kDa due, apparently, to a Trx dimer ( FIG. 16 , lane 3).
- Storage of Trx without DTT for 90 days at 4° resulted in almost complete conversion to the Trx dimer ( FIG.
- Trx dimer formation was seen when Trx was treated with diamide, a protein thiol oxidizing agent (Kosower N S et al., Methods. Enzymol, 251:123-132, 1995) ( FIG. 17 , lane 5). The formation of Trx dimer following diamide treatment was also confirmed by gel permeation chromatography (results are not shown).
- Trx H 2 O 2 treatment of Trx also caused dimerization but produced a different banding pattern to that produced by diamide ( FIG. 17 , lane 6).
- NEM NEM
- a thiol alkylating agent Gilbert H F, Methods Enzymol., 251:8-30, 1995
- FIG. 17 , lane 4 Treatment of 7 day aged Trx with NEM produced both the higher molecular weight band as in FIG. 17 , lane 4, and the bands illustrated in FIG. 17 , lane 2 (data not shown), suggesting that in the aged Trx not all the sulfhydryls are available for covalent modification.
- Freshly prepared C73S Trx and C32S/C35S Trx showed fewer bands than wild type Trx ( FIG. 18 , lanes 2 and 3, compared with lane 1).
- Treatment of C32S/C35S Trx with diamide resulted in the formation of a 23-kDa dimer ( FIG. 18 , lane 6).
- Treatment of C7 1 )S Trx with diamide caused the bands to coalesce into a single band of around 10 kDa, but there was no 23-kDa dimer formed ( FIG. 18 , lane 4).
- the effects of diamide on C37S and 02S/05S were reversed by treatment with DTT ( FIG. 18 , lanes 5 and 7).
- Trx undergoes at least 2 levels of spontaneous and induced oxidative transformation.
- the first oxidation occurs spontaneously within a few days to a form(s) that can no longer stimulate cell growth but remains a substrate for thioredoxin reductase.
- the slower oxidation occurs over a period of weeks, or can be induced by the thiol oxidizing agent diamide, and leads to a disulfide banded homodimer which not only fails to stimulate cell growth but is a poor substrate for thioredoxin reductase.
- Trx can be induced by chemical oxidation, are protected against by catalase and are reversed by the thiol reducing agent DTT is consistent with the interpretation that the changes in Trx are due to oxidation.
- Cys 73 appears to play a critical role in both levels of oxidant-induced inactivation since C73S does not lose the biological activity or its ability to act as a substrate for thioredoxin reductase upon aging.
- Trx fresh human recombinant Trx can exist in at least five different states, which probably reflect the fully reduced state of the protein as well as different intramolecular disulfide bonded states due to the five cysteine residues present in the protein. While the specific nature of these intramolecular disulfide bonds is not known, it is likely that some, at least, are due to non-natural disulfide bonded structures which form during denaturation and the oxidizing conditions of extended electrophoresis (Creighton T E, Methods Enzymol, 107:305-329, 1984).
- Trx homodimer If a solution of Trx is left long enough, or upon treatment with a strong oxidizing agent such as diamide or H 2 O 2 , there is formation of a 23-kDa Trx homodimer. Reduction of the Trx dimer by thioredoxin reductase is slow and delayed, and is stimulated by low concentrations of fresh Trx, suggesting there may be an autocatalytic process. A similar conclusion was reached by Ren X et al., Biochem., 32:9701-9705, 1993, Formation of the Trx homodimer appears to involve the Cys 73 residue since C73S, where Cys 73 is replaced with serine, does not undergo oxidation-induced homodimer formation as do Trx and C32S/C35S.
- Trx is secreted by cells into the extracellular environment, which is predominantly oxidizing, and might be expected to undergo monomeric oxidation. Considering its ease of formation, it is reasonable to assume that monomeric oxidation will precede oxidative homodimer formation. Whether this might be sufficient to prevent Trx from acting as a growth factor is not known. The formation of the oxidized monomer inside the cell is less likely since it still can be slowly reduced by thioredoxin reductase and the interior of the cell is highly reducing.
- Trx homodimer formation The physiological significance of homodimer formation is also unknown. What might be Trx homodimer has been reported in diamide-treated Jurkat cells (Sato N, et al., J. Immunol., 154:3194-3203, 1995). I have observed small amounts of the Trx homodimer by immunoblotting of untreated MCF-7 breast cancer and other cell lysates. It is intriguing to speculate that formation of an oxidized Trx monomer or homodimer in response to intracellular oxidants such as H 2 O 2 might be a way mammalian cells detect oxidant formation.
- Trx is believed to exist in normal cells at concentrations from 1 to 10 ⁇ M (Luthman M, et al., Biochem., 21:6628-6633, 1982; Berggren M, et al., Anticancer Res . (in press)), though in selected tissues and specific cell compartments this value could be much higher. It is therefore not unreasonable to assume that Trx will undergo homodimer formation in vivo. As I observed with the enhanced inactivation of Trx in phosphate buffered saline, I expect dimer formation to precede faster in vivo than observed in vitro in water. Whether dimer formation in vivo would prevent the faster oxidation to an intramolecular form is unknown. The slow autocatalytic reduction of the Trx homodimer to the monomer would be a way to restore the cell to normal operating conditions after the induction of oxidative stress.
- Trx undergoes relatively rapid (over a few days) spontaneous and oxidant-induced conversion to a form(s) that does not stimulate cell proliferation, but is still a substrate for reduction by thioredoxin reductase. There is much slower (over a period of weeks) spontaneous oxidation of Trx to a Cys73-stabilized homodimer form that is not a substrate for thioredoxin reductase and that also does not stimulate cell proliferation. Both conversions can be reversed by treatment with the thiol reducing agent DTT, and both appear to involve the Cys 73 residue.
- Cys73->Ser mutant Trx which stimulates cell proliferation and is as effective a substrate for thioredoxin reductase as Trx, did not show age or oxidation-induced loss of these activities. Thus, with time Trx gradually loses its ability to stimulate cell proliferation and to be a substrate for thioredoxin reductase, unlike the Cys 73 ->Ser mutant Trx, which retains these activities with no loss. Thus, Cys 73 is not critical for biological activity but may play a critical role in the oxidative regulation of Trx activity.
- the redox protein thioredoxin plays an important role in controlling cancer cell growth through regulation of DNA synthesis and transcription factor activity.
- Thioredoxin is overexpressed by a number of human primary cancers and its expression is decreased during dexamethasone-induced apoptosis of mouse WEH17.2 thymoma cells.
- WEH17.2 cells stably transfected with human thioredoxin cDNA showing increased levels of cytoplasmic thioredoxin to undergo apoptosis in vitro and in vivo.
- the cells were protected from apoptosis induced by dexamethasone, staurosporine, etoposide, and thapsigargin, but not by N-acetyl-sphingosine.
- the trx-transfected cells formed tumors that showed increased growth compared to wild-type, as w ell as bcl-2-transfected. WEHI7.2 cells.
- the trx- and bcl-2-transfected cell tumors both showed less spontaneous apoptosis than tumors formed by the wild-type cells.
- frx-transfected cell tumors did not show growth inhibition upon treatment with dexamethasone. This study suggests that increased thioredoxin expression in human cancers may result in an increased tumor growth through inhibition of spontaneous apoptosis and a decrease in the sensitivity of the tumor to drug-induced apoptosis.
- Trx is a low molecular weight redox protein found in both prokaryotic and eukaryotic cells (Holmgren, A. J. Biol. Chem., 264:13963-13966, 1989).
- the cysteine residues at the conserved Cys 32 -Gly-Pro-Cys 35 -Lys active site of Trx undergo reversible oxidation-reduction catalyzed by the NADPH-dependent selenium-containing flavoprotein Trx reductase (Luthman, M., et al., Biochemistry, 21:6628-6633, 1982).
- Trx Human Trx is a protein of M r 11,500 with 27% of amino acid identity to Escherichia coli but containing three additional Cys residues not found in bacterial Trx that give the human protein unique biological properties (Gasdaska, P. Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994). Trx was originally studied for its ability to act as a reducing cofactor for ribonucleotide reductase, the first unique step in DNA synthesis (Laurent, T. C., et al., J. Biol. Chem., 239:3436-3444, 1964).
- Trx has been shown to exert redox control over a number of transcription factors, including nuclear factor KB (Matthews J R., et. al., Nucleic Acids Res., 20:3821-3830, 1992), transcription factor IIIC (Cromlish, J. A, et al., J. Biol. Chem., 264:18100-18109, 1989), BZLF1 (Bannister, A. J, et al., Oncogene, 6:1243-1250, 1991), and the glucocorticoid receptor (Grippo, J. F, et al., J.
- Trx can regulate AP-1 (Fos/Jun heterodimer; Abate, C, et al., Science (Washington, D.C.), 249:1157-1161, 1990).
- Trx is also a growth factor with a unique mechanism of action.
- Human Trx stimulates the proliferation of both normal fibroblasts and a wide variety of human solid and leukemic cancer cell lines (Powis, G, et al., On col. Res., 6:539-544, 1994; Oblong, J. E, et al., J. Biol. Chem., 269:11714-11720, 1994).
- Redox activity is essential for growth stimulation by Trx, and mutant redox-inactive forms of Trx lacking the active site Cys 32 and Cys 35 residues are devoid of growth stimulating activity (Oblong. J. E, et al., J. Biol Chem. 269:1.1714-11720, 1994).
- Trx appears to stimulate cell proliferation by increasing the sensitivity of the cells to growth factors secreted by the cells themselves (Gasdaska, J. R. et al., Cell Growth Differ., 6:1643-1650, 1995).
- Trx mRNA is elevated compared to paired normal tissue in almost half of the human primary lung and colon tumors we examined (Gasdaska, P. Y, et al., Biochem. Biophys. Ada, 1218:292-296, 1994; Berggren, M, et al., Anticancer Res., 16:3459-3466, 1996).
- Other studies have found increased Trx in human neoplastic cervical squamous epithelium cells and hepatocellular carcinoma (Fujii, S, et al., Cancer (Phila.), 68:1583-1591, 1991; Kawahara, N, et al., Cancer Res., 56:5330-5333, 1996).
- Trx overexpression may be a factor in the growth of some human cancers.
- Trx gene expression is decreased during dexamethasone-induced apoptosis of mouse thymoma-derived WEHI7.2 cells (Briehl M, M, et al., Cell Death Differ., 2:41-46, 1995).
- this study we stably transfected WEHI7.2 cells with human Trx cDNA and examined the effects on both spontaneous and drug-induced apoptosis in vitro and with the cells growing in Scid mice.
- Human wild-type Trx cDNA was prepared as described previously, cloned into the NotI site of the pDC304neo mammalian transfection vector (Gallegos, A, et al., Cancer Res., 56:5765-5770, 1996) and transfected by electroporation into mouse WEH17.2 thymoma-derived cells (Harris, A. W, et al., J. Immunol, 110:431-438, 1973). Transfected cells were maintained at culture densities up to 10 cells/ml in DMEM containing 10% fetal bovine serum supplemented with 800 ⁇ g/ml G418 sulfate. All studies were conducted on clonal lines between passages 3 and 20.
- Stably transfected bcl-2 WEH17.2 cells were obtained from Dr. Roger Miesfeld (University of Arizona, Arlington, Ariz.; Lam, M, et al., Proc. Natl. Acad. Sci. USA, 91:6569-6573, 1994). Drugs were added at a culture density of 1 ⁇ 10 5 to 2 ⁇ 10 5 cells/ml. Stock solutions (10 mm) of dexamethasone were prepared in ethanol, whereas staurosporine, etoposide, thapsigargin, and N-acetyl-sphingosine were prepared in DMSO. Further dilutions were made using culture medium.
- the level of functional glucocorticoid receptors was assessed using a transient cotransfection of cells with a glucocorticoid response element/chloramphenicol acetyltransferase (“CAT”) reporter plasmid (pmmCAT; Rundlett, S. E, et al., Exp. Cell Res., 203:21.4-221, 1992) and P-galactosidase. After a 22-h recovery period, the cells were treated with 1 ⁇ M desamethasone, and CAT protein was measured after an additional 24 hr. using a CAT ELISA (Boehringer Mannheim, Indianapolis, Ind.). An aliquot of the transfected cells was stained for p-galactosidase activity and CAT activity normalized for transfection efficiency.
- CAT glucocorticoid response element/chloramphenicol acetyltransferase
- Apoptosis was measured by an ELISA for histone-associated DNA fragments (Leist, M, et al., Biochemica., 11:20-22, 1994), by morphology and by flow cytometry (Philpott, N. H, et al., Blood, 6:2244-2251, 1996).
- the criteria used for the morphological identification of apoptotic cells included condensation and margination of the chromatin with the formation of crescents, cell shrinkage, increased staining, nuclear fragmentation, cytoplasmic vacuolization, and apoptotic body formation. Cells were incubated with 20 ⁇ g/ml 7-amino actinomycin D for 30 min at 4° C. before being analyzed by flow cytometry.
- Relative fluorescence intensities of groups of 20 cells were measured at the same laser power, photomultiplier tube voltage, and line averaging setting as gray level intensities using SigmaScan software (Jandel Scientific, Corte Madera, Calif.), Because the transfected cells exhibited an uneven distribution of fluorescent staining, a template of a regular array of dots was placed over the image, and multiple (up to 90) nuclear and cytoplasmic measurements were made.
- Tumor formation by wild-type and transfected WEH17.2 cells was studied by injecting 2 ⁇ 10 7 cells in 0.1 ml of matrigel s.c. into the flanks of groups of 20 female Scid mice. Tumor volume was measured with calipers, and mice were euthanized when the tumor volume exceeded 2 cm 3 .
- 10 mice from each group were injected i.p. with 1 mg/kg/day dexamethasone in 10% ethanol in 0.9% NaCl. Control mice were injected with vehicle alone.
- three mice from each group were euthanized with CO 2 and the tumors were excised and immediately fixed in glutaraldehyde.
- the glutaraldehyde-fixed tissue was postfixed in osmium tetroxide, dehydrated in a graded series of alcohols, and embedded in epoxy resin.
- One- ⁇ m-thick sections were prepared and stained with toluidine blue for bright-field examination.
- WEHI7.2 cells were stably transfected with human trx cDNA in the pDC304neo mammalian transfection vector. I examined multiple clones and found the maximal increase in Trc mRNA compared to endogenous levels of mouse Trx mRNA, was 1.8-fold for clones Trx5 and Trx6 ( FIG. 20A ). As determined by immunofluorescent staining and confocal microscopy, the trx-transfected cells showed increased levels of Trx ( FIG. 20B ).
- Trx-like fluorescent staining was observed in the nucleus as well as the cytoplasm of the cells ( FIG. 20C ). In the wild-type cells, 60.1 ⁇ 5.1% of the fluorescent staining was in the nucleus, in the Trx5 cells it was 59.8 ⁇ 2.5%, and in the Trx6 cells it was 36.1 ⁇ 1.8%.
- the trx-transfected WEH17.2 cells were resistant to apoptosis induced by 1 uM dexamethasone as measured by histone-associated DNA fragmentation ( FIG. 21A ) or by flow cytometry ( FIG. 21B ). Histological examination of the WEHI7.2 cells revealed a classic apoptotic morphology in response to dexamethasone. However, only a small fraction of the cells undergo apoptosis at any one time, and they rapidly progress to fragmented cells. For this reason, results are expressed as relative apoptosis rather than percentage of apoptotic cells.
- Glucocorticoid receptor activity measured using a glucocorticoid receptor/CAT reporter plasmid was not decreased in the toc-transfected cells (Results of three studies not shown). I also studied the effect of trx transfection on other agents known to induce apoptosis (Table 5).
- fr-jc-transfected cells were resistant to apoptosis induced by staurosporine, a general kinase inhibitor (Kondo, Y, et al., Cancer Res., 55:2021-2023, 1995); by a cell-permeant sphingosine analogue, JV-acetyl sphingosine (Pushkareva, M, et al., Immunol. Today, 16:294-297, 1995); by thapsigargin, which blocks the uptake of intracellular Ca 2+ resulting in an increase in intracellular free Ca 2+ concentration (Lam, M, et al., Proc. Natl. Acad. Sci.
- WEHI7.2 cells transfected with the bcl-2 antiapoptotic proto-oncogene showed a similar pattern of protection against apoptosis induced by the various agents as did the toc-transfected cells (Table 5).
- Apoptosis was measured by flow cytometry as in FIG. 2 IB.
- Relative apoptosis is expressed as the ratio of the sum of regions R2 and R3 (early and late apoptotic cells, respectively) divided by region RI (live nonapoptotic cells) normalized to the ratio for vehicle treated vector-alone transfected cells. Values are the mean of 3 determinations ⁇ SE.
- Statistical analysis was by linear regression with indicator values for drugs and cells using the Stata statistical package (Stat Corp., College Station, TX). a P ⁇ 0.05 compared to vector-alone transfected control cells.
- the trx-transfected WEH17.2 cells formed tumors that grew more rapidly than tumors formed by either wild-type or bcl-2-transfected WEH17.2 cells ( FIG. 22A ).
- tumors formed by the wild-type cells showed fields of apoptotic cells adjacent to fields of viable cells, as well as apoptotic cells admixed with viable-appearing cells ( FIG. 22B ).
- the cells undergoing apoptosis exhibited the classic appearance of condensed and marginated chromatin, some in the form of crescents, and a dense cytoplasm accompanied by vacuolization.
- the trx-transfected WEHI7.2 cell tumors showed minimal numbers of cells undergoing apoptosis scattered throughout the tumor mass. Tumors formed by bcl-2-transfected WEHI7.2 cells also showed very few cells undergoing apoptosis (not shown). Areas of necrosis were seen in wild-type, trx-transfected, and bcl-2-transfected cell tumors, usually adjacent to fields of viable-appearing tumor cells or, in the case of the wild-type cells, adjacent to areas that show extensive apoptosis or next to viable-appearing cells.
- mice with dexamethasone starting at day 9 had no effect on the growth of the trx-transfected cell tumors but markedly inhibited the growth of the wild-type tumors and the bcl-2-transfected cell tumors ( FIG. 22A ). Histological examination revealed no evidence of increased apoptosis caused by dexamethasone treatment of wild-type, frx-transfected, or bcl-2-transfected cell tumors.
- Trx is present in the cytoplasm and the nucleus of cells confirms an earlier immunohistochemical study using conventional light microscopy of cervical tumor cells that reported cytoplasmic, nuclear, or cytoplasmic and nuclear localization of Trx (Fujii, S, et al., Cancer (Phila), 68:1583-1591, 1991). This is an important observation because Trx may be able to directly reduce redox-regulated nuclear transcription factors, such as AP-1 (Fox/Jun heterodimer; Abate, C, et al., Science (Washington, D.C.), 249:1157-1161, 1990).
- AP-1 Fax/Jun heterodimer
- Trx can enter the nucleus, it may not need other nuclear redox factors such as Ref-1/HAP1, as has been suggested (Abate, C, et al., Science (Washington, D.C.), 249: 157-1161, 1990).
- Trx has been reported to be necessary for assembly of the glucocorticoid receptor (Grippo, J. F, et al., J. Biol. Chem., 258:13658-13664, 1983). However, glucocorticoid receptor activity was not decreased in the transfected cells, suggesting that the effects of Trx on apoptosis appear to lie downstream of the glucocorticoid receptor.
- the trx-transfected cells also showed resistance to apoptosis induced by staurosporine etoposide, JV-acetyl sphingosine, and thapsigargin.
- Exogenously added human trx has been reported to inhibit apoptosis induced by tumor necrosis factor a in U937 human lymphoma cells (Matsuda, M, et al., J. Immunol., 147:3837-3841, 1991).
- exogenously added human Trx did not protect WEHI7.2 cells against apoptosis induced by dexamethasone (Baker, A R et al., Cell Death Differ, 3:207-213, 1996).
- Trx Tumor necrosis factor a and dexamethasone are thought to trigger apoptosis by different signaling pathways. It may also be that exogenous Trx is not taken up by WEH17.2 cells. We have found that other tumor cells take up Trx poorly, if at all (Gasdaska, J. R. et al., Cell Growth Differ., 6:1643-1650, 1995). Clearly, an increase in intracellular Trx achieved by transfection of trx in the present study is associated with resistance of the WEH17.2 cells to apoptosis induced by dexamethasone and other agents.
- Bcl-2 is believed to exert its inhibitory effects upstream of the activation of the cysteine aspartate proteases cascade (caspase) responsible for the final stages of apoptosis (Shimizu, S, et al., Oncogene. 12:2251-2257, 1996).
- the protective effects of Bcl-2 against apoptosis have been suggested to involve an antioxidant mechanism (Hockenberry, D. M, et al.
- Trx a gene that codes for a known redox-active protein, also inhibits apoptosis.
- High levels of Bcl-2 have been found in a wide variety of human cancers (Reed, J. C, et al., J Cell. Biochem., 60:23-32, 1996). Although transfection with bcl-2 is known to confer resistance to apoptosis induced by anticancer drugs and radiation, the effects of bcl-2 on tumor growth are less clear.
- Transfection with bcl-2 gives a survival advantage to cells in culture (Maeyama, Y. Kurume Med. J., 42:291-297, 1995).
- Transgenic mice overexpressing Bcl-2 under transcriptional regulation of the immunoglobulin heavy chain enhancer develop benign lymphoma that eventually progresses to high-grade malignant disease (McDonnell, T. J, et al., Nature (Lond.), 349:254-256, 1991).
- This suggests that bcl-2 also provides a survival advantage to cells in viva but that an additional change, most frequently rearrangement of myc (McDonnell, T. J., et al., Nature (Lond.), 349:254-256, 1991), is necessary for tumor growth.
- Trx system offers a novel target for agents to promote apoptosis and inhibit tumor growth, as well as to reverse the drug resistance of some cancers. It is interesting, therefore, that some 2-imidazolyl disulfide inhibitors of Trx (Kuperus, M, et al., Proc. Am. Assoc. Cancer Res., 36:426, 1995) have been shown to induce apoptosis in cancer cells and, in animal studies, by intraperitoneal and oral administration, to have antitumor effects.
- 1-methylpropyl-2-imidazolyl disulfide exhibits does-dependent antitumor activity in mice.
- Oral administration of 1-methylpropyl-2-imidazolyl disulfide in the diet of mice at up to 250 ppm reduces the number of tumors in the colon by 70%, and causes a significant reduction in the size of the remaining tumors, Injection of mice with 1-methylpropyl-2-imidazolyl disulfide at 5 mg/kg, 10 mg/kg, and 15 mg/kg reduces the volume of tumors significantly (Powis, G, et al., Anticancer Drugs, 7 (Suppl. 3); 121-126, 1996).
- trx a gene found to be overexpressed in a number of human cancers
- the trx-transfected cancer cells show an increased growth, decreased spontaneous apoptosis, and decreased sensitivity to apoptosis induced by dexamethasone. If similar effects occur in patient tumors, then trx could be a new human proto-oncogene.
- Human thioredoxin is a putative oncogene that may confer both a growth and survival advantage to tumor cells. Over-expressed thioredoxin mRNA has been found in both primary human lung and colorectal cancers. To determine the intratumor distribution and amount of thioredoxin protein in human primary tumors and to determine if its overexpression is related to proliferation or apoptosis, I studied primary human gastric carcinoma samples. An immunohistochemical assay for thioredoxin in paraffin embedded blocks was developed. Ten patients were studied with primary high risk gastric carcinoma.
- thioredoxin protein overexpression to apoptosis I utilized a paraffin based in situ assay (Tunel) and to delineate proliferation we utilized the nuclear proliferation antigen detected by Ki67.
- I found thioredoxin was localized to tumor cells and overexpressed compared to normal gastric mucosa in 8 of 10 gastric carcinomas. The thioredoxin was found at high levels in 5 of the 8 overexpressing carcinomas. The overexpression of thioredoxin was typically found in both a nuclear and cytoplasmic location in the neoplastic cells. There was a significant positive correlation (P 0.0061) with cancer cell proliferation measured by Ki67.
- Thioredoxins are low molecular weight redox proteins found in both prokaryotic and eukaryotic cells (Holmgren, A. 1989. J. Biol. Chem., 264:13963-13966).
- the cysteine (Cys) residues at the conserved -Cys-Gly-Pro-Cys-Lys active site of thioredoxin undergo reversible oxidation-reduction catalyzed by the NADPH-dependent selenium containing flavoprotein thioredoxin reductase (Luthman, M, et al., Biochem., 21:6628-6633, 1982).
- Human thioredoxin is an 11.5 kDa protein, with 27% amino acid identity to E. coli thioredoxin. It contains 3 additional Cys residues not found in bacterial thioredoxin that give it unique biological properties (Gasdaska, P. Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994).
- Thioredoxin was first studied for its ability to act as reducing cofactor for ribonucleotide reductase, the first unique step in DNA synthesis (Laurent, T. C, et al., J. Biol. Chem., 239:3436-3444, 1964). More recently thioredoxin has been shown to exert redox control over a number of transcription factors, including NF-KB (Matthews, J. R, et al., Nucl. Acids Res., 20:3821-3830, 1992). TFIHC (Cromlish, J. A, et al., J. Biol. Chem., 264:18100-18109, 1989), BZLF1 (Bannister, A.
- Thioredoxin is also a growth factor with a unique mechanism of action.
- the predicted amino acid sequence of thioredoxin is identical to that of a previously identified growth factor secreted by HTLV-1 transformed leukemic cell lines, called adult T-cell leukemia-derived factor (ADF) (Gasdaska, P. Y. et al., Biochem. Biophys. Ada., 1218:292-296, 1994).
- ADF stimulates growth of lymphoid cells (Wakasugi, N, et al., Proc Natl. Acad. Sci. USA, 87:8282-8286, 1990; Yodoi, J, et al., Adv. Cancer Res., 57:381-411, 1991).
- Human thioredoxin is known to be secreted from cells by a leaderless secretory pathway (Rubartelli, A, et al., J. Biol. Chem., 267:24161-24164, 1992) so that it could be acting extracellularly to stimulate cancer cell growth.
- thioredoxin is important for the growth, death and transformed phenotype of some human cancers.
- Stable transfection of normal fibroblasts with human thioredoxin cDNA (trx) increases their growth rate and transfection of human MCF-7 breast cancer cells with trx increases their colony formation in soft agarose (Gallegos, A., et al., Cancer Res., 56:5765-5770, 1996).
- Transfection of the MCF-7 cells with a dominant negative redox inactive mutant trx causes inhibition of colony formation and almost complete inhibition of tumor formation when the cells were inoculated into Scid mice.
- trx transfected cells form tumors that when inoculated in Scid mice grow more rapidly and show less spontaneous apoptosis than vector alone or bcl-2 transfected cells, and are resistant to growth inhibition by glucocorticoid (Baker, A, et al., Cancer Research, 57:5162-5167, 1996). These results suggest that trx offers a survival as well as a growth advantage to tumors in vivo, unlike bcl-2 which offers only a survival advantage and requires other genetic changes for tumor growth (McDonnell, T J, et al., Nature, 349:254-256, 1991).
- thioredoxin mRNA was extracted from pieces of tumor and nothing is known of its intratumor distribution, or even if the increased thioredoxin mRNA leads to an increase in thioredoxin protein. It remains to be determined if thioredoxin overexpression is related to proliferation or apoptosis in human primary tumors.
- the current study sought to develop an assay for thioredoxin in paraffin embedded blocks allowing survey of human tumors in archival tissue banks.
- SWOG Southwest Oncology Group
- Gastrointestinal Biology Laboratory made available a relevant archival paraffin block bank of gastric carcinomas.
- thioredoxin to apoptosis I also sought to refine a paraffin-based in situ assay of apoptosis (Grogan, T. M, et al., Automation of Immunohistochemistry, In Weinstein, R. S. (ed); Advances in Pathology and Laboratory Medicine, vol. 6. St. Louis, Mosby, 1993, pp. 253-283; Grogan, T M, et al.
- Paraffin blocks from ten gastric carcinoma resections were studied. These pathology samples derived from ten patients on Southwest Oncology Group (SWOG) protocol 9008 (also known as intergroup study #0116). This is a study of high risk gastric carcinoma comparing gastrectomy only versus gastrectomy plus adjuvant therapy. The patients ranging in age from 42 to 75; all had previously untreated, stage II and III B gastric carcinoma. They had biopsy proven adenocarcinoma of the stomach which had a high risk for recurrences due to evidence of carcinoma extension beyond the muscularis propria and/or having lymph node involvement. Patients with Stage O, IA or any stage with MI were not eligible. As of December 1996 this study has accrued 486 patients.
- SWOG Southwest Oncology Group
- the best signal to noise ratio was established by judging reactivity with cell lines known to be a high expressor of thioredoxin (A549 human lung cancer) and a low expressor of thioredoxin (SK BR3 human breast cancer) (Berggren, M, et al., Anticancer Res., 16:3459-3466, 1996).
- the degree of thioredoxin expression in tumor cells was judged at 400 ⁇ magnification as 4+ (very intensely positive), 3+ (moderately intensely positive), 2+ (moderate), 1+ (faint), or 0 (completely negative) throughout the sample.
- a single investigator (TG) was responsible for scoring all the samples.
- Apoptotic cells were detected utilizing the TUNEL assay (Gavrieli, Y, et al., J. Cell BioL, 119:493-501, 1992; Grasl-Kraupp, B. et al., Hepatology, 21:1465-1468, 1995) adapted to an automated in situ hybridization instrument (gen II, Ventana Medical Systems, Inc.).
- the TUNEL assay utilizes recombinant terminal deoxynucleotidyl transferase (Tdr) (GIBCO BRL) for adding homopolymer tails to the 3′ ends of DNA which are more abundant in apoptotic cells (Gavrieli, Y. et al., J.
- Biotin-16, 2′-deoxyuridine-5′ triphosphate (Biotin 16-dUTP) (Boehringer-Mannheirn, Indianapolis, Ind.) was the label used for terminal transferase in this DNA 3′-end labelling reaction.
- Biotin-16, 2′-deoxyuridine-5′ triphosphate (Biotin 16-dUTP) (Boehringer-Mannheirn, Indianapolis, Ind.) was the label used for terminal transferase in this DNA 3′-end labelling reaction.
- Avidin-Horseradish Peroxidase and 3,3′-diaminobenzidine as chromogen (Gavrieli, Y, et al, J. Cell BioL, 119:493-501, 1992; Grasl-Kraupp, B, et al., Hepatology, 21:1465-1468, 1995).
- the instrument utilized deparaffinized sections with subsequent digestion with Protease I (Ventana Medical Systems, Arlington, Ariz.) for 8 minutes VMS 1). Incubations were performed per Ventana Gen II protocol on the instrument with the final steps being as above using avidin-horse radish peroxidase and DAB detection method to visualize the apoptotic nuclei as an intense brown color (diaminobenzidine).
- Protease I Ventana Medical Systems, Arlington, Ariz.
- DAB detection method to visualize the apoptotic nuclei as an intense brown color (diaminobenzidine).
- As an enzyme control we utilized two sections from each tissue: one with Tdt enzyme and one without enzyme (negative control).
- the TUNEL assay result was scored by the number of brown-apoptotic tumor nuclei per high power field (400 ⁇ objective). The values were: 0 (absence of apoptotic cells), + (>0-2/hpf), ++ (2-4/hpf), +++ (>4-8/hpf), ++++ (>8/hpf).
- Thioredoxin expression was correlated with Ki67 expression and with apoptosis measured by the TUNEL assay using Spearman's nonparametric rank correlation test.
- the optimum signal to noise ratio was found by using the following antigen retrieval conditions: microwaving at pH 8.0 in EDTA as tested by a high thioredoxin expressor (A 549) and low thioredoxin expressing (Sk BR3) cell line.
- thioredoxin does not have a known nuclear localization sequence (Gasdaska, P. Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994). From our IHC studies it is clear that thioredoxin is specifically located within neoplastic gastric carcinoma cells and not in stromal cells or admixed B or T lymphocytes or macrophages.
- the tumor cell thioredoxin density typically exceeded that of the adjacent normal mucosa.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This is a continuation of U.S. application Ser. No. 10/600,957, filed Jun. 20, 2003, which is a continuation of U.S. application Ser. No. 06/875,578, filed Jun. 6, 2001, now U.S. Pat. No. 6,689,775, issued Feb. 10, 2004, which is a continuation of U.S. Ser. No. 09/319,292, filed on Jun. 3, 1999, now abandoned, which is a national phase filing based on International Application No. PCT/US 97/22292, filed on Dec. 5, 1997, which claimed the benefit of priority from U.S. Provisional Patent Application Ser. No. 60/031,995, filed on Dec. 6, 1996. All aforementioned applications are herein incorporated by reference in their entirety.
- This invention was made with support from the U.S. government under a grant from the US. National Institutes of Health, contract number CA48725. The U.S. government has certain rights in the invention.
- The present invention generally relates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or eliminating thioredoxin-associated apoptosis inhibition and agents that are useful in inhibiting thioredoxin stimulated cell growth.
- Thioredoxin is a low molecular weight (Mr 11,000-12,000) redox protein found in both prokaryotic and eukaryotic cells. (Holmgren A., J. Biol. Chem., 264:13963-13966, 1989), that undergoes reversible thiol reduction by the NADPH-dependent enzyme thioredoxin reductase. Human thioredoxin, which has 5 cysteine (Cys) residues, is a 11.5 kDa protein with 27% amino acid identity to E. coli thioredoxin. Human thioredoxin contains 3 additional Cys residues not found in bacterial thioredoxin that give it unique biological properties. (Gasdaska P Y, et al., Biochem. Biophys. Acta., 1218:292-296, 1994). Cys32 and Cys35 are the conserved catalytic site cysteine residues that undergo reversible oxidation to cystine. Cys92, Cys69 and Cys73 are found in mammalian but not in bacterial thioredoxins, Cys73 appears to be particularly important for maintaining the biological activity of thioredoxin in an oxidizing environment. Thioredoxin reduces a variety of intracellular proteins including enzymes such as ribonucleotide reductase which is important for DNA synthesis, and critical Cys residues in transcription factors such as NF-
K B, AP-1 and the glucocorticoid receptor, thus, altering their binding to DNA. In addition to its intracellular actions, human thioredoxin has remaskable extracellular cell growth stimulating properties. It has been reported (Gasdaska P Y, et al., Biochem. Biophys. Acta., 1218:292-296, 1994) that thioredoxin is identical to a growth factor reported to be secreted by human HTLV-1 transformed leukemia cell lines (Fox J A, et al., Proc. Natl. Acad. Sci. USA, 84:2663-2677, 1987). It has also been found that human recombinant thioredoxin will stimulate the growth of a wide variety of fibroblast and human solid tumor cell lines in culture (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995; Oblong J E, et al., J. Biol. Chem., 269:11714-11720, 1994). E. coli thioredoxin does not stimulate cell proliferation. - Thioredoxin was first studied for its ability to act as reducing co-factor for ribonucleotide reductase, the first unique step in DNA synthesis. (Laurent T C, et al., 15 J. Biol. Chem., 239:3436-3444, 1964) More recently thioredoxin has been shown to exert redox control over a number of transcription factors modulating their binding to DNA and thus, regulating gene transcription. Transcription factors regulated by thioredoxin include NF-
K B (Matthews J R, et al., Nucl. Acids Res., 20:3821-3830, 1992), TFIIIC (Cromlish J A, et al., J, Biol. Chem., 264:18100-18109, 1989), BZLFI (Bannister 20 AJ, et al., Oncogene, 6:1243-1250, 1991), the glucocorticoid receptor (Grippo J F, et al., J. Biol. Chem., 258:13658-13664, 1983) and, indirectly through a nuclear redox factor Ref-1/HAPE, thioredoxin can regulate AP-1 (Fos/Jun heterodimer) (Abate C, et al., Science 249:1157-1161, 1990). Thioredoxin is also a growth factor with a unique mechanism of action. - Human thioredoxin has been sequenced and cloned. (Gasdaska P Y, et al., Biochem. Biophys. Acta., 1218:292-296, 1994; Deiss L P, et al., Science 252:117-120, 1991). It has been shown that the deduced amino acid sequence of thioredoxin is identical to that of a previously known protein called eosinophil cytotoxicity stimulating factor (Silberstein D S, et al. Biol. Chem., 268:9138-9142, 1993) or adult T-cell leukemia-derived factor (ADF) (Gasdaska P Y, et al., Biochem. Biophys. Acta., 1218:292-296, 1994). ADF has been reported to be secreted by virally transformed leukemic cell lines and to stimulate their growth (Yodoi J, et al., Adv. Cancer Res., 57:381-411, 1991). These observations have been extended to show that human recombinant thioredoxin stimulates the proliferation of both normal fibroblasts and a wide variety of human solid and leukemic cancer cell lines. (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995) Powis G, et al., Oncol. Res., 6:539-544, 1994; Oblong J E, et al., J. Biol. Chem., 269:11714-11720, 1994). It has been shown that thioredoxin stimulates cell proliferation by increasing the sensitivity of the cells to growth factors secreted by the cells themselves. (Gasdaska J R., et al., Cell Growth Differ., 6:1643-1650, 1995).
- Recombinant modified thioredoxins, otherwise called mutant thioredoxins, have been developed, but no indications of uses were known in the art for any particular mutant form. In a wild type thioredoxin, the cysteine (Cys) residues at the conserved -Cys32-Gly-Pro-Cys35-Lys active site of thioredoxin undergo reversible oxidation-reduction catalyzed by the NADPH-dependent flavoprotein thioredoxin reductase, (Luthman M, et al., Biochem., 21:6628-6633, 1982). It has been reported that mutation of the active site Cys32 and Cys35 residues to serine (Ser) residues, either singly or together (C32S/C35S thioredoxin), results in a compound that is redox inactive (i.e., it is not a substrate for reduction by thioredoxin reductase) and that does not stimulate cell proliferation (Oblong J E, et al., J. Biol. Chem., 269:11714-11720, 1994).
- Thioredoxin mRNA has been found to be over expressed by some human tumor cells (Gasdaska P Y, et al., Biochem. Biophys. Acta., 1218:292-296, 1994; Grogan T, et al., Cancer Res., 1997, in press) and since it is secreted from cells by a leaderless secretary pathway (Rubartelli. A, et al., J. Biol. Chem., 267:24161-24164, 1992) it could be a growth factor for some human cancers (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995). However, the mechanism for cell growth stimulation by thioredoxin mRNA has been examined and found not to promote cell growth. Recombinant human thioredoxin is not taken up by cells and does not bind to high affinity cell surface receptors but appears to enhance the sensitivity of cells to endogenously produced or other growth factors, a mechanism termed voitocrine (Greek, voithos=helper) (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995).
- The in vitro cell growth stimulating activity of human thioredoxin has been previously reported for human lymphoid and solid tumor cancer cells (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995; Oblong J E, et al., J. Biol. Chem., 269:11714-111720, 1994) and for mouse fibroblast cells (Oblong J E, et al., J. Biol. Chem., 269:11714-11720, 1994). The production of a Cys73->Ser mutant thioredoxin has been previously reported. In one study it did not act like wild-type thioredoxin as a component of a complex cell growth stimulating factor called “early pregnancy factor” (Tonissen K, 10 et al., J. Biol. Chem., 268:22485-22489, 1993). In another study it was reported that Cys73->Ser mutant thioredoxin did not form a dimer, but cell growth stimulating activity by the mutant thioredoxin was not investigated in this study (Ren X, et al., Biochem., 32:9701-9705, 1993). However, the ability of the Cys73->Ser mutant and other mutant thioredoxins to stimulate cell proliferation has not been reported. There have been no prior reports of administration of mutant thioredoxins in vivo.
- It has been known that certain human tumor cells were found to over-express thioredoxin mRNA compared to normal lung tissue from the same subject (Gasdaska P Y, et al., Biochem. Biophys. Acta., 1218:292-296, 1994). It has also been known that human primary colorectal tumors have exhibited elevated levels of thioredoxin mRNA compared to normal colonic mucosa (Berggren M, et al., Anticancer Res., 16:3459-3466, 1996). It has not been known, that thioredoxin protein was present in certain human tumor cells, and it has not been known that thioredoxin protein played any role in preventing or enhancing tumor cell growth.
- While thioredoxin itself is known, its use in identifying agents that inhibit cell growth stimulated by thioredoxin has not been previously shown.
- Human thioredoxin reductase has been characterized as a protein (Oblong J E, et al., Biochem., 32:7271-7277, 1993). In addition, the general properties and the cDNA base sequence of human thioredoxin reductase is known in the art. However, it has not been disclosed or suggested in the art that thioredoxin reductase be used as an anti-tumor drug target.
- The myelodysplastic syndromes (MDS) are a heterogeneous class of life threatening diseases characterized by ineffective hematopoiesis and progressive, refractory cytopenia (List A F, et al. J. Clin. Oncol., 8:1424-1441, 1990). Transformation to acute leukemia may occur in one-third of the patients. The underlying defect is decreased multilineage progenitor cell growth associated with decreased sensitivity to growth factor stimulation (Merchav S, et al., Leukemia, 5:340-346, 1991). Very high doses of recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) and recombinant human granulocyte colony stimulating factor (G-CSF) can ameliorate neutropenia but do not improve red blood cell or platelet function (List A F, et al., J. Clin. Oncol., 8:1424-1441, 1990). Although IL-3 displays multilineage progenitor stimulatory effects in normal marrow clinical trials have shown limited ability to improve hematopoiesis in MDS (List A F, et al., Blood, 82 (Suppl. 1):377a, 1993). Thus, current treatment for MD is limited by the ability of cytokines to stimulate hematopoietic progenitor cells and the decreased sensitivity of these cells to growth factors.
- The present invention relates to the use of thioredoxin as, inter alia, a cell growth stimulator, as well as a screen for agents that are useful in reducing or preventing thioredoxin-associated apoptosis inhibition in tumor cells and agents that are useful in inhibiting thioredoxin stimulated growth of tumor cells.
- A non-limiting embodiment of the invention involves a method of inhibiting minor cell growth in a tumor cell that over-expresses thioredoxin comprising contacting said tumor cell with a cell growth inhibiting effective amount of an inhibitor of thioredoxin expression. Such agents can include, inter alia, small molecular compounds that complex with and interfere with the biological action of thioredoxin, preferably those that complex with active Cys residues, antisense inhibitors of thioredoxin expression, antibodies, or inhibitors of nucleic acid expression.
- A further non-limiting embodiment of the invention involves a method of reducing inhibition of apoptosis in tumor cells that over-express thioredoxin comprising contacting said tumor cells with an effective amount of an agent that inhibits thioredoxin. Such agents can include, inter alia, antibodies to this redoxin, compounds that inhibit the activity of this redoxin, preferably those that inhibit the activity of active Cys residues in the protein, cross-linking agents and the like.
- A further non-limiting embodiment of the invention involves a method of identifying an agent that inhibits tumor cell growth in cells that over-express thioredoxin comprising measuring thioredoxin expression or activity in a first sample of said cells; contacting a second sample of said cells with an agent to be tested; measuring expression or activity of thioredoxin in said second sample; comparing expression or activity of thioredoxin in said first sample and said second sample; whereby a decrease in expression or activity of thioredoxin in said second sample is indicative of an agent that inhibits tumor cell growth.
- A further non-limiting embodiment of the invention involves a method of identifying an agent that reduces inhibition of apoptosis in a tumor cell that over-expresses thioredoxin comprising measuring thioredoxin expression or activity in a first sample of said cells; contacting a second sample of said cells with an agent to be tested; measuring expression or activity of thioredoxin in said second sample; comparing expression or activity of thioredoxin in said first sample and said second sample; whereby a decrease in expression or activity of thioredoxin in said second sample is indicative of an agent that reduces inhibition of apoptosis.
- A further non-limiting embodiment of the invention involves a method of identifying an agent that reduces thioredoxin induced inhibition of apoptosis in a tumor cell growth.
- A further non-limiting embodiment of the invention involves a method of stimulating cell growth comprising introducing a nucleic acid encoding a human thioredoxin having Ser at amino acid reside 73 under conditions whereby said nucleic acid is expressed.
- A further non-limiting embodiment of the invention involves a composition comprising an agent that is useful in reducing or eliminating thioredoxin-associated apoptosis inhibition and an acceptable carrier.
- A further non-limiting embodiment of the invention involves a composition comprising an agent that is useful in inhibiting thioredoxin stimulated cell growth and an acceptable carrier.
- The present invention is based, at least in part, on the discovery that thioredoxin protein is over-expressed in certain human tumor cells; that thioredoxin stimulates the growth of cancer cells; that thioredoxin inhibits apoptosis; that thioredoxin is over-expressed in some human primary tumors and is correlated with increased tumor cell growth and decreased apoptosis; and that agents that inhibit thioredoxin also have anti-tumor activity.
- The present invention involves the new uses of thioredoxin, thioredoxin reductase, and mutant forms of thioredoxin for use in screening for anti-tumor agents. It has not been known in the art to use thioredoxin and/or thioredoxin reductase in a screening assay for anti-thioredoxin and/or anti-thioredoxin reductase agents for use as anti-tumor compounds.
- The present invention further relates to the use of thioredoxin and/or thioredoxin reductase antibodies for use as anti-tumor agents.
- The present invention further relates to the use of anti-sense thioredoxin or anti-sense thioredoxin reductase compounds for use as anti-tumor agents.
- The present invention further relates to the use of thioredoxin nucleic acid probes and/or thioredoxin antibodies in a diagnostic assay for certain cancers.
- The present invention further relates to the use of thioredoxin as a target for agents to be used in combination with existing and new treatment therapies, such as drugs and radiation, that reduce or prevent the thioredoxin-induced inhibition of apoptosis in tumor cells or to increase the sensitivity of tumor cells to these modalities.
- In addition, mutant forms of thioredoxin provide proteins with additional growth stimulating activity.
- These and still further objects as shall hereinafter appear are readily fulfilled by the present invention in an unexpected manner as will be readily discerned from the following detailed description of the preferred embodiments of the invention, especially when read in conjunction with the accompanying drawings.
- In contrast to the present invention, none of the above cited references teach or suggest the use of thioredoxin protein according to the claimed invention.
-
FIG. 1 shows a chart that illustrates the stimulation of human bone marrow colony formation by Cys73->Ser mutant thioredoxin in accordance with the present invention, wherein the effects of Cys73->Ser thioredoxin on colony formation are shown by (o) multilineage progenitors (CFU-GEMM); (•) erythroid progenitors (BFU-E): and (∇) myeloid progenitors (CFU-GM), measured over 10 days as described. (Values represent the mean of 4 determinations and bars represent S.D.) -
FIG. 2 shows a chart that illustrates potentiation of IL-2 induced MCF-7 breast cancer cell growth by Cys73->Ser mutant thioredoxin in accordance with the present invention, wherein cells were growth arrested for 48 hr. in medium with 0.5% serum (10 cells) then stimulated in the absence of medium with either IL-2 or Cys32->Ser mutant thioredoxin at the concentrations shown and cell number was measured after 48 hr. (Each point represents the mean of 3 determinations and bars represent S.E., and the dotted line shows stimulation by 10% serum.) -
FIG. 3 shows a chart that illustrates the inhibition of thioredoxin stimulated MCF-7 cell growth by receptor antibodies in accordance with the present invention, wherein cell proliferation was measured as described inFIG. 2 ; the concentrations of agents used were Cys73->Ser mutant thioredoxin (Thioredoxin) 1 μM, monoclonal antibodies to FGF receptor, IL-2-receptor and EGF-receptor 4 μg/ml, andEGF 10 nM; and the EGF and EGFR were added as a negative control. (Values represent the mean of 3 determinations and bars represent S.E., and the dotted line shows the effect of 10% serum alone.) -
FIGS. 4A-B illustrate comparative charts showing the effects of thioredoxin and C32S/C35S cDNA transfection on proliferation of MCF-7 cells. InFIG. 4A , 3×104 cells were plated in 3.8 cm2 plastic culture dishes in DMEM with 10% fbs and cell number measured 7 days later. InFIG. 413 , 10 cells were plated in 2 cm2 wells containing soft agarose and colonies measuring >60 microns counted 7 days later. (Control, the Neol vector alone transfected MCF-7 cells; Thioredoxin 9,Thioredoxin 12, andThioredoxin 20, MCF-7 cells transfected with human Thioredoxin cDNA;Serb 4, Serb 15, andSerb 19, MCF-7 cells transfected with C32S/C35S cDNA. Values are the mean of 3 determinations and bars are S.E. **indicates p<0.01 compared to vector-alone transfected cells.) -
FIG. 5 illustrates a chart showing the growth of Trx and C32S/C35S-transfected MCF-7 breast cells in Scid mice. Female Scid mice implanted s.c. 2 days previously with a 21 day release pellet of 0.25 mg 17-β estradiol were injected subcutaneously with 2×106transfected MCF 7 cells in 0.1 ml 0.9%, NaCl and 0.1 ml matngel. (O) represents MCFneo, pDC304 vector-alonetransfected MCF 7 cells; (▾) representsTrx 12, thioredoxin transfected cells; (▪) representsTrx 20, thioredoxin transfected cells; (∇) represents Serb 4, C32S/C35S transfected cells; and (□) represents Serb 15, C32S/C35S transfected cells. There were 4 mice per group. Tumor growth was measured twice a week for 40 days. The 17-β-estradiol pellet was replaced at 21 days. Values are mean and bars, SE. -
FIG. 6 illustrates an autoradiogram showing Northern analysis of NIH 3T3 cells stably transfected with cDNA for human Trx and a redox-inactive mutant human Trx (C32S/C35S) hybridized with a full-length 32P-labeled human Trx cDNA. The bottom band is endogenous mouse Trx mRNA, and the top band is the transfected human Trx mRNAs. The blots illustrate columns of NIH 3T3, wild-type NIH 3T3 cells; NeoC, cells transfected with the pRXneo vector; ThioAD and Thio6, cells transfected with C32S/C35S Trx in the pDC304neo vector; and Thio 9, cells transfected with human Trx cDNA in the pDC304neo vector. Values on right are molecular weight markers (in kb). Values below are the ratios of transfected Trx mRNA to endogenous Trx mRNA determined by phosphorimager analysis. -
FIG. 7 illustrates a chart showing the effects of transfection with Trx or C32S/C35S cDNA on the growth of Nit-H 3T3 cells. Cells were plated in plastic dishes at a density of 2×104 cells/cm2—in DMEM with 10% FBS and cell number measured daily. , NeoC vector alone-transfected cells. The apparent decrease in the number of cells afterday 3 is due to detachment of cells from the plastic surface: ∇, ▾, and Δ, Thio6, ThioAD, and Thio9 cells transfected with Trx cDNA; □ and ▪ NIHBH and NIHBF: cells transfected with C32S/C35S cDNA. Values are the mean of three determinations: bars, SE. *, P<0.05 compared with vector alone-transfected cells, shown fordays -
FIG. 8 illustrates a chart showing the stimulation of the proliferation of MCF-7 human breast cancer cells and mouse NIH 3T3 cells by human Trx. Cells were growth arrested in DMEM containing 0.5% FBS for 48 h so that there were 0.4×105 cells, at which time the medium was replaced with fresh DMEM with (▪) or without (□) 1 μM human Trx. Cell numbers were measured 48 h later. Values are the mean of three determinations: bars, SE. -
FIGS. 9A-B illustrate comparative autoradiograms showing Northern analysis of MCF-7 breast cancer cells stably transfected with cDNA for wild-type Trx (FIG. 9A ) and redox-inactive mutant Trx (C32S/C35S) hybridized with a full-length 32P-labeled human Trx cDNA (FIG. 9B ). MCFneo are cells transfected with pDC304 vector alone. The blots illustrate columns of MC Fneo, Trx20, Trx 14,Trx 12, and Trx9 inFIG. 9A andSerb 15, Serb 19, Serb 17, Serb 5, Serb 4 and MCFneo inFIG. 9B . The bottom band is endogenous Trx mRNA, and the top band is the transfected Trx mRNAs. Values below each column are the ratios of transfected Trx mRNA to endogenous Trx mRNA determined by phosphorimager analysis. -
FIGS. 10A-D illustrate light microscopy of Trx and C32S/C35S cDNA-transfected MCF-7 breast cancer cells. The cells were grown to 75% confluence on glass coverslips, fixed with methanol, stained with a Romanowski-type dye (Diff-Quick, Baxter), and observed with a×100 oil immersion objective. InFIG. 1A , pDC304 vector alone-transfected MCF-7 cells;FIG. 10B ,Trx 20 Trx-transfected MCF-7 cells; FIG. IOC, Serb 4 C32S/C35S-transfected MCF-7 cells; andFIG. 10D , Serb 19 C32S/C35S-transfected MCF-7 cells. -
FIGS. 11A-B illustrate comparative charts showing the effects of Trx and C32S/C35S cDNA transfection on proliferation of MCF-7 cells. InFIG. 1A , cells (3×10) were plated in 3.8m-cm2 plastic culture dishes in DMEM with 10% FBS, and cell number was measured 7 days later. InFIG. 11B , cells (104) were plated in 2-cm-wells containing soft agarose, and colonies measuring >60 μm were counted 7 days later. In bothFIGS. 11A and B, the chart shows control Neol vector alone-transfected MCF-7 cells, Trx 9,Trx 12, andTrx 20, MCF-7 cells transfected with human Trx cDNA: Serb 4, Serb 15, andSerb 19, MCF-7 cells transfected with C32/C35S cDNA. Values are the mean of three determinations: bars, SE, **, P<0.01 compared with vector alone-transfected cells. -
FIG. 12 illustrates a chart showing the growth of Trx and C32S/C35S-transfected MCF-7 breast cancer cells is Scid mice. Female Scid mice implanted s.c. 2 days previously with a 21-day release pellet of 0.25 mg of 17-β-estradiol were injected s.c. with 2×106 transfected MCF-7 cells in 0.1 ml of 0.9% NaCI and 0.1 ml of Matrigel. o, MCFneo, pDC304 vector alone-transfected MCF-7 cells: ▾,Trx 12, Trx-transfected cells; ▪,Trx 20, thioredoxin-transfected cells: ▾. Serb 4, C32S/C35S-transfected cells; □, Serb 15, C32S/C35S-transfected cells. There were four mice per group. Tumor growth was measured twice a week for 40 days. The 17-β-estradiol pellet was replaced at 21 days. Values are mean. Bars, SE. -
FIG. 13 illustrates a chart showing the stimulation of MCF-7 breast cancer cell growth by fresh and aged Trx and C73S. MCF-7 cells were growth arrested and the stimulation of cell proliferation measured over 2 days using 1 μM Trx or C73S that was fresh or had been stored as a 25 μM stock solution without reducing agent for 5 days or 90 days at 4′. Also shown for reference is the effect of 10% fetal bovine serum. Each value is the mean of 3 determinations, and bars are SEM. -
FIG. 14 illustrates a chart showing the reduction of aged Trx by thioredoxin reductase. The incubation mixture contained 0.1 M HEPES buffer, pH 7.6, 5 mM EDTA, 17 μM insulin, 100 μM NADPH, 15 μg/ml human thioredoxin reductase. Traces show the oxidation of NADPH at 340 nm at room temperature with: Line A represents 1 μM fresh Trx; Line B represents 30 nM fresh Trx; Line C represents 90-day aged 1 μM Trx; and Line D represents 1 μM. 90-day aged Trx and 30 nM fresh Trx. -
FIG. 15 illustrates a chart showing the effect of H2O2 on the reduction of Trx (filled bars) and C73S (open bars) by thioredoxin reductase. Trx solutions were treated with varying amounts of H2O2 for 18 hr. at room temperature. Reductase activity was measured by adding treated samples to a solution of 0.1 M HEPES buffer, pH 7.6, 5 mM EDTA, 17 μM. insulin, 100 μM NADPH, 15 μg/ml human thioredoxin reductase and measuring the rate of NADPH oxidation at 340 nm at room temperature. One hundred percent of thioredoxin reductase activity is defined as 0.1 absorbance unit/min/mM Trx or C73S Trx H2O2 had no effect on the oxidation of NADPH. -
FIG. 16 illustrates an electrophoretic analysis showing the effect of storage on Trx studied by SDS-PAGE. Protein was stained with silver stain.Lane 1 represents fresh Trx;lane 2 represents Trx 48 hr. at room temperature without DTT;lane 3 representsTrx 7 days at room temperature without DTT; andlane 4 represents Trx stored 90 days at 4′ without DTT. Position of molecular mass markers in kDa are shown on the left. -
FIG. 17 illustrates an electrophoretic analysis showing the oxidation and alkylation of Trx studied by SDS-PAGE.Lane 1 represents fresh Trx;lane 2 represents Trx stored at room temperature without DTT for 7 days;lane 3 represents Trx as inlane 2 treated with 3 mM 2-mercaptoethanol;lane 4 represents fresh Trx treated with 1 mM N-ethylmaleimide;lane 5 represents fresh Trx treated with 1 mM diamide;lane 6 represents fresh Trx treated with 2:1 (v:v) H2O;lane 7 represents Trx as inlane 5 treated with 3 mM 2-mercaptoethanol; andlane 8 represents Trx as inlane 6 treated with 10 mM 2-mercaptoethanol. Position of molecular mass markers in kDa are shown on the left. -
FIG. 18 illustrates an electrophoretic analysis showing the oxidation and reduction of mutant Trxs studied by SDS-PAGE.Lane 1 represents fresh Trx;lane 2 represents fresh C73S Trx;lane 3 represents fresh C32S/C35S Trx;lane 4 represents C73S Trx treated with 1 mM diamide;lane 5 represents C73S Trx as inlane 4 treated with 10 mM DTT;lane 6 represents C32S/C35S Trx treated with 1 mM diamide; andlane 7 represents C32S/C35S Trx as inlane 6 treated with 10 mM DTT. Position of molecular mass markers in kDa are shown on the left and right. -
FIG. 19 illustrates the position of cysteines in human Trx. Ribbons and ball-and-stick representation showing the relative positions of Cys32, Cys35, Cys62, Cys69 and Cys73, based on the crystal coordinates for the wild type reduced protein (Weichsel A, et al., Structure 4:735-751, 1996). None of the thiols are in a position for disulfide bond formation except for the redox active pair Cys32 and Cys35. The intermolecular disulfide bond requiring the least distortion in the protein would be between Cys32 and Cys73. The sulfhydryls for these residues are 9.1 Å apart in the model, but could possibly approach each other through local distortions in nearby residues. Both residues are in loops, making necessary distortions of energetically lower cost. The region near Cys has already been shown to adopt alternate conformations (Weichsel. A, et al., Structure 4:735-751, 1996), in support of this possibility. This figure was made with MOLSCRIPT (Sato N, et al., J. Immunol, 154:3194-3203, 1995). -
FIG. 20A shows a Northern blot hybridization analysis of total RNA extracted from: wild-type mouse WEH17.2 cells; from pDC304neo vector-alone transfected WEH17.2 cells (Neo); and from the rrx-transfected WEH17.2 clones Trx5 and Trx6. A full-length 32P-labeled trx cDNA probe was used for hybridization, Top band, transfected human Trx mRNA; bottom band, mouse Trx mRNA. The values on the right show the position of molecular weight markers (kb). - FIGS. 20B(1)-(4) illustrate fluorescence immunohistochemical staining of Trx in cells using immunoaffinity-purified rabbit antihuman Trx polyclonal antibody, biotinylated goat antirabbit IgG; fluorescein streptavidin, and laser scanning confocal microscopy. FIG. 20B(1) represents wild-type WEH17.2 cells; FIG. 20B(2) represents pDC304neo vector-alone transfected WEH17.2 cells; FIG. 20B(3) represents Trx5 trx transfected cells; and FIG. 20B(4) represents Trx6 trx-transfected cells.
- FIGS. 20C(1)-(2) illustrate a fluorescence immunohistochemical staining of Trx using Cy5-streptavidin fluorochrome and Y0Y0-1 to counterstain nuclear DNA showing that Trx is present in the cytoplasm and the nucleus of wild-type WEH17.2 cells (in FIG. 20C(1)) and Trx6 frx-transfected cells (in FIG. 20C(2)).
-
FIG. 21 shows comparative charts illustrating the effects of trx and bcl-2 transfection in WEH17.2 cells on dexamethasone-induced apoptosis. -
FIG. 21A shows a chart illustrating apoptosis measured by an ELISA for histone-associated DNA fragments, expressed as relative nucleosomal enrichment. Wild represents wild-type WEH17.2 cells; Neo represents pDC304neo vector-alone-transfected WEHI7.2; W.Hbl2 represents bcl-2-transfected WEHI7.2; and Trx5 and Trx6 represent trx-transfected WEH17.2 cells. The cells were treated with, 0.01% ethanol vehicle (▪) or I μM dexamethasone (□), and apoptosis was measured 24 h later. Columns, mean of four determinations; bars, SE. *, P<0.05 compared to Neo control. - FIGS. 21B(1)-(4) illustrate comparative charts of apoptosis measured by flow cytometry showing typical results. Regions R1, R2, and R3 of the scattergrams represent live nonapoptotic, early apoptic, and late apoptotic cells, respectively.
FIG. 21 B(1) shows pDC304neo vector-alone-transfected control cells; FIG. 21B(2) shows pDC304neo vector-alone-transfected cells treated 48 h with 1 μM dexamethasone; FIG. 21B(3) shows Trx6 trx-transfected WEH17.2 cells; andFIG. 21 B(4) shows Trx6 cells treated for 48 hr. with 1 μM dexamethasone. -
FIG. 22A shows a chart illustrating tumor formation in Scid mice by wild-type WEH17.2 cells (O and); bcl-2-transfected WEH17.2 (W. Hbl2) cells (∇ and ▾); and Trx6 rrx-transfected WEH17.2 cells (□ and ▪). Twenty mice were injected s.c. with 2×10 cells and 0.1 ml matrigel in the flank. Tumor size was measured every 3-4 days with calipers, and tumor volumes were calculated. Nine days after tumor cell injection, half of the mice were injected s.c. into the opposite flank with 1 mg/kg/day dexamethasone (o, ∇, and □) or with vehicle alone (•, ∇, and ▪). Mice were euthanized at the first measurement at which tumor volume exceeded 2 cm3 Data points, mean of mice in each group; bars, SE. Results similar to the Trx6 cells were obtained with Trx5 cells. -
FIG. 22B illustrates 1-μm sections of epoxy-embedded tumor samples taken at day 14 stained with toluidine blue O examined by bright-field microscopy. Spontaneous apoptosis in wild-type WEH1 7.2 tumor are shown in FIG. 22B(1) and Trx6 tumor showing less spontaneous apoptosis are shown in FIG. 22B(2). -
FIG. 23 illustrates thioredoxin positive gastric carcinoma (Case 2).FIGS. 23A-B show that hematoxylin and eosin stains (FIG. 23A andFIG. 23B ) reveal a pleomorphic carcinoma invading the gastric wall.FIGS. 23C-D show that the thioredoxin expression (FIG. 23C andFIG. 23D ) is present in both the nuclei and cytoplasm of tumor cells in malignant glands and in rare associated leucocytes. Thioredoxin expression is absent in the adjacent stroma (1000× to 400×). -
FIG. 24 illustrates thioredoxin negative gastric carcinoma (Case 8).FIG. 24A represents gastric carcinoma with complex glands in lower field of view with overlying normal gastric mucosa and submucosa. Hematoxylin and eosin (100×).FIG. 24B represents the same section as shown inFIG. 24A , negative control stained after biotin-avidin block to eliminate biotin receptor affect and stained with substituted irrelevant isotype matched monoclonal antibody (100×, Diaminobenzidine).FIG. 24C represents the same section as shown inFIGS. 24A and B showing faint reactivity in normal upper mucosa (+), moderate reactivity in the submucosa (++) and the underlying gastric carcinoma appears negative for thioredoxin (0) (100×).FIG. 24D represents a higher magnification ofFIG. 24(C showing detail with gastric pit cells having both nuclear and cytoplasmic stain and absent tumor staining (250×). -
FIG. 25 illustrates normal gastric mucosa-thioredoxin and Ki67 (proliferation antigen) expression.FIG. 25A shows normal gastric mucosa and gastric pits with underlying muscularis propria hematoxylin and eosin (100×).FIG. 25B shows the same section as shown inFIG. 25A , stained for thioredoxin with faint (+) mucosal staining and moderate (++) gastric pit staining (100×).FIG. 25C shows the same section as shown inFIG. 25B at higher magnification. Note the faint mucosal staining is solely cytoplasmic, while lower lying gastric pit cells are both cytoplasmic and nuclear (250×).FIG. 25D shows the nuclear Ki67 expression notable in lower mucosa and upper gastric pits (25O×). -
FIG. 26 illustrates thioredoxin intense gastric carcinoma related to strong proliferation and weak apoptosis (Case 4).FIG. 26A shows complex adenocarcinoma cell glands (400×, hematoxylin and eosin).FIG. 26B shows intense thioredoxin expression in gastric carcinoma cells (400×),FIG. 26(C shows a high percentage of Ki67 positive cells indicating high proliferation (400×).FIG. 26D shows a rare Td+−apoptotic cell 25 indicating weak apoptosis (Tunel assay, 400×, same slide). -
FIG. 27 illustrates thioredoxin negative gastric carcinoma related to weak proliferation and strong apoptosis (Case 6).FIG. 27A shows complex adenocarcinoma glands (400×, hematoxylin and eosin).FIG. 27B shows the absent thioredoxin expression (400×).FIG. 27C shows a low percentage of Ki67 positive cells indicating a low proliferative rate (400×).FIG. 27D shows a very high Tdt+ apoptotic cell rate indicating strong apoptosis (TUNEL assay, 400×, same slide). - All of the various publications cited in the present specification are incorporated by reference in their entireties.
- In order that the invention herein described may be fully understood, the following definitions are provided:
- “Nucleotide” means a monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (1′ carbon of the pentose) and that combination of base and sugar is called a “nucleoside”. The base characterizes the nucleotide. The four DNA bases are adenine (“A”), guanine (“G”), cytosine (“C”), and thymine (“T”). In RNA uracil (“U”) substitutes for T. In double stranded molecules, an A on one strand pairs with T(U) on the other, and G with C. As is conventional for convenience in the structural representation of a DNA nucleotide sequence only one strand is shown in which A on one strand connotes T on its complement and G connotes C. DNA comprises deoxyribose as the sugar while RNA comprises ribose.
- “Amino acids” are shown either by a three letter or one letter abbreviation as follows:
-
Abbreviated Designations Amino Acid A Ala Alanine C Cys Cysteine D Asp Aspartic acid E Glu Glutamic acid F Phe Phenylalanine G Gly Glycine H His Histidine I Ile Isoleocine K Lys Lysine L Leu Leucine M Met Methionine N Asn Asparagine P Pro Proline Q Gln Glutamine R Arg Arginine S Ser Serine T Thr Threonine V Val Valine W Trp Tryptophan Y Tyr Tyrosine - “DNA Sequence” means a linear array of nucleotides connected one to the other by phosphodiester bonds between the 3′ and 5′ carbons of adjacent pentoses.
- “Codon” means a DNA sequence of three nucleotides (a triplet) which encodes through mRNA an amino acid, a translation start signal or a translation termination signal. The code however, is degenerate, with some amino acids being encoded by more than one triplet codon. For example, the nucleotide triplets TTA, TTG, CTT, CTC, CTA and CTG all encode the amino acid leucine (“Leu”), TAG, TAA and TGA are translation stop signals and ATG is a translation start signal.
- “Proteins”, “peptides” and “poly peptides” are composed of a linear array of amino acids connected one to the other by peptide bonds between the alpha-amino and carboxyl groups of adjacent amino acids.
- “Genome” means the entire DNA of an organism, cell or a virus. It includes, inter alia, the structural genes coding for polypeptides, as well as regulatory regions including operator, promoter, terminator, enhancer and ribosome binding and interaction sequences.
- “Gene” means a DNA sequence which encodes through its template or messenger RNA (“mRNA”) a sequence of amino acids characteristic of a specific polypeptide.
- “cDNA” means a complementary or copy DNA prepared by using mRNA as a template for synthesizing the first strand of DNA using reverse transcriptase, an appropriate oligonucleotide primer and a mixture of nucleotides.
- “PCR” means a polymerase chain reaction whereby a specific DNA sequence, either genomic or cDNA, can be preferentially amplified by the enzyme Taq polymerase using synthetic, oligonucleotide sense and antisense primers, (which specify a target sequence), a mixture of nucleotides and a temperature thermocycling regime which allows sequential denaturing, annealing and synthesis of the target DNA between the primers.
- “Transcription” means the process of producing mRNA from a gene or DNA sequence.
- “Translation” means the process of producing a polypeptide from mRNA.
- “Expression” means the process undergone by a gene or DNA sequence to produce a polypeptide and comprises a combination of transcription and translation.
- “Plasmid” or “phagemid” means a nonchromosomal double-stranded DNA sequence comprising an intact “replicon” such that the plasmid is replicated in a host cell. When the plasmid is placed within a unicellular organism, the characteristics of that organism may be changed or transformed as a result of the DNA of the plasmid. For example, a plasmid carrying the gene for ampicillin resistance (AMPR) transforms a cell previously sensitive to ampicillin into one which is resistant to it. A cell transformed by a plasmid is called a “transformant”.
- “Recombinant DNA Molecule” or “Hybrid DNA” means a molecule consisting of segments of DNA from different genomes which have been joined end-to-end outside of living cells and able to be maintained in living cells.
- “Apoptosis” is programmed cell death activated by a genetic program to implement a series of events that cause the death and disposal of a cell. This is in contrast to cell death occurring by necrosis, usually as a result of injury to the cell.
- “Oncogene” is a gene that encodes a protein able to transform cells in culture to induce cancer in animals.
- “Over-expression” in the context of determining over-expression of thioredoxin or recombinant modified thioredoxin is characterized by a two fold increase or more of the levels of thioredoxin or recombinant modified thioredoxin in a target sample compared with a control sample.
- The following abbreviations may be used throughout the disclosure:
- “C32C35S”=Cys32->Ser32/Cys35->Ser35
- “DTT”=dithiothreitol
- “FBS”=Fetal bovine serum
- “NEM”=N-ethylmaleimide
- “Scid”=Severe combined immunodeficient
- “Trx”=thioredoxin
- In a non-limiting embodiment of the present invention, NIH-3T3 cells transfected with human thioredoxin DNA that has been directed to the nucleus of the cells by a nuclear localization signal causes malignant transformation of the cells.
- In a further non-limiting embodiment, stable transfection of mouse WEHI7.2 lymphoid cells with human thioredoxin DNA has been shown to inhibit apoptosis induced by a variety of agents including glucocorticoid, N-acetylsphingosine, staurosporine, thapsigargin and etoposide, which is similar to the pattern of inhibition of apoptosis caused by the anti-apoptotic oncogene bcl-2 in these cells. The thioredoxin transfected WEH17.2 cells form tumors in Scid mice that grow more rapidly and show less spontaneous apoptosis than vector-alone or bcl-2 transfected cells, and are resistant to growth inhibition by glucocorticoid. Therefore, the thioredoxin gene acts as an oncogene according to the standard definition of an oncogene: a gene that encodes a protein able to transform cells in culture or to induce cancer in animals (Lodish H, et al., “Cancer.” In: Lodish H, Baltimore D, Berk A, Zipursky S L, Matsudaira P, Darnell J, eds. Molecular Cell Biology. New York: Scientific American Books, pp. 1258, 1995).
- In a further non-limiting embodiment, the thioredoxin gene offers an increased survival advantage as well as a growth advantage to tumors in vivo, unlike the known anti-apoptosis oncogene bcl-2 which offers only a survival advantage and requires other genetic changes for tumor growth (McDonnell T J, et al., Nature 349:254-256, 1991).
- It has been discovered that thioredoxin DNA is over-expressed in certain human tumor cells resulting in the over production of thioredoxin. According to a technique for reproducibly retrieving antigens for immunohistochemical studies from archived paraffin, human tissue pathology samples were embedded and used it to study thioredoxin protein levels with a panel of human primary gastric carcinoma tissue samples, it has been found that thioredoxin is present in dividing normal basal crypt cells. It has been further learned that, as the cells differentiate and move down the villi to eventually be shed into the gastric lumen, thioredoxin levels decrease. By stably transfecting murine NIH 3T3 fibroblast-like cells and human MCF-7 breast cancer cells with cDNA for human wild-type thioredoxin or with cDNA for a redox-inactive mutant thioredoxin, it has been found that transfection with thioredoxin increases the density to which the NIH 3T3 cells grow in culture and stimulates anchorage-independent colony formation by MCF-7 breast cancer cells. The redox-inactive mutant thioredoxin acted in a dominant-negative manner, so that transfected MCF-7 cells showed inhibited growth and a reversal of the transformed phenotype, assessed by growth in vitro and in vivo.
- It has been shown that stable transfection of mouse NIH 3T3 normal embryonic cells with human thioredoxin cDNA increases their growth rate and cell saturation density in culture (normal NIH 3T3 cells are highly contact inhibited) which is in vitro evidence of transformation. It has also been shown that transfection of MCF-7 human breast cancer and HT-29 human colon carcinoma cells with human thioredoxin cDNA increases their colony formation in soft agarose and tumor growth by HT-29 colon cancer cells when the cells are inoculated into immunodeficient (Scid) mice.
- Trx was originally studied for its ability to act as a cofactor for ribonucleotide reductase, the first unique step in DNA synthesis (Laurent, T. C, et al., J. Biol. Chem., 239:3436-3444, 1964). Human Trx was subsequently shown to modulate the DNA binding of several transcription factors that regulate cell proliferation, including nuclear factor KB (Hayashi., T, et al., J. Biol. Chem. 268:11380-11388, 1993), the glucocorticoid receptor (Grippo, J. F, et al., J. Biol. Chem. 258:13658-13664, 1983), and, indirectly through the nuclear redox protein Ref-1, activator protein-1 (Fos/Jun heterodimer; Abate, C, et al., Science (Washington D.C.), 249:1157-1161, 1990): Cloning and sequencing of human Trx have shown that it has a predicted amino acid sequence (Gasdaska, P. Y. et al., Biochem. Biophys. Acta., 1218:292-296. 1994: Deiss. L. P, et al., Science (Washington D.C.), 252:117-120, 1991) identical to that of a growth factor secreted by virus-transformed leukemic cell lines, termed adult T-cell leukemia-derived factor (Tagaya, Y, et al., J. Immunol, 140:2614-2620, 1988; Wakasugi, N, et al., Proc. Natl. Acad. Sci. USA, 87:8282-8286, 1990). Human Trx, but not bacterial Trx, added to the culture medium stimulates the growth of a variety of normal and cancer cell lines (Wakasugi, N. et al., Proc. Nail. Acad. Sci. USA. 87:8282-8286, 1990; Yodoi, J, et al., Adv. Cancer Res., 57:381-411, 1991; Oblong, J. E, et al., J. Biol. Chem., 269:11714-11720, 1994). The added Trx is not taken up by cells (Gasdaska, J R., et al., Cell Growth & Differ., 6:1643-1650, 1995) and appears to stimulate cell growth by enhancing the action of other growth factors (Gasdaska, J. R., et al., Cell Growth & Differ., 6:1643-1650, 1995; Tagaya, Y, et al., EMBO J., 8:757-764, 1989). The redox activity of Trx is required for growth stimulation, and redox-inactive mutant Trxs do not stimulate cell growth (Oblong, J. E, et al., J. Biol. Chem., 269:11714-11720, 1994).
- Trx mRNA levels are increased compared with corresponding normal tissue in almost half human primary lung (Gasdaska, P. Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994) and colon tumors examined (Berggren, M, et al., Anticancer Res., (in press) 1996). Trx protein has been reported to be increased in human cervical neoplastic squamous epithelial cells (Fujii, S, et al., Cancer (Phila.), 68:1583-1591, 1991) and hepato-cellular carcinoma (Nakamura, H, et al., Cancer (Phila.), 69:2091-2097, 1992). Trx is excreted from cells (Ericson, M. L, et al., Lymphokine Cytokine Res., 11:201-207, 1992; Rubartelli, A, et al., J. Biol. Chem., 267:24161-24164, 1992; Rubartelli, A. et al., Cancer Res., 55:675-680, 1995) using a leaderless secretory pathway. (Rubartelli, A, et al., J. Biol. Chem., 267:24161-24164, 1992), and we have suggested that Trx might be a growth factor for some human cancers (Gasdaska. J. R, et al., Cell Growth & Differ., 6:1643-1650, 1995). However, it remains to be unequivocally demonstrated that endogenously produced Trx can affect cell proliferation. The role Trx plays in the transformed phenotype or cancer cells also is not known.
- To provide some answers to these questions, we have stably transfected murine NIH 3T3 fibroblast-like cells and human MCF-7 breast cancer cells with cDNA for human wild-type Trx or with cDNA for a redox-inactive mutant Trx. We have found that transfection with Trx increases the density to which the NIH 3T3 cells grow in culture and stimulates anchorage-independent colony formation by MCF-7 breast cancer cells. The redox-inactive mutant Trx acted in a dominant-negative manner, so that transfected MCF-7 cells showed inhibited growth and a reversal of the transformed phenotype, assessed by growth in vitro and in vivo.
- a. Materials and Methods
- Human wild-type Trx cDNA and cDNA for C32/C35S redox-inactive Trx, in which both active-site cysteine residues are replaced by serine (Oblong, J. E, et al, J. Bio. Chem. 269:11714-11720, 1994), were prepared as described previously (Gasdaska, P. Y. et al., Biochem. Biophys. Ada., 1218:292-296, 1994: Oblong, J. E, et al., J. Biol. Chem., 269:11714-11720, 1994). The cDNAs were cloned into either the KpnI or SacI sites of the pRXneo mammalian transfection vector, under constitutive control of the Rous sarcoma virus promotor (Dieken, E. S, et al., Mol. Cell. Biol, 12:589-597, 1992), or into the NotI site of the pDC304neo mammalian transfection vector, in which constitutive expression is driven by the cytomegalovirus and SV-10 promoters (Gordon, D. A, et al., Exp. Cell Res., 217:368-377, 1995). Correct orientation of the cDNAs in the vectors was confirmed by restriction digestion. The pRXneo and pDC304neo vectors were obtained from Dr. Roger Miesfeld (University of Arizona, Tucson, Ariz.).
- Human MCF-7 breast cancer cells and murine NIH 3T3 cells were obtained from the American Tissue Type Collection. (Rockville, Md.), maintained in DMEM containing 10% FBS under 6% CO2 at 37° C., and passaged before confluence. NIH 3T3 cells were transfected with Trx:pRXneo, Trx:pDC304neo, C32S/C35S:pDC304neo, or pRXneo alone. MCF-7 cells were transfected with Trx:pDC304neo, C32S/C35S:pDC304neo, or pDC304neo alone. Transfection used liposomes of N-[1,2,3-dioleolylpropyl]-N,N,N-trimethylammonium-methylsulfate (Boehringer Mannheim, Indianapolis, Ind.) according to the manufacturer's instructions. Cells were selected by growing for 4 weeks in DMEM with 10% FBS and 400 μg/ml G418 sulfate (Life Technologies, Gaithersburg, Md.). Cell colonies were isolated by trypsinization onto small squares of sterile filter paper and expanded by growing in the same medium. All studies were conducted on clonal cell lines between
passages - Northern hybridization analysis of Trx and C32S/C35S mRNA used a full-length [α-32P]dCTP-labeled human Trx cDNA probe as described previously (Gasdaska, P. Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994), and the blots were quantified using a PhosphorImager (Molecular Dynamics, Sunnyvale, Calif.). Transfected Trx and C32S/C35S mRNA levels were expressed relative to endogenous Trx mRNA levels in the cells. Western analysis of lysates from Trx and C32S/C35S-transfected MCF-7 cells, prepared by sonicating the cells in 20 mm Tris-HCl buffer (pH 8.0), 137 mm NaCl, 1 mm MgCl2, 1 mm CaCl2, 10% glycerol, 1% Triton X-100, and 1 mm phenylmethylsulfonylfluoride, or in DMEM in which the cells had been incubated at 37° C. for 6 h, was performed using immunoaffinity-purified rabbit polyclonal IgG raised against human Trx (Gasdaska, J. R., et al., Cell Growth & Differ., 6:1643-1650, 1995) which also recognizes C32S/C35S. Detection used the enhanced chemiluminescence system (Amersham Life Sciences, Rockford, Ill.), and quantification of autoradiograms was by densitometry (Eagle Eye II, Stratagene, La Jolla, Calif.).
- Colony formation by MCF-7 cells was measured in soft agarose with DMEM and 10% FBS over 7 days, as described previously, (Alley, M. C, et al., Br. J. Cancer, 52:205-224, 1985).
- Growth of cells on plastic surfaces with DMEM and 10% FBS was measured daily for NIH-3T3 cells over 4 days and for MCF-7 cells over 7 days, as described previously (Powis, G, et al., Biochem. Pharmacol. 36:2473-2479, 1987). All cell growth studies were conducted in the absence of G418 sulfate.
- Tumor formation by transfected NIH 3T3 cells was studied by the s.c. injection of 107 transfected cells in 0.1 ml of sterile 0.9% NaCl into the backs of groups of four male Scid mice or six nude mice. Tumor formation by MCF-7 cells was studied by injecting 2×107 cells in 0.1 ml of sterile 0.9% NaCl and 0.1 ml of Matrigel (Becton Dickinson, Bedford, Mass.) s.c. into the backs of groups of four female Scid mice that had been implanted s.c. 2 days previously with 21-day release pellets of 0.25 mg of 17-P-estradiol (Innovative Research, Sarasota, Fla.). The 17-P-estradiol pellet was replaced at 21 days. Tumor volume was measured with calipers (Geran, R. I, et al., Cancer Chemother. Rep., 3:1-103, 1972) twice a week for 40 days. At the end of the study, the animals were killed, and tumors and other organs were taken for histological analysis.
- Statistical analysis was by nonpaired test unless otherwise stated. Tumor growth rates in Scid mice were linearized using the cube root of the tumor volume by day for each mouse, and ANOVA was performed using Dunnett's test to determine significant differences form the vector alone-transfected (control) cell line.
- b. Trx and C32S/C35S Transfection of NIH 3T3 Cells
- Transfection of mouse NIH 3T3 cells with Trx:pRXneo yielded 6 clones stably expressing Trx mRNA, transfection with Trx:pDC304 yielded 4 clones, and transfection with C32S/C35S:pDC304 neo yielded 12 clones. The levels of transfected mRNA in some of the clones is shown in
FIG. 6 . The human Trx and C32S/C35S mRNAs were larger than the endogenous mouse Trx mRNA, probably because the transfected Trx mRNAs also contain portions of the vector promoter region, the 5′ leader sequence, or the polyadenylate tail. The level of transfected Trx mRNA expression was relatively low, being only 0.2-1.4-fold the endogenous mouse Trx mRNA. Western blotting showed no significant increase in the level of Trx protein in the cells compared with wild-type or vector alone-transfected cells (results not shown). - The Trx-transfected NIH 3T3 cells grew at the same rate on a plastic surface, but reached saturation densities up to twice that of the vector alone-transfected NIH 3T3 cells (
FIG. 7 ). The vector alone-transfected cells had the same growth characteristics of wild-type NIH 3T3 cells. NIH 3T3 cells transfected with the redox-inactive C32S/C35S Trx grew more slowly and reached a lower saturation density on a plastic surface than the vector alone-transfected cells. Neither the vector alone-transfected NIH 3T3 cells nor the Trx or C32S/C35S Trx transfected cells formed colonies in soft agarose (results not shown). - The ability of transfected NIH 3T3 cells to form tumors when inoculated into immunodeficient mice is used to identify neoplastic transforming genes (Pitot, H. C. Fundamentals of Oncology, p. 149. New York: Marcel Dekker, Inc., 1981). When the Trx-transfected NIH 3T3 cells Thio6 or ThioAD were injected i.m. into Scid or nude mice, there was no tumor formation over 40 days (results not shown). Thus. Trx expression, at least at the level obtained in this study, was not, by itself, transforming.
- c. Trx and C32/C35S Transfection of MCF-7 Breast Cancer Cells
- Human solid cancer cells generally show a greater proliferation response to added Trx than do mouse fibroblasts (Oblong, J. E, et al., 7. Biol. Chem., 269:11714-11720, 1994; Gasdaska, J. R, et al., Cell Growth & Differ., 6:1643-1650, 1995). This is shown for MCF-7 human breast cancer cells compared with NIH 3T3 cells in
FIG. 8 . Thus, we also studied the effects of Trx transfection using MCF-7 breast cancer cells. Transfection of MCF-7 cells with Trx:pDC304neo yielded 31 clones that stably overexpressed Trx mRNA, and transfection with C32S/C35S:pDC304neo yielded 45 clones stably expressing C32S/C35S mRNA. Expression of transfected mRNAs by some of the clones is shown inFIG. 9 . As seen previously with the mouse cells, the transfected human Trx mRNAs in MCF-7 cells were larger than endogenous human Trx mRNA. The level of Trx mRNA expression was up to 0.8-fold and C32S/C35S mRNA up to 2.1-fold of the endogenous Trx mRNA levels. Light microscopy showed no difference in the appearance of vector alone-transfected and Trx-transfected MC F-7 cells growing on glass coverslips (FIG. 10 ), and both were similar to wild-type MCF-7 cells. In contrast, C32S/C35S-transfected MCF-7 cells appeared more rounded and had a reduced cytoplasm-to-nucleus ratio. - Quantitative Western immunoblotting showed no significant increase in the level of Trx protein in the transfected MCF-7 cells compared with vector alone-transfected MCF-7 cells except for one clone (Table 1). There was, however, a significant 60% increase in the secretion of Trx into the medium by three of the clones compared with the vector alone-transfected MCF-7 cells. The three other clones showed a 20-50% increase of Trx in the medium, but this was not statistically significant. Thus, it appears that most of the extra Trx and C2S/C35S produced by the transfected cells is secreted into the medium.
- All of the transfected MCF-7 cells showed linear growth characteristics on plastic surfaces over 7 days. The Trx-transfected cells grew at the same rate as the vector alone-transfected MCF-7 cells (
FIG. 11 ). However, when grown in the absence of, or with 0.5% FBS for 2 days, the Trx-transfected cell grew at twice the rate of the vector alone-transfected cells (results not shown). The C32S/C35S-transfected cells grew at a significantly slower rate that was 56-78% of the vector alone-transfected cells (FIG. 11 ). Colony formation was significantly increased between 3- and 4-fold for the Trx-transfected MCF-7 cells compared with the vector alone-transfected cells, and significantly decreased up to 73% for the C32S/C35S-transfected cells when the cells were grown in soft agarose. The vector alone-transfected cells showed growth characteristics identical to those of wild-type MCF-7 cells under all conditions (results not shown). - d. Tumor Formation by Trx- and C32s/C35s Transfected MCF-7 Cells
- The vector alone-transfected MCF-7 cells injected into Scid mice formed tumors that grew at the same rate as nontransfected MCF-7 cells we have seen in other studies. Trx-transfected MCF-7 cells formed tumors in Scid mice, although they grew at a significantly slower rate than tumors formed by vector alone-transfected cells: 57% for
Trx 12 cells and 38% forTrx 20 cells (both P<0.05 by least squares regression analysis;FIG. 12 ). Tumor formation by the C32S/C35S-transfected MCF-7 cells was almost completely suppressed. Tissues from the injection site and other organs were taken for histological examination at the end of the study. The animals injected with vector alone or Trx-transfected cells showed large solid tumors. The animals injected with C32S/C35S-transfected cells showed small microscopic tumor cell deposits. There was no evidence of tumor metastasis to other organs in any of the animals. Northern analysis of the tumor taken from animals injected with Trx-transfected cells showed the presence of transfected Trx mRNA as determined by its large size (results not shown). -
TABLE 1 Trx Levels in Transfected Mcf 7 Breast Cancer Cells and MediaClone Cella Medium MCF-7 vector 1.0 ± 0.0 1.0 ± 0.0 Trx 9 0.9 ± 0.0 1.6 ± 0.5* Trx 121.2 ± 0.1* 1.2 ± 0.2 Trx 201.1 ± 0.1 1.5 ± 0.2 Serb 4 0.9 ± 0.1 1.6 ± 0.6* Serb 15 0.8 ± 0.2 1.3 ± 0.2 Serb 19 1.2 ± 0.1* I.6± Trx or redox-inactive C32S/C35S (Serb)-transfected MCF-7 breast cancer cells (106) were incubated in 5 ml of DMEM for 6 hr. and Trx in the original cell pellet or in the medium measured by quantitative Western immunoblotting. Values are a mean of three separate determinations expressed relative to vector alone-transfected cells. a*P < 0.05 by a nonpaired/test compared with vector alone-transfected cells. - e. Discussion
- Trx regulates the redox state and activity of a number of intracellular proteins that control cell growth, including ribonucleotide reductase (Laurent, T. C, et al., J. Biol. Chem., 239:3436-3444, 1964) and the DNA binding of several transcription factors (Hayashi, T, et al., J. Biol. Chem. 268:11380-11388, 1993; Grippo, J. F, et al. J. Biol. Chem., 258:13658-13664, 1983; Abate, C, et al., Science (Washington D.C.), 249:1157-1161, 1990). Recombinant human Trx added to normal and cancer cells in culture stimulates their proliferation (Gasdaska, J. R, et al., Cell Growth & Differ., 6:1643-1650, 1995). However, it has not been demonstrated that endogenously produced Trx can stimulate cell proliferation. Furthermore, the role Trx may play in malignant transformation of cells is not known. The present study was undertaken to address some of these questions. NIH 3T3 cells transfected with Trx showed an increased cell saturation density when grown as a monolayer on plastic surfaces. Loss of contact inhibition is a feature of transformed cells (Pitot. H. C., Fundamentals of Oncology, p. 149, New York: Marcel Dekker, Inc., 1981), and the cell saturation density of the Trx-transfected NIH 3T3 cells was similar to that seen with other transformed, weakly tumorigenic mouse 3T3 cell lines (Schlager, J. J, et al., Cancer Res., 53:1338-1342, 1993). However, the Trx-transfected NIH 3T3 cells did not form tumors when inoculated into immunodeficient mice. The Trx-transfected MCF-7 cells did not show increased growth on plastic surfaces in normal FBS, but exhibited significantly increased anchorage-independent growth measured by colony formation in soft agarose. It is surprising that when the Trx-transfected MCF-7 cells were grown as xenografts in Scid mice, they exhibited decreased growth rate compared with vector alone-transfected MCF-7 cells. This may be because human Trx can stimulate the immune system of mice so that Trx secreted by the transfected MCF-7 cells might promote some immune rejection, even by the Scid mice, which, although deficient in mature B and T lymphocytes, have natural killer-, myeloid-, and antigen-presenting cells (Shultz, L. D. Am. J. Anat., 191:303-311, 1991).
- Both NIH 3T3 and MCF-7 breast cancer cells transfected with the C32S/C35S Trx showed slowed growth rates on a plastic surface. In addition, colony formation by MCF-7 breast cancer cells in soft agarose was considerably decreased. When injected into Scid mice, the C32S/C35S-transfected MCF-7 cells formed only microscopic tumors. C32S/C35S is a redox-inactive mutant Trx that acts as competitive inhibitor of Trx reductase (Oblong, J. E, et al., J. Biol. Chem., 269:11714-11720, 1994). Our X-ray crystallographic studies have identified a highly conserved 12 amino acid hydrophobic surface on mammalian, but not bacterial, Trxs, which stabilizes the Cys73-mediated disulfide-bonded dimer (Weichsel, A, et al., Structure, 4:735-751, 1996). The physiological function of this Cys73-Cys73 linked Trx dimer is not known. The surface structure of C32S/C35S is very similar to that of Trx (Weichsel. A, et al., Structure, 4:735-751, 1996) so that C32S/C35S is likely to participate in the formation of a heterodimer with Trx and thus might lower Trx monomer concentrations or affect the biological activity of the dimer. Unlike wild-type Trx, C32S/C35S does not stimulate cell growth when added to the culture medium. C32S/C35S might also act as a competitive inhibitor to the normal redox-active substrates of Trx. Whatever the mechanism, it appears that C32S/C35S acts in a dominant-negative manner to inhibit the effects of endogenous Trx and, in so doing, inhibits cell growth and reverses the transformed phenotype of MCF-7 breast cancer cells.
- Most of the added Trx or C32S/C35S protein, that is produced by the transfected cells appears to be secreted into the medium. Whether the transfected Trx is produced in a different compartment to endogenous Trx, allowing it to be secreted, or whether a constant proportion of Trx is secreted is not known. Trx is known to be secreted from cells by a leaderless secretory pathway (Rubartelli, A, et al., J. Biol. Chem., 267:24161-24164, 1992). The concentrations of Trx found in the medium, up to 10 nm after 6 hr, are lower than those required to directly stimulate cell proliferation (Gasdaska, J. R, et al., Cell Growth & Differ., 6: 1643-1650, 1995). However, we have recently found that Trx at nanomolar concentrations will potentiate the growth effects of cytokines such as interleukin-2 and basic fibroblast growth factor. It remains to be established whether the extra trx is producing its effects on cell proliferation through an intracellular or an extracellular action. It should be noted that Trx binds to the surface of cells (Gasdaska, J. R, et al., Cell Growth & Differ., 6:1643-1650, 1995; Ifversen, P, et al., Hum. Antib. Hybrid, 4:115-123, 1993) so that secreted Trx could have a local effect at the outer cell surface although concentrations in the medium are low.
- The levels of transfected Trx miRNA in cells were not high, only up to 1-fold endogenous trx mRNA levels, and were independent of the mammalian transfection vector used. Typically mRNA levels resulting from transfection using such vectors are 10-50-fold or higher (Powis, G, et al., Anticancer Res., 15:1141-1146, 1995). It may be that high levels of Trx gene expression are toxic to cells. We have found only a low expression of the human Trx gene in transgenic mice. In contrast, some human tumors show very high levels of Trx mRNA compared with the normal tissue: more than 11-fold in human primary lung tumors (Gasdaska, P, et al., Proc. Am. Assoc. Cancer Res., 34:62, 1993) and even higher in human primary colon tumors (Berggren, M, et al., Anticancer Res., 17:3371-3380, 1997). It is not known why higher trx mRNA levels could not be obtained in transfected cells. We were unable to obtain transformation of NIH 3T3 cells with Trx. It remains to be demonstrated whether the much higher levels of Trx expression seen in some human tumors might be transforming.
- The observation that a redox-inactive dominant-negative Trx reverses the transformed phenotype of MCF-7 cells suggests that drugs that inhibit the redox activity of Trx might offer a novel approach to treating some forms of human cancer. Alternatively, inhibiting the enzyme responsible for the reduction of trx, the flavoprotein Trx reductase, might also lead to a selective inhibition of cancer cell growth. We have shown previously that some antitumor quinones, including doxorubicin and diaziquone, are mechanism-based (suicide substrate) inhibitors of Trx reductase both in the purified form and in intact cells (Mau, B. L, et al., Biochem. Pharmacol, 43:1621-1626, 1992). However, the antitumor quinones have many other effects that could contribute to their antitumor activity (Powis, G. Pharmacol Ther., 35:157-162, 1987). On the basis of our transfection studies, it would be of great interest to see what effect selective inhibitors of Trx or its reductase have on cancer cell growth and transformation.
- In summary, our results have shown that stable transfection of nontransformed mouse fibroblast-like cells and human breast cancer cells with human Trx leads to low levels of overexpression and increased cell saturation densities but no transformation, measured by tumor formation of NIH 3T3 cells in immunodeficient mice, Stable transfection with redox-inactive mutant Trx results in a dominant-negative effect with inhibition of mouse cell and human breast cancer cell growth and reversion of the transformed phenotype of human breast cancer cells, measured by their ability to form colonies in soft agarose and to form tumors in mice. The Trx produced appears to be secreted mostly from cells, and whether the Trx is having an intracellular or extracellular action remains to be determined.
- In the majority of the subjects tested ( 8/10), human primary gastric carcinomas thioredoxin was over-expressed in tumor cells compared to normal mucosa, and in all cases the over-expression was found only in the cancer cells and not in stromal cells or infiltrating lymphocytes. Levels of thioredoxin significantly higher than in normal dividing cells, were found in ⅝ of the over-expressing carcinomas. To relate thioredoxin over-expression to cell proliferation and apoptosis, nuclear proliferation antigen was detected by Ki67 antibody and apoptosis by the in situ terminal deoxynucleotidyl transferase (TUNEL) assay were measured in the same tissue samples. (See Table 2). Thioredoxin expression was significantly and highly positively correlated with-nuclear proliferation antigen (p<0.01) a marker of aggressive tumor growth and highly negatively correlated with apoptosis (p<0.001) a form programmed cell death that is presumed to limit tumor growth. Thus, thioredoxin is over-expressed at the mRNA and protein level in a number of human primary tumors. Further, the expression of thioredoxin protein is directly associated with highly proliferative tumors.
-
TABLE 2 Staining of Thioredoxin in Human Gastric Cancers: Comparison with Cell Proliferation and Apoptosis Tumor Tumor Thiredoxin Thioredoxin Proliferation Apoptosis Patient # Normal* Tumor Ki-67 Tunel 1. ++ ++++ +++ + 2. ++ +++ +++ + 3. ++ ++++ NE + 4. ++ ++++ ++++ + 5. ++ +++ +++ ++ 6. ++ 0 + ++++ 7. ++ + + +++ 8. ++ 0 + ++++ 9. ++ ++ +++ +++ 10. ++ ++ NE ++ Staining scored as absent (0) or weak (+) to intense (++++) *= gastric pits; NE = non evaluable - MCF-7 human breast cancer cells were transfected with cDNA for thioredoxin or with a catalytic site redox-inactive mutant thioredoxin, C32S/C35S, using two constitutive eukaryotic expression vectors (pRXneo and pDC304neo) and a number of clones were selected for each. The level of transfected thioredoxin and C32S/C35S thioredoxin mRNA was up to 2-fold the endogenous message. Both types of transfected cells showed increased thioredoxin protein production, measured by quantitative Western blotting, up to 100% that of mock-transfected cells.
- There was little difference in the growth of the transfected cells formed up to 4-fold more colonies when grown in soft agarose and the C32S/C35S transfected cells formed up to 80% fewer colonies as illustrated in
FIGS. 4A-B . - When these cells were injected into Scid mice the thioredoxin transfected cells formed tumors while the C32S/C335S transfected cells did not form tumors, as illustrated in
FIG. 5 . This was confirmed by histology. Thus, a dominant-negative redox inactive thioredoxin can reverse the transformed phenotype and inhibits tumor growth in vivo providing molecular biology evidencing that thioredoxin is a novel target for anti-cancer drug development. - Although thioredoxin is a known protein, it has not been disclosed or suggested that thioredoxin be used as a screen for anti-tumor agents. It has now been shown that stable transfection of the MCF-7 breast cancer cells with a redox-inactive mutant thioredoxin causes inhibition of anchorage-independent growth of the cells in soft agarose and causes complete inhibition of tumor formation in vivo. The redox-inactive mutant is formed from thioredoxin where the catalytic site cysteine residues are replaced with serine. Further, it was shown that the mutant thioredoxin did not inhibit monolayer growth of the cells, i.e., does not inhibit normal cell growth, while it causes inhibition of anchorage-independent growth of the cells in soft agarose, i.e., does inhibit an in vitro characteristic of tumor cell growth. This is the activity that would be expected from drugs that inhibit thioredoxin.
- a. Examples of Agents that Inhibit Thioredoxin
- Agents that inhibit thioredoxin have been identified in accordance with the present invention, such agents may be antibodies, drugs or antisense. A series of unsymmetrical 2-imidazolyl disulfides were investigated as inhibitors of the thioredoxin system and as potential anti tumor agents. Although these agents, such as 1-methylpropyl 2-imidazolyl disulfide, were originally identified as competitive inhibitors of thioredoxin reductase (Oblong J E, et al., Cancer Chemother. Pharmacol, 34:434-438, 1994) but it has now been shown that they also to bind irreversibly to Cys73 of thioredoxin and to block its reduction by thioredoxin reductase. A number of these disulfide compounds have been studied and have demonstrated anti-tumor activity against human tumor xenografts in Scid mice with up to 90% inhibition of MCF-7 breast cancer and HL-60 promyelocytic leukemia growth. It has now been demonstrated that the imidazolyl disulfides inhibit thioredoxin-dependent cell growth (Oblong J E, et al., Cancer Chemother. Pharmacol, 34:434-438, 1994) and that their growth inhibitory activity in the
National Cancer Institute 60 human tumor cell line panel correlates with levels of thioredoxin mRNA in these cell lines (Berggren M, et al., Anticancer Res., 16:3459-3466, 1996), A COMPARE correlative analysis of the activity of the lead disulfide compounds in the NCI cell line panel with over 50,000 compounds already tested for cell growth inhibition by the NCI was conducted in order to identify compounds with a similar pattern of growth inhibitory activity. Some of the compounds identified in this way were inhibitor of thioredoxin reductase and some were inhibitors of thioredoxin. - Although the general properties of human thioredoxin reductase as a protein and the cDNA base sequence of human thioredoxin reductase has been known in the art, it has now been discovered that thioredoxin reductase is useful as an anti-cancer drug target. It has now been shown above that redox activity is necessary for the growth stimulating activity of thioredoxin. Since thioredoxin reductase is the only known way for thioredoxin to be reduced biologically it is an obvious extension of the above observations that thioredoxin reductase could also be a target for the development of anti-cancer drugs.
- It has been discovered that human thioredoxin, and specifically recombinant modified thioredoxin (mutated thioredoxin), does not undergo spontaneous oxidation and/or dimer formation, or protected against breakdown by blood and tissues, may have therapeutic utility in situations where stimulation of cell growth is preferred or required. In a non-limiting embodiment of the present invention, such new uses include, and are not limited to, the beneficial use of thioredoxin and/or recombinant modified thioredoxin in stimulating cell proliferation in individuals (1) with myelodysplastic syndrome; (2) in need of bone marrow transplantation; (3) with post-chemotherapy to stimulate bone marrow growth; (4) in need of stimulation of the immune system; (5) in need of stimulation of wound healing; (6) such as transgenic animals in need of stimulation of body growth; (7) in need of simulation of the responses to cytokines and growth factors for growth stimulation effects; and (8) in gene therapy techniques.
- The underlying defect in myelodysplastic syndrome is decreased multilineage progenitor cell growth associated with decreased sensitivity to growth factor stimulation. Thioredoxin acts to increase the sensitivity of cells to growth factors and stimulates multilineage progenitor cells which provides a beneficial utility in individuals with MDS.
- In individuals in need of bone marrow transplantation, it would be of great utility to promote the growth of transplanted cells. Thioredoxin may be used to protect hematopoietic progenitor cells and to expand cells ex vivo for bone marrow cell growth. This would rely on a selective effect for bone marrow since tumor cells might also be stimulated by the thioredoxin.
- It would provide a great benefit to individuals subject to chemotherapy treatment to selectively stimulate bone marrow cell growth post-chemotherapy.
- It has been found that Cys73->Ser mutant thioredoxin will stimulate the proliferation of human immune cells in culture, which can provide a great benefit to individuals in need of stimulation of immune system cells.
- Wild-type and Cys73->Ser mutant thioredoxin also stimulates the growth of fibroblasts, which are important components of wound healing process. There would be a great advantage of using thioredoxins to stimulate wound healing, for example after surgery.
- It has been found that wild-type thioredoxin expressed as a transgene in mice may be lethal or is only weakly expressed. Therefore, it is possible that construction of transgenes with wild-type or mutant forms of thioredoxin, with or without tissue specific and/or inducible promoters, could be used to stimulate the development of the animal or the growth of selected organs.
- It has been found that thioredoxin can potentiate the response of cells in culture to growth factors and cytokines such as IL-2 and basic fibroblast growth factor (bFGF). Combinations of thioredoxin with other growth factors or cytokines therefore increases the therapeutic usefulness of these growth factors where increased cell proliferation is the desired therapeutic effect.
- Introduction of the thioredoxin or mutant thioredoxin genes into human cells provides a mechanism of improving the therapeutic usefulness of other cytokines or growth factors given directly or themselves as gene therapy, for example IL-2.
- a. Examples of Stimulation of Cell Growth Using Thioredoxin Protein
- Although thioredoxin mRNA has been found to be over expressed by some human tumor cells, it has been discovered that thioredoxin, specifically recombinant modified thioredoxin also stimulates cell growth.
- A novel mechanism or over-expression and secretion from the cells by a leaderless secretory pathway has important consequences for potential therapeutic uses of thioredoxin as explained below. It has been discovered that human recombinant thioredoxin undergoes spontaneous oxidation in air to give a form that will not stimulate cell growth. This spontaneous oxidation appears to involves Cys73 since a mutant thioredoxin where this residue has been converted to serine (Cys73->Ser thioredoxin) does not undergo this loss of activity. X-ray crystallography studies of wild-type and C73S thioredoxin show that thioredoxin has a highly conserved hydrophobic dimer forming surface and that Cys73 stabilizes homodimer formation through a Cys73-Cys73 disulfide bond (Weichsel A, et al. Structure 4:735-751 (1996)). The active site Cys residues become relatively inaccessible in the thioredoxin homodimer so that it is a very poor substrate for thioredoxin reductase. The thioredoxin homodimer does not stimulate cell proliferation. The half life of recombinant human thioredoxin in phosphate buffered 0.9% NaCI at −20° C. is 6-8 days. Thus, the wild type thioredoxin is not a good protein for therapeutic use because of is tendency to oxidize and lose biological activity.
- It has been found that wild-type thioredoxin loses its ability to stimulate cell proliferation even over a few days even before formation of the Cys73-Cys73 disulfide stabilized dimer. This appears to be due to modification of the monomeric form of thioredoxin possibly involving reversible dimerization without covalent linkage, or to other oxidative events in the protein. In contrast, it has been found that Cys73->Ser thioredoxin is stable in solution over several weeks, even at room temperature, and does not dimerize. Cys73->Ser thioredoxin is as effective as wild-type thioredoxin at stimulating cell proliferation and retains this ability with no loss over many days and, thus, appears to be more suitable as a potential therapeutic agent.
- In order to investigate whether thioredoxin and mutant thioredoxin proteins have activity in intact animals I studied the ability of the Cys73->Ser mutant thioredoxin to prolong the life of mice that had been lethally y-irradiated and which, if untreated, die from bone marrow suppression as shown in Table 3. Mice that had been injected with the Cys73->Ser mutant thioredoxin survived 850 Gy y-radiation whereas non-injected mice died. Thus, Cys7->Ser mutant thioredoxin can prevent the death of lethally y-irradiated mice. While not wishing to be bound to any particular theory, it is presumed that this effect is due to stimulation of bone marrow cell growth.
-
TABLE 3 Protection Against Radiation Induced Death by Cys73−>Ser Mutant Thioredoxin Cys72−>Ser thioredoxin mouse control day of death day of death 1 11 alive 2 16 alive 3 16 alive 4 16 alive 5 17 alive median 1.6 ± 2.1 alive Mice received 8.5 Gy y-irradiation. One group of mice was treated with Cys73−>Ser thioredoxin in 0.9% NaCl 0.85 mg/mouse injected i.v. 30 min before and 24 hr. after radiation. There were 6 mice m the control group and 4 mice in the treated group. The study was terminated on day 30. - Evidence that Cys73->Ser mutant Thioredoxin stimulates the growth of bone marrow was obtained directly by adding Cys73->Ser mutant thioredoxin directly to human bone marrow and studying its effects on colony formation by the cells, as illustrated in
FIG. 1 . Cys73->Ser mutant thioredoxin stimulates colony formation by the multilineage progenitor cells (CFU-GEMM) but does not stimulate the lineage specific erythroid progenitor (BFU-E) and myeloid progenitor (CFU-GM) cells. - 1 illustrates the stimulation of human bone marrow colony formation by Cys73->Ser mutant thioredoxin, in accordance with the present invention. Human bone marrow was obtained as excess material from normal allogeneic bone marrow donors. The effects of Cys73->Ser thioredoxin on colony formation are shown by (o) multilineage progenitors (CFU-GEMM); (•) erythroid progenitors (BFU-E); and (∇) myeloid progenitors (CFU-GM), as measured over 10 days as described. (Values are the mean of 4 determinations and bars are S.D.)
- It has further been found that Cys73->Ser thioredoxin can stimulate cell proliferation by increasing the response of the cells to other cytokines or growth factors such as interleukin-2 (IL-2) and fibroblast growth factor (FGF) as illustrated in the chart in
FIG. 2 .FIG. 2 illustrates potentiation of IL-2 induced MCF-7 breast cancer cell growth by Cys73->Ser mutant thioredoxin, in accordance with the present invention. Cells were growth arrested for 48 hr, in medium with 0.5% serum (10s cells) then stimulated in the absence of medium with either IL-2 or Cys32->Ser mutant thioredoxin at the concentrations shown, Cell number was measured after 48 hr. Each point on the chart represents the mean of 3 determinations and bars represent S.E. The dotted line shows stimulation by 10% serum. - In addition, antibodies to the receptors for the growth factors can block the response to these agents, in accordance with the present invention as shown in
FIG. 3 .FIG. 3 illustrates the inhibition of thioredoxin stimulated MCF-7 cell growth by receptor antibodies, in accordance with the present invention. Cell proliferation was measured as described above in the context ofFIG. 2 . The concentrations of agents used were Cys73->Ser mutant thioredoxin (Thioredoxin) 1 μM; monoclonal antibodies to FGF receptor, IL-2-receptor and EGF-receptor 4 μg/ml; andEGF 10 nM. The EGF and EGFR were added as a negative control. Values represent the mean of 3 determinations and bars represent S.E. The dotted line shows the effect of 10% serum alone. - Therefore, the discovery that human thioredoxin, and specifically recombinant modified thioredoxin, does not undergo spontaneous oxidation and/or dimer formation has a tremendous potential in vivo utility in situations where stimulation of cell growth is required. In addition, it may be advantageous to modify the thioredoxin structure to increase the potency and therapeutic usefulness, such as changing the amino acid sequence at the site of proteolytic cleavage to prevent breakdown by plasma enzymes.
- Thioredoxin/mutant thioredoxin may have use after bone marrow transplantation of cancer patients or together with chemotherapy to stimulate bone marrow recovery, or to stimulate the immune system in patients with AIDS. There may be other potential therapeutic applications for thioredoxin/mutant thioredoxin such as increasing the rate of wound healing. If a thioredoxin or mutant thioredoxin gene could be introduced into an animal as a transgene this might result in an increased growth rate of the animal. A thioredoxin transgenic mouse has been developed, although the levels of gene expression are very low and the animal does not show an increased growth rate. However, a gene for mutant thioredoxin might be more effective in this regard. The use of mutant thioredoxins may not be limited to the Cys73->Ser mutant. Mutation of the other Cys residues can also affect biological activity. There are also other amino acid residues on the hydrophobic domain of the molecule that X-ray crystallographic studies have shown might also be important for dimer formation. Mutation of these and possibly other amino acid residues, might alter the biological activity of thioredoxin.
- The in vitro cell growth stimulating activity of human thioredoxin has been previously reported for human lymphoid and solid tumor cancer cells (Gasdaska J R., et al., Cell Growth Differ., 6:1643-1650, 1995; Oblong J E, et al., J. Biol. Chem., 269:11714-11720, 1994) and for mouse fibroblast cells (Oblong J E, et al., J. Biol. Chem., 269:11714-11720, 1994). The production of a Cys73->Ser mutant thioredoxin has been previously reported. In one study it did not act like wild-type thioredoxin as a component of a complex cell growth stimulating factor called “early pregnancy factor” (Tonissen K, et al., J. Biol. Chem., 268:22485-22489, 1993). In another study it was reported that Cys73->Ser mutant thioredoxin did not form a dimer, but cell growth stimulating activity by the mutant thioredoxin was not investigated in this study (Ren X, et al, Biochem., 32:9701-9705, 1993). However, the ability of the Cys73->Ser mutant and other mutant thioredoxins to stimulate cell proliferation has not been reported. There have been no prior reports of administration of wild-type or mutant thioredoxins in vivo.
- b. Role of Oxidative Inactivation of Thioredoxin as a Cellular Growth Factor
- Thioredoxin (Trx) is a widely distributed redox protein that regulates several intracellular redox-dependent processes and stimulates the proliferation of both normal and tumor cells. We have found that when stored in the absence of reducing agents, human recombinant Trx undergoes spontaneous oxidation, losing its ability to stimulate cell growth, but is still a substrate for NADPH-dependent reduction by human thioredoxin reductase. There is a slower spontaneous conversion of Trx to a homodimer that is not a substrate for reduction by thioredoxin reductase and that does not stimulate cell proliferation. Both conversions can be induced by chemical oxidants and are reversible by treatment with the thiol reducing agent—dithiothreitol. SDS-PAGE suggests that Trx undergoes oxidation to monomeric form(s) preceding dimer formation. We have recently shown by X-ray crystallography that Trx forms a dimer that is stabilized by an intermolecular Cys73-Cys73 disulfide bond. A Cys73->Ser mutant Trx (C73S) was prepared to determine the role of Cys73 in oxidative stability and growth stimulation. C73S was as effective as Trx in stimulating cell growth and was a comparable substrate for thioredoxin reductase. C73S did not show spontaneous or oxidant-induced loss of activity and did not fort a dimer. The results suggest that Trx can exist in monomeric forms, some of which are mediated by Cys73 that do not stimulate cell proliferation but can be reduced by thioredoxin reductase. Cys73 is also involved in formation of an enzymatically inactive homodimer, which occurs on long term, storage or by chemical oxidation. Thus, although clearly involved in protein inactivation, Cys73 is not necessary for the growth stimulating activity of Trx.
- Trx is a redox protein found in both eukaryotes and prokaryotes (Holmgren A., Annu. Rev. Biochem., 54:237-271, 1985). The redox activity of Trx arises from a highly conserved Trp-Cys-Gly-Pro-Cys-Lys active site sequence where the 2 cysteine residues (Cys) undergo reversible oxidation to cystine. Reduction of Trx is catalyzed by thioredoxin reductase (Luthman M, et al., Biochem., 21:6628-6633, 1982). Trx was originally identified in Escherichia coli as a hydrogen donor for ribonucleotide reductase (Laurent T C, et al., J. Biol. Chem., 239:3436-3444, 1964). Trx has since been found to act as an intracellular dithiol-disulfide reductase and to modulate the activity of a number of intracellular proteins (Fountoulakis M., J. Biol. Chem., 267:7095-7100, 1992;
Kistner 25 A. et al., Toxicon., 31:1423-1434, 1993; Silverman R B et al., Biochem. Biophys. Res. Commun., 155:1248-1254, 1988) including the DNA binding of transcription factors (Hayashi T, et al., J. Biol. Chem., 268:11380-11388, 1993; Gaiter D, et al., Eur. J. Biochem., 221:639-648. 1994; Grippo J F et al., J. Biol. Chem., 258:13658-13664, 1983; Cromlish J A et al., J. Biol. Chem., 264:1.8100-18109, 1989). Trx-like sequences are found in other proteins including protein disulfide isomerase (Freedman R B et al., Trends Biochem. ScL., 19:331-336, 1994). There is evidence that Trx may play a role in the growth and transformed phenotype of some cancers. Trx is over expressed by a number of human cancers compared with normal tissue (Berggren M, et al., Anticancer Res. 17:3377-3380, 1997); Gasdaska P Y et al., Biochem. Biophys. Acta, 1218:292-296, 1994, Nakamura H, et al., Cancer 69:2091-2097, 1992). It has recently been shown that transfection of human cancer cells with, a dominant-negative mutant human Trx inhibits anchorage-independent growth in vitro and tumor formation in vivo (Gallegos A, et al., Cancer Res. 56:5765-5770, 1996). - As well as having intracellular actions, Trx acts exogenously as a redox-active growth factor. Human Trx is identical to the leukemic cell autocrine growth factor adult T-cell leukemic factor (Gasdaska P Y et al., Biochem. Biophys. Ada., 1218:292-296, 1994), and stimulates the growth of both normal fibroblasts (Oblong J E et al., J. Biol. Chem., 269:11714-11720, 1994) and human hematologic and solid tumor cancer cells in culture (Wakasugi N, et al. Proc. Natl. Acad. Sci USA, 87:8282-8286, 1990; Gasdaska J R et al., Cell Growth Differ., 6:1643-1650, 1995). Trx appears to act by a helper mechanism that sensitizes the cells to growth factors secreted by the cells themselves (Gasdaska J R et al., Cell Growth Differ, 6:1643-1650, 1995). Mutant human Trxs, where the Cys32 and Cys35 residues at the catalytic site (numbering of amino acid residues is from the N-terminal methionine, although this may be removed in some forms of Trx) are converted to serines (Ser) either singly or together, are redox inactive and do not stimulate cell growth (Oblong J E, et al., J. Biol. Chem., 269:11714-11720, 1994). Trx is secreted from cells by a leaderless secretory pathway (Rubartelli A, et al., J. Biol. Chem., 267:24161-24164, 1992) and could be acting as an autocrine factor for the growth of some cancer cells (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995).
- We have found that E. coli Trx, unlike human Trx, does not stimulate the growth of human solid cancer cells (Gasdaska J R, et al., Cell Growth Differ., 6:1643-1650, 1995). The structures of E. coli and human Trx are similar, and both are substrates for human thioredoxin reductase. However, the surface residues of the two forms vary considerably (Weichsel A, et al., Structure 4:735-751, 1996). Human Trx has 3 additional cysteine residues, Cys62, Cys69 and Cys73, in addition to those in the active site, which do not normally form intramolecular disulfide bonds (Weichsel A, et al., Structure 4:735-751, 1996; Forman-Kay J D et al., Biochem., 30:2685-2698, 1991). Trx can also form a homodimer with al 100 A2 interface domain and a disulfide bond between Cys73 from each monomer (Weichsel A, et al., Structure 4:735-751, 1996). During our studies of cell growth stimulation by Trx we observed that storage of the Trx without a reducing agent for even a few days resulted in a loss of its growth-stimulating activity, although the Trx remained a substrate for reduction by thioredoxin reductase. We have, therefore, examined the, role of spontaneous and induced oxidation of Trx and cysteine-deleted mutant Trxs, and their ability to stimulate cell proliferation.
- (i) Preparation of Thioredoxins
- Recombinant human Trx and Cys32->Ser/Cys35->Ser mutant Trx (C32S/C35S) were prepared and purified as previously described (Oblong J E et al., J. Biol. Chem., 269:11714-11720, 1994). Cys73->Ser mutant human Trx (C73S) was prepared from single-stranded, sense strand human Trx cDNA ligated by polyethylene glycol precipitation into the pBluescript KS vector (Stratagene, La Jolla, Calif.) using helper phage. The single-stranded cDNA was used for oligonucleotide-directed in vitro mutagenesis (Version 2.1 Kit, Amersham, Buckinghamshire, U.K.) using
oligonucleotide 5′-TGTTGCATGGATTTGACTTC-3′. Point mutagenesis was confirmed by dideoxy sequencing of base-denatured double-stranded. DNA using the Sequenase Version 2.0 kit (USB, Cleveland, Ohio). Novel Nde1 and BamH1 restricted sites were introduced at the 5′ and 3′ ends of the mutant Trx cDNA by oligonucleotide-directed PCR. Ndel/BamHI restricted fragments were extracted from agarose gels, ligated into a suitably restricted pET-3a expression vector (Studier F W et al., Methods Enzymol., 185:60-89, 1991), transformed into E. coli BL21 cells and confirmed by dideoxy sequencing. C73S Trx was expressed and purified as previously described (Oblong J E et al., J. Biol. Chem., 269:11714-11720, 1994). All Trxs were stored at −20° as a 25 μM stock solution in 5 mM DTT. Before use, the DTT was removed by passing the Trx solution through a PD-10 desalting column (Pharmacia, Uppsala, Sweden). The Trx solution was kept at 4° and used within 2 hr. (fresh) or stored in water or 0.1 M potassium phosphate-buffered 0.9% NaCI at 4° or −20° for specified times. Oxidized Trx for cell growth studies was prepared by adding a 5-fold molar excess of H2O2, to a 25 μm Trx stock solution without DTT and 1 hr. later removing unrecalled H2O2 using a PD-10 column. - (ii) Cell Growth Studies
- MCF-7 human breast cancer cells were obtained from the American Type Culture Collection (Rockville, Md.) maintained in DMEM containing 10% fetal bovine serum at 37° and 6% CO2, and passaged at 75% confluence. The effect of Trx and modified Trxs on MCF-7 cell growth was determined as previously described (Gasdaska J R et al., Cell Growth Differ., 6:1643-1650, 1995). Briefly, 105 cells were plated in a 35-mm culture dish in DMEM containing 10% fetal bovine serum and, after attachment for 24 hr., growth arrested using DMEM with 0.5% fetal bovine serum for 48 hr. The medium was then replaced with DMEM containing Trx or other additions for 2 days and cell number measured with a hemocytometer. All incubations were conducted in triplicate.
- (iii) Thioredoxin Reductase Assay
- Human placenta thioredoxin reductase, specific activity 33.3 μmol Trx reduced/min/mg protein, was prepared as previously described (Oblong J E et al., Biochem., 32:7271-7277, 1993). Reduction of Trx and C73S by thioredoxin reductase was measured by the oxidation of NADPH at 340 nM with insulin as the final electron acceptor as described by Luthman and Holmgren (Luthman M, et al., Biochem., 21:6628-6633, 1982).
- (iv) Electrophoresis
- A 25 μM solution of fresh Trx, mutant C73S or C32S/C35S Trxs, Trxs that had been aged at room temperature for 48 hr., 7 days, 90 days; or Trxs treated for 1 hr. with 1 mM diamide, 10 mM DTT, 3 mM 2-mercaptoethanol or 2:1 (v:v) H2O2, was mixed with an equal volume of loading buffer containing 3% SDS, 10% glycerol and 0.1% bromophenol blue in 0.05 M Tris-HCI, pH 6.8. Approximately 0.02 ng of the protein was 30 loaded in each lane of a 24×45 cm 16.5% polyacrylamide resolving gel (pH 8.4) containing 0.3% SDS, a 10% spacer gel and a 6% stacking gel and separated by electrophoresis using an anode buffer of 0.2M Tris-HCI, pH 8.9 and cathode buffer of 0.1 M Tris-HCI, 0.1% SDS, pH 8.2. The gel was run for 1. hr. at 400 volts before loading the samples and then at 400 volts for 24 hr. before fixing in 50% methanol, 7.5% acetic acid for 20 min, followed by 5% methanol, 7.5% acetic acid for 20 min, followed by 10% glutaraldehyde for 20 min. The gel was soaked in 2 L H2O overnight to remove unbound SDS and then silver stained (ICN Silver Stain Kit, Irvine, Calif.), Similar observations were made when the gels were stained with Coomassie Blue.
- (v) Growth Stimulation
- Cys73->Ser mutant Trx (C73S) stimulated the proliferation of human MCF-7 breast cancer cells. The EC50 for growth stimulation by C73S was 350 nM and the maximum effect was seen at 1 μM, which is similar to values we have previously reported for stimulation of MCF-7 cell proliferation by recombinant human Trx (Gasdaska J R et al., Cell Growth Differ 6:1643-1650, 1995). Storage of Trx in the absence of a reducing agent such as DTT at 40 for 5 days resulted in a 78% loss, and for 90 days a 98% loss of cell growth stimulating activity (
FIG. 13 ). In contrast C37S showed no loss of activity when stored under these conditions. Trx stored in the presence of bovine catalase at 1 unit/ml did not lose biological activity over a 5-day period (results not shown). - (i) Reduction of Thioredoxin by Thioredoxin Reductase
- C73S was a good substrate for reduction by human placental thioredoxin reductase with a Km of 0.20 μM and a Vmax of 6.3 nmol/min/μg. These values are similar to those we have previously found for fresh Trx, which were a Km of 0.33 μM and a Vmax of 5.9 nmol/min/μg (Oblong J E et al., Biochem., 32:7271-7277, 1993).
- The effect of storing Trx without DTT on its ability to act as a substrate for thioredoxin reductase was investigated (Table 4). When stored in H2O either at −20° or at room temperature Trx showed a loss of activity with a half-life of 20-30-days. The loss of Trx activity was more rapid when stored in phosphate-buffered 0.9% NaCl, with a half life of 8 days. Phosphate buffer is known to contain small amounts of iron (Poyer J L et al., J. Biol. Chem., 246:263-269, 1971), which could catalyze an oxidative process increasing the loss of Trx activity. Alternatively, the lower pH of the solution in water could stabilize Trx or the increase in ionic strength of phosphate-buffered 0.9% NaCl could enhance the formation of the inactive homodimer of Trx. The aged Trx showed a slow, delayed reduction by thioredoxin reductase that was stimulated by catalytic amounts of fresh Trx (
FIG. 14 ). It is important to note that the loss of activity of Trx as a substrate for thioredoxin reductase was much slower than the loss of activity as a stimulator of cell growth. C73S did not show a loss of activity as substrate for thioredoxin reductase upon storage for up to 30 days. The ability of Trx to act as a substrate for thioredoxin reductase was completely inhibited by treatment with 5 molar equivalents of H2O2, whereas C37S remained fully active after treatment with 100 molar equivalents of H2O2 (FIG. 15 ). -
TABLE 4 Effect of Storage of Thioredoxins As Substrates for Thioredoxin Reductase InH20 In PBS −20° +21° −20° −21° t½(days) t½(days) t½ (days) t½ (days) Trx 30.5 20.1 8.2 7_8 C73S stable* stable* stable* stable* 25 μMstock solution of Trx of C73S in H2O or phosphate buffered 0.9% NaCl (PBS) free of D77 were stored frozen at −20° or at room temperature (+21°) for up to 60 days and their ability to act as a substrate for reduction by human placental thioredoxin was measured. A first order decrease in activity was found for Trx and the results are expressed as half-life *<10% loss of activity over 30 days. - (vii) Multiple Forms of Thioredoxin
- Electrophoretic analysis of freshly prepared human Trx stored in DTT showed a mixture of 5 bands of apparent molecular weights ranging from 8.1 to 11 kDa (
FIGS. 16 , 17, and 18, lane 1). Storage of Trx at room temperature without DTT resulted in a change in the banding pattern with disappearance of the 8.1-kDa band by 48 hr. (FIG. 16 , lane 2). Storage of Trx without DTT for 7 days resulted in the loss of additional bands and the appearance of a new band at 23 kDa due, apparently, to a Trx dimer (FIG. 16 , lane 3). Storage of Trx without DTT for 90 days at 4° resulted in almost complete conversion to the Trx dimer (FIG. 16 , lane 4). Treatment of 7-day aged Trx (FIG. 17 , lane 2) with 2-mercaptoethanol resulted in the reappearance of the fresh Trx banding pattern, except for the 8.1-kDa band, which did not reappear (FIG. 17 , lane 3). Loss of the smaller bands and dimer formation was seen when Trx was treated with diamide, a protein thiol oxidizing agent (Kosower N S et al., Methods. Enzymol, 251:123-132, 1995) (FIG. 17 , lane 5). The formation of Trx dimer following diamide treatment was also confirmed by gel permeation chromatography (results are not shown). H2O2 treatment of Trx also caused dimerization but produced a different banding pattern to that produced by diamide (FIG. 17 , lane 6). Treatment of Trx with NEM, a thiol alkylating agent (Gilbert H F, Methods Enzymol., 251:8-30, 1995), gave a single band with a slightly elevated apparent molecular weight, but no dimer formation (FIG. 17 , lane 4). Treatment of 7 day aged Trx with NEM produced both the higher molecular weight band as inFIG. 17 ,lane 4, and the bands illustrated inFIG. 17 , lane 2 (data not shown), suggesting that in the aged Trx not all the sulfhydryls are available for covalent modification. None of the changes caused by NEM were reversed with 2-mercaptoethanol treatment (data not shown). 2-Mercaptoethanol reversed Trx dimer formation caused by both diamide and H2O2, treatment (FIG. 17 ,lanes 7 and 8) but was less effective at reversing changes in the monomeric banding pattern of Trx produced by H2O2, (FIG. 17 , lane 8). - Freshly prepared C73S Trx and C32S/C35S Trx showed fewer bands than wild type Trx (
FIG. 18 ,lanes FIG. 18 , lane 6). Treatment of C71)S Trx with diamide caused the bands to coalesce into a single band of around 10 kDa, but there was no 23-kDa dimer formed (FIG. 18 , lane 4). The effects of diamide on C37S and 02S/05S were reversed by treatment with DTT (FIG. 18 ,lanes 5 and 7). - (viii) Discussion
- The study shows that human recombinant Trx undergoes at least 2 levels of spontaneous and induced oxidative transformation. The first oxidation occurs spontaneously within a few days to a form(s) that can no longer stimulate cell growth but remains a substrate for thioredoxin reductase. The slower oxidation, occurs over a period of weeks, or can be induced by the thiol oxidizing agent diamide, and leads to a disulfide banded homodimer which not only fails to stimulate cell growth but is a poor substrate for thioredoxin reductase. The fact that similar changes in Trx can be induced by chemical oxidation, are protected against by catalase and are reversed by the thiol reducing agent DTT is consistent with the interpretation that the changes in Trx are due to oxidation. Cys73 appears to play a critical role in both levels of oxidant-induced inactivation since C73S does not lose the biological activity or its ability to act as a substrate for thioredoxin reductase upon aging.
- We have shown by SDS-PAGE that fresh human recombinant Trx can exist in at least five different states, which probably reflect the fully reduced state of the protein as well as different intramolecular disulfide bonded states due to the five cysteine residues present in the protein. While the specific nature of these intramolecular disulfide bonds is not known, it is likely that some, at least, are due to non-natural disulfide bonded structures which form during denaturation and the oxidizing conditions of extended electrophoresis (Creighton T E, Methods Enzymol, 107:305-329, 1984). The observation that C317S and C32S/C35S exhibit a simpler banding pattern than wild-type Trx upon SDS-PAGE also suggests that the banding pattern is due to disulfide bond formation. X-ray structural analysis indicates that in addition to a disulfide bond between Cys32 and Cys35, the only other intramolecular disulfide bond that could form in the nondenatured Trx is between Cys73 and Cys32 although even this would require a different conformation of the protein (Weichsel A, et al., Structure 4:735-75.1, 1996). With the exception of a possible slight modification in Cys69 there is no evidence that Cys32, Cys35 or Cys62 are oxidized in Trx crystals formed in the presence of 5 mM DTT (Weichsel A, et al., Structure 4:735-751, 1996). The fact that treatment of Trx with NEM produces only one band implies that prior to denaturation and electrophoresis fresh Trx exists as a single species. The number of free thiols in fresh Trx was determined to be 4.5 to 4.6/molecule by Ellman's reagent (Ellman G L, Arch. Biochem. Biophys., 82:70-77, 1959) (data not shown), indicating that all five cysteines are in the sulfhydryl form. Treatment of NEM-alkylated Trx with oxidizing or reducing agents produces no change in the banding pattern (data not shown), which is further evidence that all 5 sulfhydryls have been alkylated. Oxidation of cysteines to sulfenic or sulfinic acids is unlikely to occur spontaneously (Claiborne A et al., FASEB J 7:1483-1490, 1993). It is noteworthy that H2O2 treatment of Trx gives rise to a different monomeric banding pattern than that of spontaneously oxidized Trx. The original monomeric banding pattern is also not regenerated by treatment with DTT. As has been previously suggested for NADH peroxidase (Poole L B et al., J. Biol. Chem., 264:12330-12338, 1989), we speculate that H2O2 oxidizes the cysteines to sulfenic acids and to the irreversible sulfinic or sulfonic acid states.
- During the same time interval that there was a loss of the growth stimulating activity of Trx, there was a shift of the electrophoretic banding pattern. There was a collapse of the banding pattern with loss of some of the Trx monomeric bands over 7 days, suggesting that Trx may be undergoing “native” intramolecular disulfide bond formation prior to electrophoresis, which prevents the formation of random disulfidebond formation seen with denaturation and electrophoresis of fresh Trx. A similar phenomena has been observed with bovine pancreatic trypsin inhibitor (Creighton T E, Methods Enzymol., 107:305-329, 1984; Weissman J S, et al., Science 253:1386-1393, 1995). Alleviation of aged Trx with NEM gave more than one protein product, indicating that aged Trx exists in multiple forms and not all the sulfhydryls are available for reaction. Since C73S does not undergo a similar shift in banding pattern and does not undergo loss of growth stimulating activity, it can be assumed that Cys73 is involved in this intramolecular disulfide bond formation, perhaps with Cys32 (
FIG. 19 ). Thus, spontaneous aging of Trx over a few days results in the inability of Trx to stimulate cell growth, although Trx is still a substrate for reduction by thioredoxin reductase. Analysis of the X-ray structure of Trx shows that Cys73 is by far the most accessible cysteine residue and possibly the most reactive (Page D L, Am. J. Surg. Pathol, 15:334-349, 1991). - If a solution of Trx is left long enough, or upon treatment with a strong oxidizing agent such as diamide or H2O2, there is formation of a 23-kDa Trx homodimer. Reduction of the Trx dimer by thioredoxin reductase is slow and delayed, and is stimulated by low concentrations of fresh Trx, suggesting there may be an autocatalytic process. A similar conclusion was reached by Ren X et al., Biochem., 32:9701-9705, 1993, Formation of the Trx homodimer appears to involve the Cys73 residue since C73S, where Cys73 is replaced with serine, does not undergo oxidation-induced homodimer formation as do Trx and C32S/C35S. Ren X et al., Biochem., 32:9701-9705, 1993 have shown C73S does not undergo oxidative homodimer formation induced by selenodithioglutathione. We recently reported the X-ray crystal structure of Trx and identified a largely hydrophobic dimer forming interface that is stabilized by a Cys73-Cys73 disulfide bond (Weichsel A, et al., Structure 4:735-751, 1996). Our observation that Trx undergoes a faster loss of activity with thioredoxin reductase in PBS versus water indicates that iron-induced oxidation or an increase in ionic strength may stabilize and enhance dimer formation, which is consistent with the hydrophobic nature of the dimer interface observed in crystals of human Trx.
- The importance of the monomeric oxidative form(s) of Trx is unknown. While the structural nature is yet to be identified, it does have different biological activity in our in vitro system. Trx is secreted by cells into the extracellular environment, which is predominantly oxidizing, and might be expected to undergo monomeric oxidation. Considering its ease of formation, it is reasonable to assume that monomeric oxidation will precede oxidative homodimer formation. Whether this might be sufficient to prevent Trx from acting as a growth factor is not known. The formation of the oxidized monomer inside the cell is less likely since it still can be slowly reduced by thioredoxin reductase and the interior of the cell is highly reducing.
- The physiological significance of homodimer formation is also unknown. What might be Trx homodimer has been reported in diamide-treated Jurkat cells (Sato N, et al., J. Immunol., 154:3194-3203, 1995). I have observed small amounts of the Trx homodimer by immunoblotting of untreated MCF-7 breast cancer and other cell lysates. It is intriguing to speculate that formation of an oxidized Trx monomer or homodimer in response to intracellular oxidants such as H2O2 might be a way mammalian cells detect oxidant formation. Trx is believed to exist in normal cells at concentrations from 1 to 10 μM (Luthman M, et al., Biochem., 21:6628-6633, 1982; Berggren M, et al., Anticancer Res. (in press)), though in selected tissues and specific cell compartments this value could be much higher. It is therefore not unreasonable to assume that Trx will undergo homodimer formation in vivo. As I observed with the enhanced inactivation of Trx in phosphate buffered saline, I expect dimer formation to precede faster in vivo than observed in vitro in water. Whether dimer formation in vivo would prevent the faster oxidation to an intramolecular form is unknown. The slow autocatalytic reduction of the Trx homodimer to the monomer would be a way to restore the cell to normal operating conditions after the induction of oxidative stress.
- In summary, we have found that human recombinant Trx undergoes relatively rapid (over a few days) spontaneous and oxidant-induced conversion to a form(s) that does not stimulate cell proliferation, but is still a substrate for reduction by thioredoxin reductase. There is much slower (over a period of weeks) spontaneous oxidation of Trx to a Cys73-stabilized homodimer form that is not a substrate for thioredoxin reductase and that also does not stimulate cell proliferation. Both conversions can be reversed by treatment with the thiol reducing agent DTT, and both appear to involve the Cys73 residue. A Cys73->Ser mutant Trx, which stimulates cell proliferation and is as effective a substrate for thioredoxin reductase as Trx, did not show age or oxidation-induced loss of these activities. Thus, with time Trx gradually loses its ability to stimulate cell proliferation and to be a substrate for thioredoxin reductase, unlike the Cys73->Ser mutant Trx, which retains these activities with no loss. Thus, Cys73 is not critical for biological activity but may play a critical role in the oxidative regulation of Trx activity.
- The redox protein thioredoxin plays an important role in controlling cancer cell growth through regulation of DNA synthesis and transcription factor activity. Thioredoxin is overexpressed by a number of human primary cancers and its expression is decreased during dexamethasone-induced apoptosis of mouse WEH17.2 thymoma cells. We examined the ability of WEH17.2 cells stably transfected with human thioredoxin cDNA showing increased levels of cytoplasmic thioredoxin to undergo apoptosis in vitro and in vivo. The cells were protected from apoptosis induced by dexamethasone, staurosporine, etoposide, and thapsigargin, but not by N-acetyl-sphingosine. When inoculated into severe combined immunodeficient mice, the trx-transfected cells formed tumors that showed increased growth compared to wild-type, as w ell as bcl-2-transfected. WEHI7.2 cells. The trx- and bcl-2-transfected cell tumors both showed less spontaneous apoptosis than tumors formed by the wild-type cells. Unlike tumors formed by the wild-type and bcl-2-transfected WEH17.2 cells, frx-transfected cell tumors did not show growth inhibition upon treatment with dexamethasone. This study suggests that increased thioredoxin expression in human cancers may result in an increased tumor growth through inhibition of spontaneous apoptosis and a decrease in the sensitivity of the tumor to drug-induced apoptosis.
- Trx is a low molecular weight redox protein found in both prokaryotic and eukaryotic cells (Holmgren, A. J. Biol. Chem., 264:13963-13966, 1989). The cysteine residues at the conserved Cys32-Gly-Pro-Cys35-Lys active site of Trx undergo reversible oxidation-reduction catalyzed by the NADPH-dependent selenium-containing flavoprotein Trx reductase (Luthman, M., et al., Biochemistry, 21:6628-6633, 1982). Human Trx is a protein of Mr 11,500 with 27% of amino acid identity to Escherichia coli but containing three additional Cys residues not found in bacterial Trx that give the human protein unique biological properties (Gasdaska, P. Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994). Trx was originally studied for its ability to act as a reducing cofactor for ribonucleotide reductase, the first unique step in DNA synthesis (Laurent, T. C., et al., J. Biol. Chem., 239:3436-3444, 1964). More recently, Trx has been shown to exert redox control over a number of transcription factors, including nuclear factor KB (Matthews J R., et. al., Nucleic Acids Res., 20:3821-3830, 1992), transcription factor IIIC (Cromlish, J. A, et al., J. Biol. Chem., 264:18100-18109, 1989), BZLF1 (Bannister, A. J, et al., Oncogene, 6:1243-1250, 1991), and the glucocorticoid receptor (Grippo, J. F, et al., J. Biol Chem., 258:13658-13664, 1983), and indirectly, through nuclear redox factor Ref-1/HAPE, Trx can regulate AP-1 (Fos/Jun heterodimer; Abate, C, et al., Science (Washington, D.C.), 249:1157-1161, 1990).
- Trx is also a growth factor with a unique mechanism of action. Human Trx stimulates the proliferation of both normal fibroblasts and a wide variety of human solid and leukemic cancer cell lines (Powis, G, et al., On col. Res., 6:539-544, 1994; Oblong, J. E, et al., J. Biol. Chem., 269:11714-11720, 1994). Redox activity is essential for growth stimulation by Trx, and mutant redox-inactive forms of Trx lacking the active site Cys32 and Cys35 residues are devoid of growth stimulating activity (Oblong. J. E, et al., J. Biol Chem. 269:1.1714-11720, 1994). Studies with 125I-labeled Trx have revealed no high-affinity binding sites that might suggest receptors for Trx on the surface of cancer cells (Gasdaska, J. R, et al., Cell Growth Differ., 6:1643-1650, 1995). Trx appears to stimulate cell proliferation by increasing the sensitivity of the cells to growth factors secreted by the cells themselves (Gasdaska, J. R. et al., Cell Growth Differ., 6:1643-1650, 1995).
- It has been found that Trx mRNA is elevated compared to paired normal tissue in almost half of the human primary lung and colon tumors we examined (Gasdaska, P. Y, et al., Biochem. Biophys. Ada, 1218:292-296, 1994; Berggren, M, et al., Anticancer Res., 16:3459-3466, 1996). Other studies have found increased Trx in human neoplastic cervical squamous epithelium cells and hepatocellular carcinoma (Fujii, S, et al., Cancer (Phila.), 68:1583-1591, 1991; Kawahara, N, et al., Cancer Res., 56:5330-5333, 1996). It has recently been shown that human breast cancer cells transfected with a dominant negative, redox-inactive mutant Trx show reduced anchorage-independent growth in vitro and an almost complete inhibition of tumor formation in vivo (Gallegos, A, et al., Cancer Res. 56:5765-5770, 1996). Thus, Trx overexpression may be a factor in the growth of some human cancers.
- It has previously been reported that Trx gene expression is decreased during dexamethasone-induced apoptosis of mouse thymoma-derived WEHI7.2 cells (Briehl M, M, et al., Cell Death Differ., 2:41-46, 1995). To further study the effects of Trx on apoptosis, in this study we stably transfected WEHI7.2 cells with human Trx cDNA and examined the effects on both spontaneous and drug-induced apoptosis in vitro and with the cells growing in Scid mice.
- a. Materials and Methods
- (i) Cells
- Human wild-type Trx cDNA was prepared as described previously, cloned into the NotI site of the pDC304neo mammalian transfection vector (Gallegos, A, et al., Cancer Res., 56:5765-5770, 1996) and transfected by electroporation into mouse WEH17.2 thymoma-derived cells (Harris, A. W, et al., J. Immunol, 110:431-438, 1973). Transfected cells were maintained at culture densities up to 10 cells/ml in DMEM containing 10% fetal bovine serum supplemented with 800 μg/ml G418 sulfate. All studies were conducted on clonal lines between
passages - (ii) mRNA Expression
- Northern blot hybridization analysis was performed as described previously using a full-length [o-32P]dCTP-labeled human Trx cDNA probe (Gasdaska P Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994). Blots were quantified using a Molecular Dynamics PhosphorImager.
- (iii) Glucocorticoid Receptors
- The level of functional glucocorticoid receptors was assessed using a transient cotransfection of cells with a glucocorticoid response element/chloramphenicol acetyltransferase (“CAT”) reporter plasmid (pmmCAT; Rundlett, S. E, et al., Exp. Cell Res., 203:21.4-221, 1992) and P-galactosidase. After a 22-h recovery period, the cells were treated with 1 μM desamethasone, and CAT protein was measured after an additional 24 hr. using a CAT ELISA (Boehringer Mannheim, Indianapolis, Ind.). An aliquot of the transfected cells was stained for p-galactosidase activity and CAT activity normalized for transfection efficiency.
- (iv) Apoptosis
- Apoptosis was measured by an ELISA for histone-associated DNA fragments (Leist, M, et al., Biochemica., 11:20-22, 1994), by morphology and by flow cytometry (Philpott, N. H, et al., Blood, 6:2244-2251, 1996). The criteria used for the morphological identification of apoptotic cells included condensation and margination of the chromatin with the formation of crescents, cell shrinkage, increased staining, nuclear fragmentation, cytoplasmic vacuolization, and apoptotic body formation. Cells were incubated with 20 μg/ml 7-amino actinomycin D for 30 min at 4° C. before being analyzed by flow cytometry.
- (v) Immunofluorescence Staining
- Cells were centrifuged onto 0.17-mm-thick quartz coverslips, air dried for 10 min. fixed with 4% methanol-free formaldehyde for 20 min at room temperature, washed for 15 min in PBS, pH 7.2, and permeabilized with 100% methanol at −20° C. for 6 min. The coverslips were then stored at −20° C. until immunostaining, when they were allowed to come to room temperature and blocked with 1% BSA in PBS. This was followed by a 1:10 dilution of goat serum in PBS, before reacting for 1 h with a 1:100 dilution of immunoaffinity purified rabbit antihumanTrx polyclonal antibody (Berggren, M, et al., Anticancer Res., 1.6:3459-3466, 1996). After being washed with PBS, the coverslips were exposed to a 1:100 dilution of goat antirabbit biotinylated IgG for h, washed with PBS, exposed to a 1:50 dilution of fluorescein streptavidin fluorochrome, and again washed with PBS. Cells were examined using a Leica TCS-4D laser scanning confocal microscope with an excitation wavelength of 488 nm. For subcellular localization studies of Trx, Cy5(indodicarbocyanine) streptavidin was used as the fluorochrome, followed by digestion for 1 h at room temperature with 100 μg/ml RNase A and DNA stained with 25 nM YOYO-1 iodide for 10 min. Cells were then examined by laser scanning confocal microscopy at excitations of 488 nm (YOYO-1) and 647 nm (Cy5). Relative fluorescence intensities of groups of 20 cells were measured at the same laser power, photomultiplier tube voltage, and line averaging setting as gray level intensities using SigmaScan software (Jandel Scientific, Corte Madera, Calif.), Because the transfected cells exhibited an uneven distribution of fluorescent staining, a template of a regular array of dots was placed over the image, and multiple (up to 90) nuclear and cytoplasmic measurements were made.
- (vi) In Vivo Tumor Growth
- Tumor formation by wild-type and transfected WEH17.2 cells was studied by injecting 2×107 cells in 0.1 ml of matrigel s.c. into the flanks of groups of 20 female Scid mice. Tumor volume was measured with calipers, and mice were euthanized when the tumor volume exceeded 2 cm3. Nine days after tumor cell injection, 10 mice from each group were injected i.p. with 1 mg/kg/day dexamethasone in 10% ethanol in 0.9% NaCl. Control mice were injected with vehicle alone. On day 14, three mice from each group were euthanized with CO2 and the tumors were excised and immediately fixed in glutaraldehyde.
- (vii) Preparation of Tissue for Bright-Field Examination
- The glutaraldehyde-fixed tissue was postfixed in osmium tetroxide, dehydrated in a graded series of alcohols, and embedded in epoxy resin. One-μm-thick sections were prepared and stained with toluidine blue for bright-field examination.
- b. Results
- WEHI7.2 cells were stably transfected with human trx cDNA in the pDC304neo mammalian transfection vector. I examined multiple clones and found the maximal increase in Trc mRNA compared to endogenous levels of mouse Trx mRNA, was 1.8-fold for clones Trx5 and Trx6 (
FIG. 20A ). As determined by immunofluorescent staining and confocal microscopy, the trx-transfected cells showed increased levels of Trx (FIG. 20B ). The relative fluorescence intensity of wild-type WEHI7.2 cells (±SE; n=20) was 1.00±0.05; of Trx5 cells, 2.15±0.14 (P<0.001 compared to wild type); and of Trx6 cells, 1.87±0.11 (P<0.001 compared to wild type). Trx-like fluorescent staining was observed in the nucleus as well as the cytoplasm of the cells (FIG. 20C ). In the wild-type cells, 60.1±5.1% of the fluorescent staining was in the nucleus, in the Trx5 cells it was 59.8±2.5%, and in the Trx6 cells it was 36.1±1.8%. - Compared to both wild-type or vector-alone-transfected cells, the trx-transfected WEH17.2 cells were resistant to apoptosis induced by 1 uM dexamethasone as measured by histone-associated DNA fragmentation (
FIG. 21A ) or by flow cytometry (FIG. 21B ). Histological examination of the WEHI7.2 cells revealed a classic apoptotic morphology in response to dexamethasone. However, only a small fraction of the cells undergo apoptosis at any one time, and they rapidly progress to fragmented cells. For this reason, results are expressed as relative apoptosis rather than percentage of apoptotic cells. Glucocorticoid receptor activity measured using a glucocorticoid receptor/CAT reporter plasmid was not decreased in the toc-transfected cells (Results of three studies not shown). I also studied the effect of trx transfection on other agents known to induce apoptosis (Table 5). Compared to vector-alone-transfected cells, fr-jc-transfected cells were resistant to apoptosis induced by staurosporine, a general kinase inhibitor (Kondo, Y, et al., Cancer Res., 55:2021-2023, 1995); by a cell-permeant sphingosine analogue, JV-acetyl sphingosine (Pushkareva, M, et al., Immunol. Today, 16:294-297, 1995); by thapsigargin, which blocks the uptake of intracellular Ca2+ resulting in an increase in intracellular free Ca2+ concentration (Lam, M, et al., Proc. Natl. Acad. Sci. USA, 91:6569-6573, 1994); and by etoposide, a topoisomerase II inhibitor (Onishi, Y, et al. Biochem. Biophys. Ada., 1175:147-154, 1993). WEHI7.2 cells transfected with the bcl-2 antiapoptotic proto-oncogene (W.HB 12 cells) showed a similar pattern of protection against apoptosis induced by the various agents as did the toc-transfected cells (Table 5). -
TABLE 5 Effect of Trx and Bcl-2 Transfection On Apoptosis Induced by Different Agents Relative Apoptosis Neo Trx5a Trx6a W.Hb 12a Dexamethasone 19.2 ± 0.6 4.4 ± 0.7 7.7 ± 1.2 0.7 ± 0.0 Staurosporine 58.3 ± 9.8 5.3 ± 0.0 9.9 ± 1.1 4.8 ± 0.7 N-Acetyl-sphingosine 58.8 ± 7.1 11.1 ± 9.8 22.6 ± 4.5 5.5 ± 1.3 Etoposide 162.5 ± 12.1 6.0 ± 0.6 20.9 ± 4.1 4.5 ± 0.7 Thapsigargin 4.3 ± 0.9 2.3 ± 1.8 1.8 ± 1.2 0.9 ± 0.61 pDC304neo vector-alone-transfected WEH17.2 cells (Neo), bcl-2-transfected WEH17.2 cells (W.Hbl2), and Trx5 and Trx-6 trx-transfected WEH17.2 cells were treated with 1 μM dexamethasone for 48 h, 100 nM staurosporine for 21 hr., 100 μM N-acetyl-sphingosine for 24 hr., 1 μM etoposide for 15 hr., or 50 nM thapsigargin for 24 hr. The times were determined to be optimum for detecting apoptosis with each agent. Apoptosis was measured by flow cytometry as in FIG. 2 IB. Relative apoptosis is expressed as the ratio of the sum of regions R2 and R3 (early and late apoptotic cells, respectively) divided by region RI (live nonapoptotic cells) normalized to the ratio for vehicle treated vector-alone transfected cells. Values are the mean of 3 determinations ±SE. Statistical analysis was by linear regression with indicator values for drugs and cells using the Stata statistical package (Stat Corp., College Station, TX). aP < 0.05 compared to vector-alone transfected control cells. - When inoculated into Scid mice, the trx-transfected WEH17.2 cells formed tumors that grew more rapidly than tumors formed by either wild-type or bcl-2-transfected WEH17.2 cells (
FIG. 22A ). Upon histological examination, tumors formed by the wild-type cells showed fields of apoptotic cells adjacent to fields of viable cells, as well as apoptotic cells admixed with viable-appearing cells (FIG. 22B ). The cells undergoing apoptosis exhibited the classic appearance of condensed and marginated chromatin, some in the form of crescents, and a dense cytoplasm accompanied by vacuolization. The trx-transfected WEHI7.2 cell tumors showed minimal numbers of cells undergoing apoptosis scattered throughout the tumor mass. Tumors formed by bcl-2-transfected WEHI7.2 cells also showed very few cells undergoing apoptosis (not shown). Areas of necrosis were seen in wild-type, trx-transfected, and bcl-2-transfected cell tumors, usually adjacent to fields of viable-appearing tumor cells or, in the case of the wild-type cells, adjacent to areas that show extensive apoptosis or next to viable-appearing cells. Treatment of the mice with dexamethasone starting at day 9 had no effect on the growth of the trx-transfected cell tumors but markedly inhibited the growth of the wild-type tumors and the bcl-2-transfected cell tumors (FIG. 22A ). Histological examination revealed no evidence of increased apoptosis caused by dexamethasone treatment of wild-type, frx-transfected, or bcl-2-transfected cell tumors. - c. Discussion
- WEH17.2 cells stably transfected with human trx showed a maximal increase of 1.8-fold in Trx mRNA compared to endogenous levels of mouse Trx mRNA. This relatively low level of overexpression is similar to the experience with trx transfection of mouse NIH 3T3 cells and human MCF-7 breast cancer cells (Gallegos, A, et al., Cancer Res., 56:5765-5770, 1996), suggesting that higher levels of unregulated trx expression may be toxic to cells. As determined by immunofluorescent staining and confocal microscopy, the frx-transfected cells showed approximately 2-fold increased levels of Trx. The finding that Trx is present in the cytoplasm and the nucleus of cells confirms an earlier immunohistochemical study using conventional light microscopy of cervical tumor cells that reported cytoplasmic, nuclear, or cytoplasmic and nuclear localization of Trx (Fujii, S, et al., Cancer (Phila), 68:1583-1591, 1991). This is an important observation because Trx may be able to directly reduce redox-regulated nuclear transcription factors, such as AP-1 (Fox/Jun heterodimer; Abate, C, et al., Science (Washington, D.C.), 249:1157-1161, 1990). If Trx can enter the nucleus, it may not need other nuclear redox factors such as Ref-1/HAP1, as has been suggested (Abate, C, et al., Science (Washington, D.C.), 249: 157-1161, 1990).
- The trx-transfected cells were resistant to apoptosis induced by dexamethasone. Trx has been reported to be necessary for assembly of the glucocorticoid receptor (Grippo, J. F, et al., J. Biol. Chem., 258:13658-13664, 1983). However, glucocorticoid receptor activity was not decreased in the transfected cells, suggesting that the effects of Trx on apoptosis appear to lie downstream of the glucocorticoid receptor. The trx-transfected cells also showed resistance to apoptosis induced by staurosporine etoposide, JV-acetyl sphingosine, and thapsigargin. Exogenously added human trx has been reported to inhibit apoptosis induced by tumor necrosis factor a in U937 human lymphoma cells (Matsuda, M, et al., J. Immunol., 147:3837-3841, 1991). However, it has been found that exogenously added human Trx did not protect WEHI7.2 cells against apoptosis induced by dexamethasone (Baker, A R et al., Cell Death Differ, 3:207-213, 1996). Tumor necrosis factor a and dexamethasone are thought to trigger apoptosis by different signaling pathways. It may also be that exogenous Trx is not taken up by WEH17.2 cells. We have found that other tumor cells take up Trx poorly, if at all (Gasdaska, J. R. et al., Cell Growth Differ., 6:1643-1650, 1995). Clearly, an increase in intracellular Trx achieved by transfection of trx in the present study is associated with resistance of the WEH17.2 cells to apoptosis induced by dexamethasone and other agents.
- The pattern of resistance to drug-induced apoptosis caused by a trx transfection is similar to that produced by transfection with the human proto-oncogene bcl-2. Bcl-2 is believed to exert its inhibitory effects upstream of the activation of the cysteine aspartate proteases cascade (caspase) responsible for the final stages of apoptosis (Shimizu, S, et al., Oncogene. 12:2251-2257, 1996). The protective effects of Bcl-2 against apoptosis have been suggested to involve an antioxidant mechanism (Hockenberry, D. M, et al. Cell, 75:241-251, 1993), although this is disputed based on the ability of Bcl-2 to block apoptosis caused by agents that are thought not to act by an oxidant mechanism (Jacobsen, M. D, et al., EMBO J., 13:1899-1910, 1994) or caused by hypoxia (Jacobsen, M. D, et al., Nature (Lond.), 374:814-816, 1995). The antioxidants N-acetyl-cysteine, pyrrolidine dithio-carbamate. Trolox. (a water-soluble vitamin E analogue), and butylated hydroxytoluene protect rat thymocytes against drug-induced apoptosis (Wolfe, J. T, et al., FEBS Lett., 352:58-62, 1994; Salgo, M. G, et al., Arch. Biochem. Biophys., 333:482-488, 1996). We have previously reported that Trolox, catalase, and superoxide disimutase protect murine WEH17.2 cells against dexamethasone-induced apoptosis (Baker, A. F, et al., Cell Death Differ., 3:207-213, 1996). It is intriguing, therefore, that trx, a gene that codes for a known redox-active protein, also inhibits apoptosis. The mechanism by which Trx inhibits apoptosis remains to be established, but its pattern of antiapoptotic activity similar to Bcl-2 suggests that it also may act upstream of the cysteine proteases.
- WEH17.2 cells transfected with trx formed tumors in Scid mice that grew considerably faster than tumors formed by the wild-type parental cells or by bcl-2-transfected cells. This may be due, in part, to a decreased rate of spontaneous apoptosis that occurred in the frx-transfected cell tumors. High levels of Bcl-2 have been found in a wide variety of human cancers (Reed, J. C, et al., J Cell. Biochem., 60:23-32, 1996). Although transfection with bcl-2 is known to confer resistance to apoptosis induced by anticancer drugs and radiation, the effects of bcl-2 on tumor growth are less clear. Transfection with bcl-2 gives a survival advantage to cells in culture (Maeyama, Y. Kurume Med. J., 42:291-297, 1995). Transgenic mice overexpressing Bcl-2 under transcriptional regulation of the immunoglobulin heavy chain enhancer develop benign lymphoma that eventually progresses to high-grade malignant disease (McDonnell, T. J, et al., Nature (Lond.), 349:254-256, 1991). This suggests that bcl-2 also provides a survival advantage to cells in viva but that an additional change, most frequently rearrangement of myc (McDonnell, T. J., et al., Nature (Lond.), 349:254-256, 1991), is necessary for tumor growth. Our studies using WEHI17.2 thymoma cells show that bcl-2-transfected cells formed tumors that grew faster than tumors formed by wild-type WEH17.2 cells. This may be due to a reduction in the rate of spontaneous apoptosis observed in the bcl-2 transfected cell tumors compared to the wild-type tumors. It was not possible to distinguish a difference in the rates of spontaneous apoptosis between the trx and bcl-2-transfected cell tumors. Paradoxically, the bcl-2-transfected cell tumors still showed growth inhibition by high-dose dexamethasone treatment, as did wild-type cell tumors. There was no evidence for increased apoptosis caused by dexamethasone treatment of wild-type, rrx-transfected, or bcl-2-transfected cell tumors, so the possibility remains that in vivo dexamethasone does not inhibit tumor growth in vivo by a mechanism that involves increasing the rate of apoptosis.
- The results of this study and our previous work (Gallegos, A, et al., Cancer Res., 56:5765-5770, 1996) suggest that the Trx system offers a novel target for agents to promote apoptosis and inhibit tumor growth, as well as to reverse the drug resistance of some cancers. It is interesting, therefore, that some 2-imidazolyl disulfide inhibitors of Trx (Kuperus, M, et al., Proc. Am. Assoc. Cancer Res., 36:426, 1995) have been shown to induce apoptosis in cancer cells and, in animal studies, by intraperitoneal and oral administration, to have antitumor effects. In particular, 1-methylpropyl-2-imidazolyl disulfide exhibits does-dependent antitumor activity in mice. Oral administration of 1-methylpropyl-2-imidazolyl disulfide in the diet of mice at up to 250 ppm, reduces the number of tumors in the colon by 70%, and causes a significant reduction in the size of the remaining tumors, Injection of mice with 1-methylpropyl-2-imidazolyl disulfide at 5 mg/kg, 10 mg/kg, and 15 mg/kg reduces the volume of tumors significantly (Powis, G, et al., Anticancer Drugs, 7 (Suppl. 3); 121-126, 1996).
- In summary, it has been shown that transfection with r, a gene found to be overexpressed in a number of human cancers, can inhibit apoptosis of cancer cells in culture included by a variety of agents. In animals, the trx-transfected cancer cells show an increased growth, decreased spontaneous apoptosis, and decreased sensitivity to apoptosis induced by dexamethasone. If similar effects occur in patient tumors, then trx could be a new human proto-oncogene.
- Human thioredoxin is a putative oncogene that may confer both a growth and survival advantage to tumor cells. Over-expressed thioredoxin mRNA has been found in both primary human lung and colorectal cancers. To determine the intratumor distribution and amount of thioredoxin protein in human primary tumors and to determine if its overexpression is related to proliferation or apoptosis, I studied primary human gastric carcinoma samples. An immunohistochemical assay for thioredoxin in paraffin embedded blocks was developed. Ten patients were studied with primary high risk gastric carcinoma. To relate thioredoxin protein overexpression to apoptosis I utilized a paraffin based in situ assay (Tunel) and to delineate proliferation we utilized the nuclear proliferation antigen detected by Ki67. In this survey I found thioredoxin was localized to tumor cells and overexpressed compared to normal gastric mucosa in 8 of 10 gastric carcinomas. The thioredoxin was found at high levels in 5 of the 8 overexpressing carcinomas. The overexpression of thioredoxin was typically found in both a nuclear and cytoplasmic location in the neoplastic cells. There was a significant positive correlation (P=0.0061) with cancer cell proliferation measured by Ki67. There was a significant negative correlation (P=0.0001) with apoptosis measured by the Tunel assay. Thus, human primary gastric tumors that are highly expressive of thioredoxin have both a higher proliferative rate and a lower rate of spontaneous apoptosis than tumors that do not express thioredoxin. Whether this thioredoxin-related combined growth and survival advantage translates into poor clinical outcome remains to be determined.
- Thioredoxins are low molecular weight redox proteins found in both prokaryotic and eukaryotic cells (Holmgren, A. 1989. J. Biol. Chem., 264:13963-13966). The cysteine (Cys) residues at the conserved -Cys-Gly-Pro-Cys-Lys active site of thioredoxin undergo reversible oxidation-reduction catalyzed by the NADPH-dependent selenium containing flavoprotein thioredoxin reductase (Luthman, M, et al., Biochem., 21:6628-6633, 1982). Human thioredoxin is an 11.5 kDa protein, with 27% amino acid identity to E. coli thioredoxin. It contains 3 additional Cys residues not found in bacterial thioredoxin that give it unique biological properties (Gasdaska, P. Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994).
- Thioredoxin was first studied for its ability to act as reducing cofactor for ribonucleotide reductase, the first unique step in DNA synthesis (Laurent, T. C, et al., J. Biol. Chem., 239:3436-3444, 1964). More recently thioredoxin has been shown to exert redox control over a number of transcription factors, including NF-KB (Matthews, J. R, et al., Nucl. Acids Res., 20:3821-3830, 1992). TFIHC (Cromlish, J. A, et al., J. Biol. Chem., 264:18100-18109, 1989), BZLF1 (Bannister, A. J, et al., Oncogene, 6:1243-1250, 1991), the glucocorticoid receptor (Grippo, J. F, et al., J. Biol. Chem., 258:13658-13664, 1983) and, indirectly through another redox factor Ref-1, AP-1 (Fos/Jun heterodimer) (Bannister, A. J, et al., Oncogene, 6:1243-1250, 1991). Thioredoxin modulates the binding of the transcription factors to DNA and thus, regulates gene transcription.
- Thioredoxin is also a growth factor with a unique mechanism of action. The predicted amino acid sequence of thioredoxin is identical to that of a previously identified growth factor secreted by HTLV-1 transformed leukemic cell lines, called adult T-cell leukemia-derived factor (ADF) (Gasdaska, P. Y. et al., Biochem. Biophys. Ada., 1218:292-296, 1994). ADF stimulates growth of lymphoid cells (Wakasugi, N, et al., Proc Natl. Acad. Sci. USA, 87:8282-8286, 1990; Yodoi, J, et al., Adv. Cancer Res., 57:381-411, 1991). It has been shown that human recombinant thioredoxin stimulates the proliferation of normal fibroblasts and human solid tumor cancer cells even in the absence of serum (Powis, G, et al., Oncol Res., 6:539-544, 1994; Oblong, J. E, et al., J. Biol. Chem., 269:11714-11720, 1994). It does this by increasing the “sensitivity of the cells to growth factors secreted by the cells themselves (Gasdaska, J. R, et al., Cell Growth Differ., 6:1643-1650, 1995). For example thioredoxin at nM concentrations, as are found in human serum (Kitaoka, Y, et al., Immunol. Lett., 41:155-161, 1994), increases the sensitivity of human breast cancer cells to interleukin-2 (1-2) and basic fibroblast growth factor (bFGF) by 1000 and 100 fold, respectively (unpublished observations). The term “voitocrine”, from the Greek “to help”, has been coined to describe this growth stimulating activity of thioredoxin (Gasdaska, J. R, et al., Cell Growth Differ., 6:1643-1650, 1995). Mutant redox-inactive forms of thioredoxin lacking the active site cysteine residues and E. coli thioredoxin are devoid of growth stimulating activity (Oblong, J. E, et al., J. Biol. Chem., 269:11714-11720, 1994). Human thioredoxin is known to be secreted from cells by a leaderless secretory pathway (Rubartelli, A, et al., J. Biol. Chem., 267:24161-24164, 1992) so that it could be acting extracellularly to stimulate cancer cell growth.
- Our work has shown that thioredoxin is important for the growth, death and transformed phenotype of some human cancers. Stable transfection of normal fibroblasts with human thioredoxin cDNA (trx) increases their growth rate and transfection of human MCF-7 breast cancer cells with trx increases their colony formation in soft agarose (Gallegos, A., et al., Cancer Res., 56:5765-5770, 1996). Transfection of the MCF-7 cells with a dominant negative redox inactive mutant trx causes inhibition of colony formation and almost complete inhibition of tumor formation when the cells were inoculated into Scid mice. In
recent studies 1 have shown that stable transfection of mouse thymoma cells with human trx inhibits apoptosis induced by a variety of agents including glucocorticoid, staurosporine, N-acetylsphingosine, thapsigargin and etoposide, which is similar to the pattern of inhibition seen with the antiapoptotic oncogene bcl-2 in these cells (Baker, A, et al. Cancer Research, 57:5162-5167, 1996). The trx transfected cells form tumors that when inoculated in Scid mice grow more rapidly and show less spontaneous apoptosis than vector alone or bcl-2 transfected cells, and are resistant to growth inhibition by glucocorticoid (Baker, A, et al., Cancer Research, 57:5162-5167, 1996). These results suggest that trx offers a survival as well as a growth advantage to tumors in vivo, unlike bcl-2 which offers only a survival advantage and requires other genetic changes for tumor growth (McDonnell, T J, et al., Nature, 349:254-256, 1991). - It has previously been reported that almost half of human primary lung cancers examined overexpress thioredoxin mRNA compared to normal lung tissue from the same subject (Gasdaska, P. Y, et al., Biochem. Biophys. Acta., 1218:292-296, 1994). Recently it has been found that more than half of human primary colorectal tumors have elevated levels of thioredoxin mRNA, up to over 100 fold for one subject, compared to normal colonic mucosa taken from within 5 cm of the tumor from the same subject (Berggren, M, et al., Anticancer Res., 16:3459-3466, 1996). In these studies, however, thioredoxin mRNA was extracted from pieces of tumor and nothing is known of its intratumor distribution, or even if the increased thioredoxin mRNA leads to an increase in thioredoxin protein. It remains to be determined if thioredoxin overexpression is related to proliferation or apoptosis in human primary tumors. These are clearly important questions that are now addressed in the present studies utilizing primary human gastric carcinoma samples.
- The current study sought to develop an assay for thioredoxin in paraffin embedded blocks allowing survey of human tumors in archival tissue banks. To this end the Southwest Oncology Group (SWOG) Gastrointestinal Biology Laboratory made available a relevant archival paraffin block bank of gastric carcinomas. Furthermore, to relate thioredoxin to apoptosis I also sought to refine a paraffin-based in situ assay of apoptosis (Grogan, T. M, et al., Automation of Immunohistochemistry, In Weinstein, R. S. (ed); Advances in Pathology and Laboratory Medicine, vol. 6. St. Louis, Mosby, 1993, pp. 253-283; Grogan, T M, et al. Kinetic-mode, Automated Double-labeled Immunohistochemistry and In Situ Hybridization in Diagnostic Pathology, Advances in Pathology and Laboratory Medicine. 8:79-100, 1995). Finally, to relate thioredoxin to proliferation, I utilized the previously developed assay of the nuclear proliferation antigen detected by Ki67 (Miller, T, et al., Blood 83:1460-1466, 1994).
- a. Methods
- (i) Patient Samples
- Paraffin blocks from ten gastric carcinoma resections were studied. These pathology samples derived from ten patients on Southwest Oncology Group (SWOG) protocol 9008 (also known as intergroup study #0116). This is a study of high risk gastric carcinoma comparing gastrectomy only versus gastrectomy plus adjuvant therapy. The patients ranging in age from 42 to 75; all had previously untreated, stage II and III B gastric carcinoma. They had biopsy proven adenocarcinoma of the stomach which had a high risk for recurrences due to evidence of carcinoma extension beyond the muscularis propria and/or having lymph node involvement. Patients with Stage O, IA or any stage with MI were not eligible. As of December 1996 this study has accrued 486 patients.
- (ii) Immunohistochemistry
- Five micron thick sections were deparaffinized and then subjected to antigen unmasking with one of two methods with heat plus citrate buffer a pH 6.6 or microwave plus EDTA buffer at pH 8.0 as previously described (Grogan, T. M, et al., Automation of Immunohistochemistry, In Weinstein, R. S. (ed); Advances in Pathology and Laboratory Medicine, vol. 6. St. Louis, Mosby, 1993, pp. 253-283; Grogan. T. M, et al. Kinetic-mode, Automated Double-labeled Immunohistochemistry and In Situ Hybridization in Diagnostic Pathology, Advances in Pathology and Laboratory Medicine, 8:79-100, 1995). The best signal to noise ratio was established by judging reactivity with cell lines known to be a high expressor of thioredoxin (A549 human lung cancer) and a low expressor of thioredoxin (SK BR3 human breast cancer) (Berggren, M, et al., Anticancer Res., 16:3459-3466, 1996).
- All tumor samples and control cell lines were stained using a standard immunohistochemical method as previously described (Grogan, T. M, et al., Automation of immunohistochemistry, In Weinstein, R. S. (ed); Advances in Pathology and Laboratory Medicine, vol. 6. St. Louis, Mosby, 1993, pp. 253-283; Grogan, T. M, et al. Kinetic-mode, Automated Double-labeled Immunohistochemistry and In Situ Hybridization in Diagnostic Pathology, Advances in Pathology and Laboratory Medicine, 8:79-100, 1995). To obviate biotin receptor reactivity, biotin-avidin blocking was performed first. Then the primary antibody (polyclonal rabbit anti-human thioredoxin) (Berggren, M, et al., Anticancer Res., 16:3459-3466, 1996) was utilized at a titer of 1/200 after titration of control cell lines. The best signal to noise ratio was found following microwaving at pH 8.0 with EDTA buffer. Sections were treated with biotinylated goat-anti-rabbit antibody and then with avidin-peroxidase complex, each for 30 minutes at 42° C. in an automated immunostainer (VMS ES, Ventana Medical Systems, Tucson, Ariz.) (Grogan, T. M, et al., Automation of Immunohistochemistry, In Weinstein, R. S. (ed); Advances in Pathology and Laboratory Medicine, vol. 6. St. Louis, Mosby, 1993, pp. 253-283; Grogan, T. M, et al. Kinetic-mode, Automated Double-labeled Immunohistochemistry and In Situ Hybridization in Diagnostic Pathology, Advances in Pathology and Laboratory Medicine, 8:79-100, 1995). Sections were counterstained with methyl green, dehydrated, rinsed in xylene and coverslipped.
- The degree of thioredoxin expression in tumor cells was judged at 400× magnification as 4+ (very intensely positive), 3+ (moderately intensely positive), 2+ (moderate), 1+ (faint), or 0 (completely negative) throughout the sample. A single investigator (TG) was responsible for scoring all the samples.
- Additional immunohistochemical assays employed antibody to proliferation antigens, Ki67 (Ventana, Tucson, Ariz.), also using the biotin-avidin labelled method after avidin blocking (Miller, T, et al., Blood, 83:1460-1466, 1994). The degree of Ki67 staining, again judged at 400× magnification, was classified as the percentage of nuclear positive tumor cells listed as: absent (0), >0-5% (+), 6-25% (++), 26-50(+++), >51% (+++).
- (iii) Apoptosis Assay
- Apoptotic cells were detected utilizing the TUNEL assay (Gavrieli, Y, et al., J. Cell BioL, 119:493-501, 1992; Grasl-Kraupp, B. et al., Hepatology, 21:1465-1468, 1995) adapted to an automated in situ hybridization instrument (gen II, Ventana Medical Systems, Inc.). The TUNEL assay utilizes recombinant terminal deoxynucleotidyl transferase (Tdr) (GIBCO BRL) for adding homopolymer tails to the 3′ ends of DNA which are more abundant in apoptotic cells (Gavrieli, Y. et al., J. Cell BioL, 119:493-501, 1992; Grasl-Kraupp, B, et al. Hepatology, 21:1465-1468, 1995). Biotin-16, 2′-deoxyuridine-5′ triphosphate (Biotin 16-dUTP) (Boehringer-Mannheirn, Indianapolis, Ind.) was the label used for terminal transferase in this
DNA 3′-end labelling reaction. Avidin-Horseradish Peroxidase and 3,3′-diaminobenzidine as chromogen (Gavrieli, Y, et al, J. Cell BioL, 119:493-501, 1992; Grasl-Kraupp, B, et al., Hepatology, 21:1465-1468, 1995). - The instrument utilized deparaffinized sections with subsequent digestion with Protease I (Ventana Medical Systems, Tucson, Ariz.) for 8 minutes VMS 1). Incubations were performed per Ventana Gen II protocol on the instrument with the final steps being as above using avidin-horse radish peroxidase and DAB detection method to visualize the apoptotic nuclei as an intense brown color (diaminobenzidine). As an enzyme control we utilized two sections from each tissue: one with Tdt enzyme and one without enzyme (negative control).
- The TUNEL assay result was scored by the number of brown-apoptotic tumor nuclei per high power field (400× objective). The values were: 0 (absence of apoptotic cells), + (>0-2/hpf), ++ (2-4/hpf), +++ (>4-8/hpf), ++++ (>8/hpf).
- b. Statistical Analysis
- Thioredoxin expression was correlated with Ki67 expression and with apoptosis measured by the TUNEL assay using Spearman's nonparametric rank correlation test.
- c. Results
- The optimum signal to noise ratio was found by using the following antigen retrieval conditions: microwaving at pH 8.0 in EDTA as tested by a high thioredoxin expressor (A 549) and low thioredoxin expressing (Sk BR3) cell line.
- Immunohistochemical localization of thioredoxin (positive staining) was found in the tumor cells of 8 of 10 gastric carcinoma samples (Table 2, supra). Seven of these eight showed both nuclear and cytoplasmic staining (
FIG. 23 ). The two cases with no tumor thioredoxin showed positive staining in the adjacent normal mucosa and are important controls, suggesting these are true, not false-negative, tumors (FIG. 24 ). - Among the eight thioredoxin positive gastric carcinomas there was a range of positivity from faint (+) to intense (++++) with five cases having high level thioredoxin (+++ to ++++) and three having low level (+ to ++) (Table 2, supra).
- In all samples there was the adjacent normal mucosa where the strongest staining was found in the gastric mucosal pits (++) while faint staining was found in the superficial mucosa (+). The localization differed based on site with gastric pits showing both nuclear and cytoplasmic staining while the middle mucosa had only cytoplasmic staining (
FIG. 25 ). - Increased levels of thioredoxin levels positively correlated with increased cell proliferation as measured by Ki67 expression (r=0.861, p=0.0061) and negatively correlated with apoptosis as measured by the Tunel assay (r=0.949, p—0.00010 (see Table 2, and
FIGS. 26 and 27 ). - d. Discussion
- An important aspect enabling this study is the development of two methodologic refinements: (Holmgren, A. 1989. J. Biol. Chem., 264:13963-13966) the use of heatbased antigen unmasking methods to allow optimal, reliable measurement of thioredoxin by IHC in archival paraffin embedded tissues; and (Luthman, M., Holmgren, A. Biochem., 21:6628-6633) adaptation of the Tdt based TUNEL assay to an automated procedure on an automated in situ machine. The heat-based antigen optimization of IHC entailed heating the paraffin section in 5 mM EDTA in 0.1 M TRIS, pH 8.0. The specificity of the reaction was assured by the finding of high positive signal in A549 human lung carcinoma, a known high level thioredoxin expressor as determined by prior Western blotting (Berggren, M. et al, Anticancer Res., 16:3459-3466, 1996). SK BR3 breast carcinoma cells likewise served as low level expressor control also established by prior Western blotting. The gastric tumor samples themselves also served as positive and negative, same-slide controls. In particular, within the entrapped normal gastric mucosa gastric pits and mid-level mucosal cells showed thioredoxin signal while surface mucosal cells were negative. There was a clear difference in the subcellular localization of thioredoxin in normal positive gastric cells, the lower level in the pits showed cytoplasmic and scattered nuclear staining, while the higher mid-level graduation staining was typically lighter and restricted to the cytoplasm. The significance of this differential distributions is not known. Thioredoxin does not have a known nuclear localization sequence (Gasdaska, P. Y, et al., Biochem. Biophys. Ada., 1218:292-296, 1994). From our IHC studies it is clear that thioredoxin is specifically located within neoplastic gastric carcinoma cells and not in stromal cells or admixed B or T lymphocytes or macrophages. The tumor cell thioredoxin density typically exceeded that of the adjacent normal mucosa. The minimal background staining and strong signal to noise in all the samples, as illustrated in
FIGS. 23-27 , demonstrate the refinement of the thioredoxin paraffin assay we have developed. - In this survey of 10 primary human gastric carcinomas we have determined the extent of thioredoxin overexpression and determined its localization and its relationship to proliferation and cell survival (apoptosis) status. We found thioredoxin is overexpressed, compared to normal gastric mucosa, in the malignant cells of 8 of 10 gastric carcinomas. The thioredoxin protein was found at high levels in five of the eight overexpression carcinomas. The expression was typically found in both a nuclear and cytoplasmic location in the neoplastic cells. There was a significant positive correlation (p<0.01) between increased levels of thioredoxin expression and cell proliferation measured by Ki67 expression. There was also a significant negative correlation (p<0.0001) between increased levels of thioredoxin and apoptosis measured by the TUNEL assay. Thus, human primary gastric tumors highly expressive of thioredoxin have both a higher proliferative rate and a lower rate of spontaneous apoptosis than tumors with absent or low thioredoxin (
FIG. 26 ). This finding is consistent with our experimental observation that the stable transfection of mouse WEHI7.2 cells with human wild type thioredoxin leads to increased tumor growth rate in vivo associated with a decreased rate of spontaneous apoptosis (Baker, A, et al., Cancer Research, (in press) 1996). We have also found that transfection of human MCF-7 breast cancer cells with a dominant-negative redox inactive mutant thioredoxin inhibits tumor growth in vivo (McDonnell, T. J, et al., Nature, 349:254-256, 1991). Thus, overexpression of thioredoxin in gastric carcinoma is associated with increased cell growth and cell survival giving the cells doubly immortalizing properties. Whether this will translate in patients into more aggressive tumor growth, as seen in animals with thioredoxin transfected tumor cells, and a poor prognosis remains to be determined. - There have been 2 reports of the immunohistochemical distribution of thioredoxin in human primary tumors, Fujii et al., Cancer, 68:1583-11591, 1991 reported that, while the squamous and glandular cells of normal human cervix showed no thioredoxin IHC, the immediate and superficial layers of cervical squamous neoplastic tissue, as well as invasive squamous cell carcinoma showed cytoplasmic and nuclear staining for thioredoxin. A study by Kawahara, N, et al., Cancer Res., 56:5330-5333, 1996 has reported enhanced expression of thioredoxin in human hepatocellular carcinoma compared to adjacent non-cancerous liver, with both a nuclear and cytoplasmic localization of the staining. Thus, thioredoxin, overexpression appears to be a common phenomenon among a diversity of human neoplasms.
- Future studies are required to confirm the relationship between thioredoxin overexpression, increased gastric cancer proliferation and increased cell survival. The newly developed ability to simultaneously perform combined TUNEL and IHC assays on a single tissue section should allow more precise definition of the relationship of thioredoxin to cell proliferation or cell death, since the phenotype of individual apoptotic or proliferative cells may now be discerned by these double labelled assays.
- Finally, correlative clinical studies are anticipated to relate thioredoxin expression, Ki67 and apoptosis index to pathogenic grade, response to chemotherapy, disease free survival or overall survival thus defining the impact of thioredoxin on human carcinomas. Our patient data on the SWOG 9008 (Intergroup 0116) study of high risk gastric carcinomas which is now ongoing and has accrued 486 gastric carcinoma patients would seem to be the ideal patient cohort to study. Now that we have developed paraffin-based assays for thioredoxin, Ki67 and Tdt apoptosis by the Tunel assay in a standardized optimized manner, the full clinical study testing the clinical impact of thioredoxin is now feasible.
- All of the various publications cited above are hereby incorporated by reference in their entireties.
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/694,577 US20100166724A1 (en) | 1996-12-06 | 2010-01-27 | Uses of thioredoxin |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3199596P | 1996-12-06 | 1996-12-06 | |
PCT/US1997/022292 WO1998024472A1 (en) | 1996-12-06 | 1997-12-05 | Uses of thioredoxin |
US31929299A | 1999-06-03 | 1999-06-03 | |
US09/875,578 US6689775B2 (en) | 1999-06-03 | 2001-06-06 | Uses of thioredoxin |
US10/600,957 US20030223980A1 (en) | 1996-12-06 | 2003-06-20 | Uses of thioredoxin |
US12/694,577 US20100166724A1 (en) | 1996-12-06 | 2010-01-27 | Uses of thioredoxin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/600,957 Continuation US20030223980A1 (en) | 1996-12-06 | 2003-06-20 | Uses of thioredoxin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100166724A1 true US20100166724A1 (en) | 2010-07-01 |
Family
ID=23241647
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/875,578 Expired - Fee Related US6689775B2 (en) | 1996-12-06 | 2001-06-06 | Uses of thioredoxin |
US10/600,957 Abandoned US20030223980A1 (en) | 1996-12-06 | 2003-06-20 | Uses of thioredoxin |
US12/694,577 Abandoned US20100166724A1 (en) | 1996-12-06 | 2010-01-27 | Uses of thioredoxin |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/875,578 Expired - Fee Related US6689775B2 (en) | 1996-12-06 | 2001-06-06 | Uses of thioredoxin |
US10/600,957 Abandoned US20030223980A1 (en) | 1996-12-06 | 2003-06-20 | Uses of thioredoxin |
Country Status (1)
Country | Link |
---|---|
US (3) | US6689775B2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689775B2 (en) * | 1999-06-03 | 2004-02-10 | Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona | Uses of thioredoxin |
US6767536B1 (en) * | 1998-03-02 | 2004-07-27 | Ramot At Tel Aviv University Ltd. | Recombinant Staphylococcus thioredoxin reductase and inhibitors thereof useful as antimicrobial agents |
AU2002230049A1 (en) * | 2001-01-30 | 2002-08-12 | The Provost, Fellows And Scholars Of The College Of The Holy And Unidivided Trinity Of Queen Elizabe | Thioredoxin derived from h. pylori, which is capable of inhibiting nf-kappa b activation |
US7378251B2 (en) * | 2002-07-16 | 2008-05-27 | Rigel Pharmaceuticals, Inc. | Methods of identifying compounds that modulate IL-4 receptor-mediated IgE synthesis utilizing a thioredoxin-like 32 kDa protein |
US20070218981A1 (en) * | 2004-04-16 | 2007-09-20 | Cyberview Technology, Inc. | Casino no-ticket in cashless methods allowing the redemption of large prizes |
KR101058230B1 (en) | 2009-03-16 | 2011-08-22 | 배재대학교 산학협력단 | Marker for diagnosis of breast cancer comprising thioredoxin 1, and diagnosis kit of breast cancer using the same |
US9382587B2 (en) | 2009-03-16 | 2016-07-05 | Paichai University Industry-Academic Cooperation Foundation | Diagnosis of breast cancer based on expression level of thioredoxin-1 |
CN111712571B (en) * | 2017-12-13 | 2024-02-09 | 大守伊织 | Gene-altered non-human model animals |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849737A (en) * | 1995-04-14 | 1998-12-15 | The Regents Of The University Of California | Compositions and methods for treating pain |
US20020055131A1 (en) * | 1999-06-03 | 2002-05-09 | Garth Powis | Uses of thioredoxin |
US20070010543A1 (en) * | 2005-07-01 | 2007-01-11 | Dynogen Pharmaceuticals, Inc. | Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
US20070105945A1 (en) * | 2005-11-07 | 2007-05-10 | Indian Institute Of Science | Antimalarial drug containing synergistic combination of curcumin and artemisinin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8903003D0 (en) | 1989-09-12 | 1989-09-12 | Astra Ab | NOVEL MEDICAL USE |
JP2000502269A (en) | 1995-12-18 | 2000-02-29 | アボツト・ラボラトリーズ | Extraction and monitoring of body fluids |
-
2001
- 2001-06-06 US US09/875,578 patent/US6689775B2/en not_active Expired - Fee Related
-
2003
- 2003-06-20 US US10/600,957 patent/US20030223980A1/en not_active Abandoned
-
2010
- 2010-01-27 US US12/694,577 patent/US20100166724A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849737A (en) * | 1995-04-14 | 1998-12-15 | The Regents Of The University Of California | Compositions and methods for treating pain |
US20030223980A1 (en) * | 1996-12-06 | 2003-12-04 | Garth Powis | Uses of thioredoxin |
US20020055131A1 (en) * | 1999-06-03 | 2002-05-09 | Garth Powis | Uses of thioredoxin |
US20070010543A1 (en) * | 2005-07-01 | 2007-01-11 | Dynogen Pharmaceuticals, Inc. | Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
US20070105945A1 (en) * | 2005-11-07 | 2007-05-10 | Indian Institute Of Science | Antimalarial drug containing synergistic combination of curcumin and artemisinin |
Also Published As
Publication number | Publication date |
---|---|
US20020055131A1 (en) | 2002-05-09 |
US20030223980A1 (en) | 2003-12-04 |
US6689775B2 (en) | 2004-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100166724A1 (en) | Uses of thioredoxin | |
Baker et al. | Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo | |
Piwnica-Worms et al. | Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src | |
Zhau et al. | Expression of c‐erb B‐2/neu proto‐oncogene in human prostatic cancer tissues and cell lines | |
Takenaga et al. | Expression of antisense RNA to S100A4 gene encoding an S100-related calcium-binding protein suppresses metastatic potential of high-metastatic Lewis lung carcinoma cells | |
Amati et al. | The c‐Myc protein induces cell cycle progression and apoptosis through dimerization with Max. | |
Goodrich et al. | Abrogation by c-myc of Gl phase arrest induced by RB protein but not by p53 | |
JP4351896B2 (en) | Pharmaceutical composition for cancer treatment comprising p38 / JTV-1 as active ingredient and screening method for pharmaceutical composition for cancer treatment | |
Blaydes et al. | Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2 | |
Tonello et al. | Role of sympathetic activity in controlling the expression of vascular endothelial growth factor in brown fat cells of lean and genetically obese rats | |
Miyashiro et al. | Midkine expression in human breast cancers: expression of truncated form | |
Empereur et al. | Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion | |
US11752193B2 (en) | Administering methylation-controlled J protein (MCJ) SIRNA to a kidney cell | |
Gasdaska et al. | Human thioredoxin reductase gene localization to chromosomal position 12q23–q24. 1 and mRNA distribution in human tissue | |
Larocca et al. | Differential sensitivity of leukemic and normal hematopoietic progenitors to the killing effect of hyperthermia and quercetin used in combination: Role of heat‐shock protein‐70 | |
KR20000075739A (en) | Inhibitors of leaderless protein export | |
CA2274116C (en) | Use, of an inhibitor of thioredoxin, for inhibiting tumor growth | |
Liu et al. | Comparison of bax, waf1, and IMP dehydrogenase regulation in response to wild‐type p53 expression under normal growth conditions | |
WO1998024472A9 (en) | Uses of thioredoxin | |
EP0648123A1 (en) | INHIBITORS OF PROTEIN TYROSINE-PHOSPHATASE -g(a) FOR TREATMENT OF TUMORS. | |
JP2002511764A (en) | PAK kinase genes and polypeptides and methods of using them | |
EP1309603A1 (en) | Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof | |
EP0971731B1 (en) | Suppression of malignancy utilizing ribonucleotide reductase r1 | |
AU677589B2 (en) | Methods and compositions for increasing the sensitivity of acell to a DNA damaging agent | |
Yoneda et al. | Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF ARIZONA;REEL/FRAME:023936/0844 Effective date: 20100209 |
|
AS | Assignment |
Owner name: ARIZONA BOARD OF REGENTS, ACTING ON BEHALF OF THE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:POWIS, GARTH;REEL/FRAME:024048/0153 Effective date: 20000307 Owner name: PROLX PHARMACEUTICALS CORP.,ARIZONA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KIRKPATRICK, LYNN;REEL/FRAME:024048/0189 Effective date: 20090105 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |